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1.  A Collaborative Model for Assessing Trauma-Informed Practice in Agencies and 
Systems: A Promising Practice for Reducing Stigma
Authors
Laurie Drabble; Vivian Brown
What is your project or initiative?
This project was designed to explore the benefi ts of a trauma-informed systems assessment and 
improvement initiative conducted in the context of a family drug treatment court (FDTC).
Why did you develop this?
A growing body of literature documents the importance of trauma-informed and trauma-specifi c 
services and systems change in both addiction treatment and child welfare fi elds.
Who is the target audience?
Dependency courts, child welfare, and addiction treatment fi elds.
Is this based on established work, or does it draw from other existing work?
See the following references: 
• Brown, V. B., M. Harris, R. Fallot. 2013. Moving toward trauma-informed practice in addiction 
treatment: a collaborative model of agency assessment. Journal of Psychoactive Drugs 45(5): 386-
393. https://doi.org/10.1080/02791072.2013.844381.
• Drabble, L., S. Jones, and V. Brown. 2013. Advancing Trauma-Informed Systems Change in a 
Family Drug Treatment Court Context. Journal of Social Work Practice in the Addictions 13(1): 91-
113. https://doi.org/10.1080/1533256X.2012.756341
• Fallot, R. D., and M. Harris. 2006. Trauma-Informed Services: A Self-Assessment and Planning 
Protocol. Washington, DC: Community Connections. Available at: theannainstitute.org/
TISA+PPROTOCOL.pdf (accessed May 27, 2021). 
How does your project or initiative work?
The trauma-informed systems assessment involved a collaborative trauma-informed “walk-through” 
of several key partner organizations involved in a FDTC. The systems included the family dependency 
treatment court, child welfare agencies, and substance use disorder treatment agencies working with 
the parents who were referred to the FDTC (see references below for details about the intervention and 
study). The assessment is a tool for helping agencies and systems recognize potential trauma triggers 
within their agency and develop mitigation strategies for addressing change. The assessment includes 
questions such as whether the facility/system off ers a safe place for clients/families; whether screening 
includes substance use, mental health, and trauma questions; the degree to which clients receive clear 
explanations and information about program procedures; types of choices clients are given about 
services; and sensitivity of staff  to the potential of re-traumatization during certain procedures. The 
assessment is designed to reveal actionable opportunities for improvement in systems and practices.
What are the results? If results are not yet available, what results do you hope to achieve?
The assessment process, trauma-informed training, and practice adaptations helped to reduce stigma 
experienced by parents with substance use problems in two ways (see Drabble et al., 2013, included 
above). 
1. Benefi ts for clients. A common response regarding the benefi ts of implementing trauma-
informed systems change is that service providers “have a higher level of sensitivity and respect 
for parents…in part, because of the trauma-informed trainings.” The process challenged 
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providers to “really try to put ourselves in their shoes and treat each other the way we want to 
be treated” and makes providers “think about what we do and when we do it and why we do it 
the way... and it just makes us more aware of how we interact with our parents or how we talk 
to them or how we ask them to do things.” The strengths-based and trauma-informed approach 
in made parents feel “heard” and “not judged.” The parents were more likely to engage in the 
process and to open up in the court setting. 
2. Support and advocacy through peer mentors. Research about the intervention underscored 
the value of a peer support program (a key program component of the FDTC), which matches 
clients with mentor parents who are in recovery and have been through the child welfare system. 
Mentor parents were critical in helping to normalize the process of both trauma recovery and 
recovery from addiction. They also helped to mitigate the potential stigma of involvement in the 
child welfare system by sharing their own experience and helping parent navigate successfully 
through the court and child welfare process. In addition to providing reducing stigma and 
providing support and hope for clients, peer mentors also provided important, needed insights 
to lawyers, social workers, other offi  cials, and the judge in understanding what the parent 
goes through as they navigate the system. Peer mentors were frequently mentioned as key in 
prompting systems change because they are the window for the court into the lived experience 
of parents and children in family drug treatment courts.
Contact information
Laurie Drabble, San Jose State University 
laurie.drabble@sjsu.edu
Keywords
criminal justice, lived experience, simulation, training, trauma-informed, young adults
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2.  A Team around You: Continuous Connected Care Supported by Technology, 
Supporting the Person Dealing with Addiction and Their Loved Ones
Authors
Alexandra T. Greenhill, MD, CCFP; Samantha Yarwood; James Drage
What is your project or initiative?
Our project creates a bundle of curated services around a core care planning and coordination 
technology platform, enabling collaboration and continuity of care and support while addressing the 
individual, social, structural, and environmental contexts needed to treat addiction and to prevent 
recurrence of use.
Why did you develop this?
Lack of continuity of care and 24/7 support, as well as numerous distinct gaps and barriers to accessing 
services leads to frequent recurrence of use, in spite of the success of a given eff ort to obtain and retain 
treatment. The current annual rates of recurrence of use are 40% to 60%. The “yo-yo” or “snakes and 
ladders” nature of the experience is profoundly demoralizing for the impacted person, as well as loved 
ones, and leads to a societal perception of stigma or “mark of disgrace” associated with the idea of “why 
couldn’t the person stay well after the initial success of the treatment they were given?” Yet continuous 
care is not readily available and even when in place, tends to not be coordinated or technologically-
augmented, preventing the support teams from collaborating well, identifying early signs of recurrence 
of use, and also from gathering data on what works in order to create continuous quality improvement 
(CQI) of the off ered program. In addition, addiction often leads to isolation, and the lack of knowledge 
about addiction amongst the family and friends on the patient side means they don’t have a support 
network to lean on and too often are the victims of stigmatization, which reduces the changes of 
successful treatment and prevention of a relapse.
Who is the target audience?
Clinical service and care delivery, payers, and health system stakeholders.
Is this based on established work, or does it draw from other existing work?
Evidence-informed from established work, including research like: 
• Journey Mapping Substance Use Treatment: An Exploration of Health Care Provider and Peer 
Experiences in Delivering and Receiving Primary Care. Available at: https://bcpsqc.ca/wp- content/
uploads/2018/03/Journey-Mapping-Substance-Use-Treatment-Report-1.pdf (accessed May 27, 
2021.)
How does your project or initiative work?
In our proposed solution, people with addiction can access, through one platform, a suite of services 
that, in combination, are appropriate to their needs throughout the journey of dealing with addiction. 
Whether it’s treatment, outpatient, or follow-up, the services act as a guided pathway on their journey 
of dealing with addiction. The platform uses a combination of human-delivered services with advances 
in technology and devices to better diagnose, treat, and support people with addiction. The platform 
also enables the person to rally family and friends, and through the technology platform, educate them 
on addiction and how to support their loved one. Family and friends, through the technology platform, 
can also off er them the support that they may need. Monitoring of patterns using data analytics will 
help alert the team supporting the patient to assist with early intervention to prevent a recurrence 
of use. In addition, using the Institute for Healthcare Improvement Plan-Do-Study-Act methodology, 
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augmented with the data gathered, will help with CQI in identifying patterns, gathering feedback on 
what works and what doesn’t, and rapidly test new approaches.
What are the results? If results are not yet available, what results do you hope to achieve?
As current rates of recurrence of use are 40% to 60%, we intend to reduce this to at least 20 to 30%. The 
use of a technology-enabled approach will enable us to:
1. provide continuous support for people with addiction and eliminate the barriers to ask for help 
when they need it;
2. identify early signs of potential relapse and intervene, thus decreasing the stigma people with 
addiction experience living with the seemingly inevitable ever-present threat of a relapse; and 
3. enable family and friends to learn more about addiction, destigmatizing the disease for the 
immediate support network of the person, who then, can more eff ectively support their loved 
one being treated for addiction.
Contact information





3.  Abolish Stigma: Examine Our Own Biases as Health Care Workers
Authors
Emma Klug; T. Celeste Napier, PhD; Adam Wilson, PhD; Ruchi Fitzgerald, MD, FAAFP
What is your project or initiative?
The initiative is an innovative partnership between Rush University Medical Center addiction education 
experts and Live4Lali. Live4Lali is a local not-for-profi t organization that provides essential harm 
reduction services, peer recovery coaching, and is a leader in education and advocacy locally and 
nationally. Together, the partners implemented a novel, interdisciplinary training for medical students 
with the goal of identifying bias in future healthcare providers and to orient them towards actively 
reducing substance use disorder (SUD) stigmas present in modern health systems.
Why did you develop this?
It is well established that healthcare providers may harbor negative perceptions of patients with SUD 
that both deter patients from engaging with treatment and negatively impact recovery. The high 
prevalence of SUD indicates that students will likely encounter patients aff ected by SUD irrespective 
of what medical specialty they choose to pursue. Accordingly, to provide the best care for patients 
aff ected by SUD, it is essential for all medical students to be provided training on the stigmatization of 
SUD along with standard therapeutics. This initiative is designed to impact students early in the medical 
school years, and may be duplicated in other health professional schools.
Who is the target audience?
The initiative is designed for all health professional students, recognizing that stigma is a far reaching 
issue and patient care is executed in interprofessional settings. Faculty are also encouraged to attend 
the training.
Is this based on established work, or does it draw from other existing work?
The initiative drew upon the experience of its community partner, Live4Lali, resting on the value of 
inclusion of the voices of persons with lived experience with SUD to lead a project on stigma training for 
future health care providers. Upon review of other medical school curricula, few other medical colleges 
include curriculum dedicated to examining stigma surrounding SUD in the health care setting.
How does your project or initiative work?
Content is provided to medical students in a 2 hour, synchronous virtual meeting. The session was 
driven by group dialogue and stigma didactics facilitated by trained health educators with lived SUD 
experiences. The educators fi rst provide background on harm reduction and Live4Lali’s services before 
sharing their own experiences with stigma in healthcare settings. These educators then lead a didactic 
presentation focusing on the eff ects of stigma and discrimination on individuals and communities, 
common misconceptions and misrepresentations of SUD, the power of using de-stigmatizing language, 
and provide actionable steps for healthcare providers to actively work towards reducing the harm 
stigma will infl ict on their future patients. This session is to be held annually for medical students and 
can be used for other health professional colleges. Within the session, breakout rooms are off ered for 
students to meet with the educators to examine their own biases about SUD, recognizing that without 
such dialogue, overcoming stigma about SUD is not feasible.
What are the results? If results are not yet available, what results do you hope to achieve?
At the conclusion of the session students completed a post-session evaluation to assess attitudes 
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towards SUDs and provide feedback on the session. Evaluation results are compiled by the faculty 
in order to positively shape future sessions. A pilot session was performed in March 2021. Faculty 
reviewed evaluations and the dialogue during the session; reinforcing the essential need for the session 
earlier in the medical school curriculum.
Contact information
Emma Klug, Rush Medical College 
emma_klug@rush.edu
Keywords
education, lived experience, training, workforce
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4.  Addressing and Redirecting Stigmatizing Behaviors in the Healthcare System through 
Job-Specifi c Trainings
Authors
Jodi Maiolo, MPH, CPH; Crystal Welch, MSN, RN; Shanen Wright, BS
What is your project or initiative?
This project involves a combination of targeted digital advertising, an electronic learning (e-learn) 
curriculum, and the engagement of “champions” among various hospital departments, from hospital 
security to billing personnel, nurses, physicians, and more. The e-learn curriculum is a newly developed, 
interactive training session created and tested by a combination of physicians and nurses who have 
extensive experience with substance use disorders (SUD) and non-clinical individuals. The curriculum 
has two tracks, for clinical and non-clinical staff , to reach, educate, and impact individuals with the most 
eff ective stigma reduction training for their work environment.
Why did you develop this?
Despite available education and the recognition of SUD as a legitimate medical diagnosis, employees 
of healthcare systems like hospitals are often among the most stigmatizing groups regarding SUD. 
After assessing stigma in Huntington, West Virginia and fi nding that healthcare professionals were not 
performing better than the average person regarding stigmatizing beliefs, a plan was developed to 
address stigma among various community groups, starting with employees of two local hospitals.
Who is the target audience?
Decision makers and employees of healthcare systems, as well as community advocates for SUD stigma 
reduction.
Is this based on established work, or does it draw from other existing work?
This is based on a 2019 campaign does by Marshall Family Medicine and Quality Insights to assess SUD 
stigma at the local level and determine methods for future stigma reduction that may be eff ective. 
Healthcare workers scored among the highest in stigmatizing beliefs and attitudes in that assessment.
How does your project or initiative work?
Individuals from each department and area of the two local hospitals will be approached to participate 
in the e-learn system trainings. It is also being worked on as a potential inclusion in mandatory on-
boarding trainings for new hires.
What are the results? If results are not yet available, what results do you hope to achieve?
We hope to assess improved scores from pre-test to post-test knowledge checks once the system is 
utilized, and to then gather qualitative research long-term regarding the interactions of individuals with 
SUD and employees in our two local hospitals.
Contact information





5.  Addressing Stigma as Part of a Massive Open Online Foundational Addiction Course 
for Professional Healthcare Training Programs
Authors
Ellen L. Edens, MD, MPE; Belinda Platt, BS; Shannon Drew, MD; Robert Heimer, PhD; Ayana Jordan, MD, 
PhD; Robert Krause, DPN, MSN, APRN-BC; Lindsay Powell, DPN; Elizabeth Roesler, MMS, PA-C; Jeanette 
M. Tetrault, MD; Adina Bowe, MD; Amanda Calhoun, MD, MPH; Deepa R. Camenga, MD, MHS; Maureen 
Dinnan, JD; Deborah Finnell, DNS, CARN-AP, FAAN; Myra Mathis, MD; Sarah T. Melton, PharmD, BCPP, 
BCACP, FASCP; Marissa Rocha, RN; Arial Sloan, MD; Andrew Wilbur, MD; Allen Zweben, PhD; Miriam 
Giles, BA; Kathryn Cates- Wessel, BA
What is your project or initiative?
A massive open online course (MOOC) foundational course on addiction. The course is fully online, 
interactive, and freely available. The course consists of 6 modules, each with 3-5 short lessons per 
module, in-video quiz questions, a clinical case vignette, interprofessional panel discussions, an 
interactive map activity allowing students to identify treatment settings in their geographic region, and 
a module quiz.
Why did you develop this?
Despite improvements over the past 20 years, healthcare for persons who use alcohol and other drugs 
largely remains siloed in a specialty-care substance use treatment system that is inaccessible or not 
desired by many who may benefi t from it. To move to a more integrated care model that addresses a 
range of substance use-related health problems, educational eff orts are needed to prepare the current 
and future interprofessional healthcare workforce. Central to expanding to an integrated care model 
is addressing stigma of substance use-related conditions among healthcare providers and trainees. 
To increase substance use education among healthcare trainees, interprofessional faculty from Yale 
University with substance-use related expertise designed a foundational, easily accessible, fl exible, 
and transportable curriculum appropriate for interprofessional healthcare profession students using a 
MOOC format.
Who is the target audience?
Healthcare profession students and trainees and interprofessional faculty needing curriculum content.
Is this based on established work, or does it draw from other existing work?
The online design was based upon known trends for adult learning theory and for online learning 
including clear objectives; brief, targeted segments rather than extended lectures; interactivity (e.g., 
discussion forums to post learner questions or comments, refl ection prompts, an activity to locate 
local substance use treatment resources); demonstration of clinical application of knowledge (e.g. case 
vignettes and video demonstration of skills, interprofessional roundtable discussions); and information 
recall (e.g., through quizzes).
How does your project or initiative work?
2 of the 6 modules focused on stigma. The fi rst module focused on learning objectives of avoiding 
stigmatizing language and using patient-centered language and communication. The last module 
focused on structural determinants of health and social disparities, including historical factors in 
substance use disorder (SUD) treatment that exacerbated stigma. The other 4 modules focused on 
screening and diagnosis, treatment options, medications for SUD, and psychological and behavioral 
therapies for SUD. Although not directly, many components of these modules (e.g., neurobiology of 
addiction) indirectly addressed stigma.
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What are the results? If results are not yet available, what results do you hope to achieve?
A 10-item assessment evaluated self-effi  cacy in screening, diagnosing, discussing treatment options, 
and providing supportive care for individuals with SUD (e.g., “I am confi dent screening patients for at-
risk substance use”), with a possible range of 0-50. 485 healthcare students and trainees from programs 
in nursing, medicine, social work, physician assistance, and psychology completed the assessment prior 
to course initiation. 310 (64%) completed the course and 174 completed the post-course assessment 
(56% of completers). A Linear Mixed-eff ects Model found that self-effi  cacy scores increased dramatically 
(26.5 to 39.2, p < .001). Despite limitations in the study design and lower than expected response 
rate, fi ndings suggest that an interactive, online, and foundational substance use course including 
substantial stigma-focused content can substantially improve substance use treatment self-effi  cacy 
among a healthcare students and trainees.
Contact information





6.  ASAP: Access to Syringes at Pharmacies. Reducing Pharmacy-Based Stigma to Increase 
the Sale and Purchase of Over-the- Counter Syringes in Arizona
Authors
Beth Meyerson; Danielle Russell; Jon Agley; Nina Vadiei; Keith Bentele
What is your project or initiative?
Access to Syringes at Pharmacies (ASAP), is a pharmacy-level intervention to reduce pharmacist and 
pharmacy technician ambivalence (stigma) about selling syringes without a prescription to customers 
who inject drugs. This two-year NIDA-funded project (R03DA053252) will iteratively develop and beta-
test the ASAP intervention with pharmacies in three Arizona counties (Pima, Maricopa and Mohave). 
The intervention involves:
• Accredited online/on-demand development training for pharmacy staff  about the importance 
of reducing blood-borne illness through access to sterile syringes; the role of pharmacies in 
an underfunded public health system in a state without syringe access legislation; and specifi c 
practices which can be engaged when customers request to purchase syringes. The intervention 
content is an adaptation of Fuller et al’s training with motivational interview components, online 
accredited delivery, and intentional focus on ambivalence reduction. 
• Pharmacies will work with our team to iteratively develop ASAP in the formative (PY01) year; 
followed by a 3-county beta-test of ASAP in diff erent pharmacies. Test pharmacies track syringe 
sales using a QR code method which transmits sales data to the research team at the time of 
purchase. 
• ‘Secret shopper’ attempts to purchase syringes at pharmacies (“Buy Studies”), will measure 
baseline and post-intervention pharmacy syringe sales and the degree to which stigma was 
expressed and/or experienced by community ‘buyers.’ 
• We are raising funds for this evaluation of syringe sales. Results will not be available until 2022, 
though we hope to observe a signifi cant reduction in pharmacy staff  ambivalence about selling 
non-prescription syringes for likely injection drug use, and increases syringe sales. The plan is to 
submit an R01 application for a Hybrid Type II study (implementation/impact) in three states.
Why did you develop this?
Arizona (AZ) is among 21 states without state law permitting syringe service programming (SSP). SSPs 
are locally permitted in a few locations, and underground programs also exist. The lack of access 
to sterile syringes throughout AZ has resulted in high rates of hepatitis C and HIV. Two of AZ’s 15 
counties were identifi ed by CDC as being at risk for an HIV or HCV outbreak (Mohave) or as being 
among counties contributing to over 50% of new HIV infections in the U.S. (Maricopa). Community 
pharmacies have long been seen as an opportunity to expand health access to populations who are 
underserved. Our 2019 study found that less than half (42.3%) of AZ community pharmacists have 
personally dispensed syringes for likely injection drug use in the past 2 years. This lack of experience 
selling syringes and developing comfort doing so likely predicts future pharmacy syringe sales to people 
who inject drugs. That same year, Arizonans who sought to purchase syringes at pharmacies without a 
prescription reported experiencing stigma and judgement by pharmacy staff  when requesting to buy 
syringes, having internalized feelings of stigma, and observing inconsistent policies and practices by 
pharmacies regarding syringe sales. The reported outcomes included decisions that pharmacies were 
“syringe access points of last resort,” and that participants would have to share or reuse their syringes 
without access to sterile syringes.
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Who is the target audience?
Our target audience is community pharmacy staff  (pharmacists and technicians) working in three 
Arizona counties. The project is also advised by a Community Advisory Board comprised of pharmacy 
staff  and harm reduction community partners.
Is this based on established work, or does it draw from other existing work?
Yes on both counts.
How does your project or initiative work?
See project/initiative above.
What are the results? If results are not yet available, what results do you hope to achieve?
Reduction in reported pharmacy staff  enacted stigma during syringe purchase and increase in syringe 
sales at pharmacies.
Contact information
Beth Meyerson, University of Arizona 
bmeyerson@arizona.edu
Keywords
education, harm reduction, pharmacy
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7.  Begin the Turn: A Mobile, Multidisciplinary Recovery Unit Meeting People 
Experiencing Substance Use Disorder Where They Are At
Authors
David T. O’Gurek, MD; Jonetta Gibbs, MS; Sam Stern, MD; Joseph D’Orazio, MD; Kathleen Reeves, MD
What is your project or initiative?
Begin the Turn, part of the Center for Urban Bioethics within the Lewis Katz School of Medicine at 
Temple University, is an integrative, trauma-informed, community-based outreach and mobile care 
recovery program, serving persons experiencing opioid use disorder through buprenorphine services, 
counseling, case management, and rehabilitative services and opportunities.
Why did you develop this?
With its location in and near the Kensington and North Philadelphia neighborhoods, The Temple 
University Health System is situated in the heart of the neighborhoods of Philadelphia deeply aff ected 
by the overdose crisis and was poised to serve as a leader in addressing this public health crisis in 
North Philadelphia and beyond.
Who is the target audience?
Begin the Turn initiated treatment services at two locations in Kensington – one at the corner of F & 
Allegheny and another at the corner of Ruth & Somerset. These sites were identifi ed as locations with 
high rates of overdose and overdose death. The populations served at these sites including individuals 
experiencing homelessness in the immediate and surrounding areas who are able to access street-side 
services.
Is this based on established work, or does it draw from other existing work?
Based on the CeaseFire model, an initiative launched in Chicago in 1999 that uses prevention, 
intervention, and community-mobilization strategies to reduce gun violence, the program was 
developed to serve as a model around community engagement to address addiction, particularly 
among individuals experiencing homelessness. This model was selected based on its public health 
strategies and community-based approaches; however, modifi cations included centralizing the 
community mobilization, education, and services around delivering buprenorphine treatment.
How does your project or initiative work?
All new patients to the program complete a self-administered adverse childhood experience (ACE) 
assessment and a social needs questionnaire after engagement with an outreach worker. After 
completion, the patient completes an intake assessment and biopsychosocial assessment by our 
behavioral health director and a comprehensive medical evaluation with a waivered physician. Patients 
are initially seen weekly for buprenorphine treatment for 4 weeks. After 4 weekly visits, visits are spread 
out to biweekly for 2 visits and then monthly based on progress and absence of opioids in the urine 
drug screen. No medication is stored on the mobile unit; rather, patients receive prescriptions to be 
fi lled at local pharmacies. Established patients are provided ongoing behavioral health counseling, case 
management, connections with social services, acute care needs with a bridge to primary care, and 
buprenorphine treatment with a low-barrier harm reduction approach. When the COVID-19 pandemic 
hit and aff ected North Philadelphia, Begin the Turn has maintained its presence in Kensington. 
Although the unit was re-purposed to assist the Temple Health System perform COVID-19 testing, the 
team adapted taking to the street to deliver care, maintaining behavioral health treatment and case 
management virtually with in-person contact for buprenorphine care. Begin the Turn’s commitment to 
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the community seeks to continue to reduce the stigma of addiction and deliver evidence-based care to 
ensure for our community there is hope beyond addiction.
What are the results? If results are not yet available, what results do you hope to achieve?
Since July of 2019, Begin the Turn has engaged with over 400 individuals. While our model is innovative 
in creation and design without another model like it nationally, early data suggests that our retention 
rates in care are similar to that of other programs caring for a similar population. This data shows 
that our population have high rates of prior overdose (49.7%) as well as use intravenously (67.3%). 
Additionally, our population has signifi cant rates of trauma with average adverse childhood experience 
scores of 4.6 and 63% having a score of 4 or greater.
Contact information
David O’Gurek, Center for Urban Bioethics, Lewis Katz School of Medicine at Temple University 
david.ogurek@tuhs.temple.edu
Keywords
lived experience, medications for opioid use disorder, trauma-informed  
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8.  Changing the Narrative: De-stigmatizing Substance Use, Addiction, and Pain in the 
Media
Authors
Maia Szalavitz; Leo Beletsky, JD, MPH; Sarah Wakeman, MD; Kate Nicholson, JD; Tracie Gardner;  
Zachary Siegel, MA
What is your project or initiative?
Our project is called Changing the Narrative. We’re a network of reporters, researchers, academics, 
and advocates concerned about the way that media represents drug use, addiction, and chronic pain. 
Our mission is to help journalists and opinion leaders provide accurate, humane, and scientifi cally 
grounded information in this contested terrain. We off er expert sources—including people with lived 
experience of the issues—and up-to-date, fact-checked, and evidence-based information on news and 
controversies.
Why did you develop this?
Most people today seek information about addiction from the media. Through analyzing news articles 
we found that critical sources of information were often fi lled with stigma, inaccurate stereotypes, and 
outdated perspectives on treatment and policy. We developed Changing the Narrative because stigma 
cannot be eff ectively addressed so long as so many communicators continue to traffi  c in these harmful 
tropes. These stigmatizing narratives are also a barrier to more humane treatment and eff ective policy. 
Ultimately, Changing the Narrative presents what the research actually shows to help journalists and 
others with large platforms do better.
Who is the target audience?
We focus much of our eff orts on journalists who are covering the overdose crisis and issues related 
to chronic pain, opioid treatment, and harm reduction. However, our reach goes well beyond the 
news media. Our toolkit and style guide is open access and made freely available to anyone who 
communicates to the public about addiction, drug use, and chronic pain. Nonprofi ts, organizers, 
activists, professors, researchers, and health care providers have all used our toolkit and style guide in 
a professional capacity.
Is this based on established work, or does it draw from other existing work?
While Changing the Narrative is an original project, it is modeled on best practices in health 
communication and media style guides for other delicate topics, such as climate change, suicide, and 
criminal justice. Since our inception in 2018, we have made updates as the research literature and 
discourse evolves. We closely follow research related to media/content analysis, such as from the Johns 
Hopkins Stigma Lab. The Stigma Lab concluded: “establishing journalistic standards to de-stigmatize 
the language of addiction is a public health priority,” which is precisely what Changing the Narrative was 
created to do.
How does your project or initiative work?
We maintain a glossary of fl awed narratives, tropes, and often misunderstood topics that is fact 
checked and easy to navigate. This is constantly updated with new entries and examples as fl awed 
stories develop and get traction. We also intervene in instances where a media publication or 
prominent communicator perpetuates stigma or inaccurate information. Multiple prominent journalists 
on the addiction beat collaborate with Changing the Narrative. They are constantly plugged into the 
latest news and research and when they see stigmatizing, misleading, or inaccurate articles, they take 
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it to a group and discuss how to intervene. We email the reporter/ editor to request corrections and 
direct them to our style guide and expert directory to help prevent further errors. If after sending 
corrections behind the scenes results in no engagement, we publicly advocate for corrections on social 
media channels.
What are the results? If results are not yet available, what results do you hope to achieve?
Our objectives are diffi  cult to measure but we have documented progress and change over time, 
especially in the realm of person-fi rst language. Years ago, terms like “addict,” “alcoholic,” or worse, 
“drug abuser,” were constantly used in media articles and by policymakers and health care providers. 
Since founding members of Changing the Narrative consulted with the Associated Press for their style 
guide entry on addiction, use of such stigmatizing nouns is less common. We’ve also been instrumental 
in excising phrases like “addicted baby” and debunking myths like fi rst-responders “overdosing” 
on fentanyl from passive exposure. Still, there is much to do; many writers, communicators, and 
professionals still use terms like “substance abuse” without recognizing that labeling people who 
use drugs as “abusers” is stigmatizing. In the future, we aim to collaborate with media researchers to 
analyze quantitative change over time.
Contact information
Zachary Siegel, Health in Justice Action Lab, Northeastern University 
z.siegel@northeastern.edu
Keywords
awareness, lived experience, person-centered language, policy and guidelines
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9.  Collaborating with Community Partners in Educating Emergency Department Health 
Care Providers on Caring for People with Substance Use Disorder
Authors
Kimberly Dion, PhD, RN, CNE, CARN; Cherry Sullivan, MPH; Michele Farry, BS
What is your project or initiative?
Our initiative was to identify and meet the needs of emergency department health care providers 
(EDHCPs) to care for people with substance use disorder (SUD), and their families, through the use of 
inter-collaborative trainings.
Why did you develop this?
The emergency department is often the fi rst point of contact for engagement in harm reduction 
practice and self-care management for people who use drugs. Since SUD is a chronic and relapsing 
brain disease, the EDHCPs often see individuals multiple times for issues related to their drug use. 
This experience can set the stage for future health care interactions. However, EDHCPs are confronted 
with increasing numbers of people with SUD accessing services and they often lack the training and 
resources to assist this marginalized population. Agencies working with people with SUD reported 
participant’s refusal to seek health care services due to experiences of stigma and discrimination.
Who is the target audience?
Our targeted audience were EDHCPs in four Western Massachusetts emergency departments. 
Attendees included physicians, nurses, patient care technicians, security, and patient registration staff .
Is this based on established work, or does it draw from other existing work?
Our educational sessions drew from existing work from area resources and inter collaborative teams of 
individuals with the goal of decreasing stigma in the emergency department setting.
How does your project or initiative work?
We queried fi ve EDHCPs to inquire about specifi c problems they were having caring for people with 
SUD. The myriad of responses ranged from a supportive tone to a stigmatizing and discriminating one. 
Themes were developed and tailored presentations based on the hospital responses were developed. 
Discussions were held with the unit manager to solicit feedback on present resources in the hospital. 
Five 60-90-minute educational presentations were held with EDHCPs at four hospitals in Massachusetts 
over a period of 8 weeks. An addiction certifi ed Registered Nurse developed and led the informational 
sessions. Throughout the presentation, representatives from community agencies presented 
information on what they do and how they could help the EDHCPs to support the patient and family of 
those with SUD. Agencies included Hampshire Hope, local DART police offi  cers, recovery coaches, and 
Tapestry Harm Reduction Services. The focus of the presentation was on recognizing addiction and 
supporting patients and their families throughout the addiction trajectory including recovery. EDHCPs 
were provided with information about trauma-informed care principles, the physiology of addiction, 
stages of change visual, the impact of stigma, recovery-focused language, their role in harm reduction 
education, state resources and area recovery supports for each hospital. The impact of stigma was 
delivered through the use of quotes of people who use drugs about the care they received in the 
hospital. The examples of the care included stigmatizing and supportive outcomes.
What are the results? If results are not yet available, what results do you hope to achieve?
All attendees were asked to complete an anonymous feedback sheet using a Likert scale to evaluate 
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how helpful they found the information in the presentation. The EDHCP written evaluations were 
positive with all but two reporting the information was “very useful,” and two reporting “helped me 
some.” Written comments included staff  reporting an appreciation for hearing real patient experiences, 
the change in their mindset towards addiction, how to begin the conversation with an individual, and 
practical harm reduction education that they could incorporate into their practice. Many were unaware 
of local agencies targeting care for people with SUD and stated an appreciation of the knowledge of 
the area resources that could be shared with patients and families. All agencies were provided with 
a one-page resource and referral sheet to be able to provide referral to patients and their family 
members. This easy-to-use reference was identifi ed as a welcomed tool for the clinicians. Lessons 
learned included an understanding that health care providers need ongoing SUD training, an easy and 
accessible community resource referral sheet, and institutional support to provide culturally sensitive 
care to people with SUD. Future research should include interviewing people with SUD post emergency 
department visit to evaluate changes in care.
Contact information
 Kimberly Dion, UMass Amherst
kadion@nursing.umass.edu
Keywords
care coordination, education, emergency medicine, person-centered language, training, trauma-
informed, workforce
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10.  Collaborating with Community Partners to Develop a Harm Reduction and Stigma 
Curriculum for Primary Care Clinic Teams Distributing Intranasal Naloxone and Safer 
Consumption Supplies in the San Francisco Safety Net
Authors
Saundra Nguyen, MD, MPH; Jar-Yee Liu, BS; Tatyana Roberts, BS, MPH; Joanna Eveland, MD; and 
Members of the SF AIDS Foundation including Ro Giuliano, John Halifax, Seth Katz, Cassie Chichian, 
Kelani Clark, and Jen Jeff ries
What is your project or initiative?
In response to sharp increases in mortality from opioid overdoses in the last few years, the San 
Francisco Health Network launched a pilot to distribute intranasal naloxone and safer consumption 
supplies (including safer smoking kits, safer injection kits, and fentanyl test strips) in safety-net primary 
care clinics with the goal of preventing overdose deaths, increasing safety around substance use, and 
overcoming barriers to access of substance use prevention and treatment services. Given the diversity 
of roles and experiences with harm reduction and substance use in our primary care clinics, our 
project aimed to develop a standardized harm reduction and stigma training that could be adapted 
to individual clinic sites and serve as a foundation for these pivotal patient interactions. We strived to 
include the voices of people with lived experiences in our trainings—both in the development of the 
curriculum and via narratives of their personal experiences with harm reduction, stigma, and overdose 
prevention.
Why did you develop this?
Stigma has long been recognized as a major barrier to accessing care and services and can take many 
forms, including stigma from individuals, self-stigma, and institutional stigma. Experiences of stigma 
in the health care setting can occur before the clinic encounter, starting at the front desk and waiting 
room. Therefore, interventions to raise awareness and reduce stigma within the clinic setting can 
positively impact patient experience and threshold to engage in care. We developed this training to 
accommodate for the varying levels of harm reduction experience across our diff erent primary care 
clinic sites and to educate team members about the eff ects of stigma on people who use substances. 
We hope this will lead to a more non-judgmental and non-stigmatizing culture and environment.
Who is the target audience?
Any clinic staff  member who will interact with patients who use substances, including front desk 
workers, medical assistants, nurses, behavioral health team members, social work, providers (MDs, 
NPs, trainees). Our pilot sites include Ward 86 (HIV Primary Care), Richard Fine People’s Clinic, Castro 
Mission Health Center, Curry Senior Center, Family Health Center, and Tom Waddell Urban Health 
Center.
Is this based on established work, or does it draw from other existing work?
This work was developed in collaboration with our community partners at the SF AIDS Foundation 
who have signifi cant experience in harm reduction, gave input on curriculum development, and lent 
their voices and personal narratives. We also drew from existing harm reduction and stigma materials 
available from the National Harm Reduction Coalition and the SF DOPE Project’s Overdose Prevention 
training.
How does your project or initiative work?
Our training has three components: 
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1. The foundational Harm Reduction and Addressing Stigma session conducted either in-person or 
virtually at each clinic site, 
2. A self-paced Overdose Prevention and Intranasal Naloxone module, and 
3. Videos created by the SF AIDS Foundation reviewing the contents of the safer consumption 
supplies (safer smoking kits, safer injection kits, and fentanyl test strips). 
Throughout the training, we include testimonials (text and video) from community members sharing 
their experiences with harm reduction, stigma, and overdose. For 1), we review harm reduction 
principles, eff ects of stigma, and ways to mitigate stigma in a discussion format. We meet with site 
champions at each clinic to assess the educational needs for each site including which team member 
roles will be distributing the supplies, the number of people being trained, and level of experience 
with harm reduction and patients who use substances. Based on these factors, the PowerPoint and 
discussion are adapted accordingly. We then identify a date for 1-1.5 hours of protected time to 
conduct the training either in-person or virtually. For 2) and 3), team members are asked to complete 
and review the modules on their own or as a group with support from their clinic site champions 
who can answer questions and provide on-site demonstrations for the intranasal naloxone and safer 
consumption kits.
What are the results? If results are not yet available, what results do you hope to achieve?
For the Harm Reduction and Stigma training, we are assessing the overall impact of the training by 
measuring pre and post levels of stigma using the Drug Stigmatization Scale (Palamar et al., 2011). 
We also want to look at how participants’ perspectives and practices around harm changed after the 
training. For the Overdose Prevention and Safer Consumption modules, we are assessing competency 
for use of intranasal naloxone and the safer consumption supplies.
Contact information
Saundra Nguyen, University of California San Francisco 
saundra.nguyen@ucsf.edu
Keywords
harm reduction, lived experience, training, workforce
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11.  Colliding Stigmas: Pain and Addiction in an Overdose Crisis
Authors
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What is your project or initiative?
National Pain Advocacy Center (NPAC), www.nationalpain.org, is a new non-profi t that seeks to unite 
those aff ected by the stigmas of pain and addiction. Although NPAC’s focus is on pain, our team 
includes experts in addiction, drug policy, stigma, racial disparities, and a diverse group of people with 
lived experience of pain as well as those in recovery from a use disorder. By giving everyone a seat at 
the table, we hope to foster understanding and a deeper recognition that both conditions are widely 
misunderstood, under-treated, and subject to considerable stigma. Together, we advocate for better 
drug policy choices. People with pain and people with addiction (and, especially, people with both) have 
long faced stigmas in society and the healthcare system. People with pain are often perceived as weak 
or malingering. People with use disorders are similarly shamed for weakness or indulgence. These 
biases exist not only in society at large but are also refl ected and perpetuated by the language we use 
and the treatment systems upon we rely. Pain stigma is rooted partly in pain’s subjectivity, the failure to 
understand of chronic pain as a disease, and religious notions of pain as punishment (the latin “poena” 
literally means punishment). Stigma surrounding use disorders relate to structural marginalization, 
poor cultural understanding of addiction, and punitive drug laws, their aggressive prosecution and 
related social norms around substance use. Systemic racism pervades our drug policy and informs 
the stigma that people with pain and people who use drugs experience. People of Color already 
wrongly have their pain rated as less severe by many clinicians and, because of the way we have waged 
the drug war disproportionately against communities of Color, are more often perceived as “drug 
seeking” and less likely to receive pain medication. The nexus between racism and drug regulation, 
legalization, and prosecution in the US is well documented and a primary source of stigma. Stigma and 
discrimination are intimately connected. Amidst a drug overdose crisis, stigma has caused the pain 
and addiction communities to be at odds with one another, when in fact they share many interests. 
Stigmas surrounding people who use drugs have begun to impact people who use opioids to manage 
physical pain. Some in the pain community have responded by lashing out against those with addiction, 
in eff ect doubling down on this stigma, while failing to recognize that they are simply perpetuating 
a stigma to which they are now subjected. A glaring example of this blame is the harmful hashtag 
#PatientsNotAddicts. Similarly, some in the addiction community blame a call to treat pain in the 1990s 
on the addictions and overdose deaths that fl owed from liberalized prescribing, and indirectly, on 
people with pain. NPAC seeks to promote common interests in drug policy reform, anti-racism, and de-
stigmatization.
Why did you develop this?
There was no group focused on advocacy that included the full spectrum of those aff ected by the 
opioid/overdose crisis and drug policy.
Who is the target audience?
Policymakers and the general public. Changing mindsets or public understanding goes hand in hand 
with changing policy.
Is this based on established work, or does it draw from other existing work?
Among our team members are scholars, like Daniel Goldberg, JD, PhD and Leo Beletsky, JD, MPH, who 
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are experts in stigma and the nexus between policymaking, stigma and discrimination. Our founder 
and others have deep expertise in anti-discrimination work. Our team also includes many involved in 
the Changing the Narrative group, www.changingthenarrative.news, which focuses on better education 
of the media and policymakers about addiction in the hopes of allaying stigma.
How does your project or initiative work?
Our project is primarily education and advocacy focused – but we are a large tent, including people with 
a variety lived experience as well as professionals who are clinicians, scientists, experts in pain, experts 
in addiction, and a signifi cant cohort of drug policy and human rights experts. We work together to 
educate and develop better policy and learn from one another.
What are the results? If results are not yet available, what results do you hope to achieve?
We only very recently launched, https://nationalpain.org/press-releases. 
Contact information





12.  Combating Stigma Surrounding Chronic Pain and Substance Use with 
Interprofessional Education
Authors
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What is your project or initiative?
A set of interprofessional education (IPE) trainings were developed to improve the treatment of 
patients with chronic pain who exhibit substance misuse behaviors. The IPE trainings incorporate 
case-based scenarios with video vignettes or simulation using live standardized patients to facilitate 
interprofessional (IP) discussions. During each training, participants practice use of person-fi rst, non-
stigmatizing language while working as part of an IP team to develop and prioritize holistic treatment 
options. The trainings are freely-available for adaptation by other institutions.
Why did you develop this?
Our IP team of university faculty identifi ed a gap in education in chronic pain and substance use 
treatment. A key objective of this project was to teach health profession students and working clinicians 
how to recognize and avoid stigmatizing language and provide holistic, unbiased, and compassionate 
care for people with pain and substance use disorders. A team-based IP approach was chosen to 
diversify learners’ perspectives, spark conversations, and encourage holistic treatment planning.
Who is the target audience?
The program targets team-based learning needs of health profession students (primarily medicine, 
nursing, pharmacy, social work, and physician assistants) and working primary care clinicians (including 
medical assistants and diverse clinic staff ).
Is this based on established work, or does it draw from other existing work?
In response to the opioid crisis, our team was funded by the Washington State Department of Health 
in 2017 to develop an opioid education program focused on health science student learning needs. We 
subsequently received additional funding to expand the student training and develop a program for 
working clinicians. Further grant support led to the development of a third IPE training that builds on 
the original patient case to address improved access and reduced stigma regarding medications for 
addictions treatment.
How does your project or initiative work?
A two-part series of IPE trainings was implemented for health profession students from multiple 
institutions in Washington State. In the fi rst 2-hour training, students are introduced to a longitudinal 
patient case of an older person who has developed opioid misuse behaviors after an accident resulted 
in chronic back pain. The case uses either video vignettes or a live trained standardized patient. Small 
IP teams are asked to meet and share perspectives from their unique discipline to create a holistic 
treatment plan for their patient. The case progresses for a second 2-hour session where the patient has 
increased their use of opioids and alcohol. During this second IPE session, students consider whether 
specifi c medications for addiction treatment are indicated.
What are the results? If results are not yet available, what results do you hope to achieve?
Since 2019, more than 1,400 health profession students have participated in one or both of the student 
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IPE trainings. Additionally, 12 rural clinics in Washington State have participated in the clinic-based 
trainings. Overall, the feedback on the trainings has been positive. Matched data from student pre- and 
post-surveys indicate improved confi dence in utilizing non-stigmatizing language when caring for a 
patient with pain who takes opioids (p<0.05, paired student t-test). Narrative comments from the 2020 
pilot suggest that students valued the content surrounding non-stigmatizing language. Additionally, 
students report improved understanding of their profession’s role and the roles of other healthcare 
team members in providing care (p<0.05, paired student t-test). We are currently investigating how 
learners respond to a longitudinal case through evaluation of the submitted holistic treatment plans.
Contact information
Marian Wilson, Washington State University 
marian.wilson@wsu.edu
Keywords
chronic pain, education, interprofessional, person-centered language, training
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13.  Combating Stigma to Aid Reentry and Recovery (C-STARR): A Behavioral Intervention 
to Reduce the Stigma of Addiction and Criminal Involvement
Authors
Kelly E. Moore, PhD
What is your project or initiative?
Combatting Stigma to Aid Reentry and Recovery (C-STARR) is a brief group intervention designed to 
reduce the negative consequences of stigma among people with substance use disorders (SUD) who 
are currently or have previously been involved in the criminal justice system. The intervention involves 
learning new ways to cope with judgments and rejection experiences from other people, including 
family members, employers, healthcare/treatment providers, and criminal justice staff . In addition, the 
intervention focuses on how to cope with the judgments that justice-involved people with SUD often 
have toward themselves (i.e., self-stigma).
Why did you develop this?
People with SUD who have been involved in the criminal justice system are among the most highly 
stigmatized groups in our society. They experience stigma from the general public, when applying for 
jobs and housing, and also when engaging in treatment settings. Stigma has a signifi cant impact on 
the way people think, feel, and behave. Stigma can be particularly harmful to this population when it 
interferes with engagement in substance use treatment because this has direct implications for staying 
out of the legal system. However, there are no current stigma-reduction interventions for justice-
involved people.
Who is the target audience?
Justice-involved people who have SUD may be interested to hear about this new intervention that could 
help them better navigate stigma. In addition, mental health providers, particularly those who work in 
the criminal justice system, may fi nd that this intervention would be benefi cial for the clients they serve.
Is this based on established work, or does it draw from other existing work?
C-STARR was adapted for justice-involved people from an existing intervention designed to reduce 
addiction self-stigma (developed by Dr. Jason Luoma). Dr. Luoma’s addiction self-stigma intervention 
was developed using the theory of acceptance and commitment therapy, which, in short, suggests that 
many of the emotional diffi  culties humans experience are a result of trying to avoid experiencing stress 
or pain. Research has shown that Dr. Luoma’s intervention is eff ective in reducing substance use and 
shame, as well as improving substance use treatment retention (Luoma et al., 2012; Gul et al., 2020).
How does your project or initiative work?
Dr. Kelly E. Moore and her research team are currently pilot testing in-person and virtual C-STARR 
groups with adults enrolled in drug recovery court and probation-required substance use treatment 
settings in Northeast Tennessee. C-STARR involves 3 two-hour group sessions that involve clarifying 
one’s values, understanding how stigma interferes with living a full life, committing to engage in valued 
action even when confronted with stigma-related barriers, and learning how to accept and cope with 
diffi  cult thoughts and emotions that come up along the way.
What are the results? If results are not yet available, what results do you hope to achieve?
Dr. Moore’s lab is collecting pre- and post-intervention data to determine whether C-STARR can improve 
levels of distress, coping with stigma, and engagement in treatment, among other outcomes. We are 
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also conducting qualitative interviews with people who complete the intervention to better understand 
how the intervention can address their experience with stigma. Qualitative interviews conducted thus 
far suggest that participants enjoy participating in C-STARR and fi nd it helpful for coping with stigma. 
Broadly, we hope this intervention can help justice-involved people with SUD with successful recovery 
and community re-entry, and spark a bigger conversation about addressing the lack of stigma reduction 
eff orts in the criminal justice system.
Contact information





14.  Creating Civic Engagement to Improve Healthcare Access for People who Use Drugs 
in Arizona: The Drug Policy Research and Advocacy Board
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What is your project or initiative?
The Arizona Drug Policy Research and Advocacy Board (DPRAB), is a civic engagement intervention 
involving the development and support of a statewide coalition of people with lived experience, 
research partners, harm reduction organizations, and providers of medication for opioid use disorder 
(MOUD). The key outcome is a sustained consumer-driven healthcare reform movement. The creation 
and development of this partnership emerged from funded research projects focused on MOUD 
system improvement (Vitalyst, FORE). Improving the MOUD system in Arizona is our initial focus. 
The co-chairs are Christopher Abert, Executive Director of the Southwest Recovery Alliance and Nick 
Stavros, CEO of Community Medical Systems. The DPRAB was modeled after a local drug user union, 
Community Health Advisory Committee (CHAC) located in Phoenix, Arizona.
Why did you develop this?
Our recent survey of people who use drugs in Maricopa County (Phoenix) conducted with the CHAC 
found that 40% of respondents avoided seeking medical care in the past year because they were afraid 
of being mistreated by healthcare providers. Those who did seek medical care at urgent care and 
emergency room settings reported three key experiences at the hands of healthcare providers:
1. medical maltreatment (wrong or denied treatment), 
2. socially expressed stigma and discrimination, and 
3. verbal or physical abuse. 
Medical providers ignored healthcare complaints to instead fi xate on illicit substance use, even when 
this was not the reason for healthcare seeking. A second study demonstrated the need for pharmacy 
practice change to reduce pharmacy staff  enactment of stigma at the time customers request to 
purchase syringes without a prescription and for likely injection drug use. The confl uence of COVID-19, 
HIV, Hepatitis C, and overdose pandemics has revealed systemic MOUD system inequities that must be 
corrected. Temporary policies to improve MOUD patient safety and treatment access during COVID-19 
created a policy window of opportunity to examine the evidence of systems improvement from these 
key and temporary changes. The DPRAB has been designed and will be tested as a civic-engagement 
systems change model. The fi rst focus is MOUD systems change in Arizona. Establishing the DPRAB, 
civically engaged community-provider-policy partnership will help assure future and lasting systems 
change, producing equity of access and improving community health by reducing overdoses, increasing 
overall health, and reducing incarceration in Arizona.
Who is the target audience?
Healthcare practitioners (MOUD initially), policy makers in local, state and federal settings (legislative, 
administrative), and people in the community with lived experience who want to develop and share 
their voice.
Is this based on established work, or does it draw from other existing work?
Yes on both counts.
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How does your project or initiative work?
This DPRAB intervention involves: 
• Recruitment and support of DPRAB members from across Arizona urban, rural, suburban and 
tribal communities with personal lived experience using illegal and/or stigmatized drugs and/or 
professional experience working in evidence-based drug treatment programs. Membership by 
professionals in other healthcare settings will be expanded in future years. 
• Individuated group member training with focus on 1) community-driven research, 2) 
systems improvement evidence and 3) how to develop and engage in evidence-based policy 
communications.
What are the results? If results are not yet available, what results do you hope to achieve?
Key outcomes include: 
1. improved member self-effi  cacy to engage in evidence-based policy communications to improve 
the health of people who use drugs through systems change, 
2. improved perceptions of credibility among practice partners and policy makers (administrative 
and legislative) about evidence for systems change, and
3. development of community relationships with practice and policy partners to advance systems 
change.
Contact information
Danielle Russell, Arizona State University 
dmrusse4@asu.edu
Keywords
harm reduction, lived experience, medications for opioid use disorder, policy and guidelines
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15.  Creating Long-Lasting Stigma Reduction among Community Pharmacists
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Mark Strand, PhD
What is your project or initiative?
Creating Long-Lasting Stigma Reduction among Community Pharmacists
Why did you develop this?
Pharmacists have been shown to have signifi cant stigma toward patients with opioid misuse behaviors. 
Stigma among community pharmacists is highly concerning and can have long term negative public 
health impacts because of the proximity of community pharmacies to all patients, the trusted nature of 
the profession, and the fact that every single opioid prescription must cross the hands of a pharmacist. 
Stigma reduction among community pharmacists is vital to provision of appropriate prevention, 
education, and follow-up care in order to address the opioid crisis. The Opioid and Naloxone Education 
(ONE Rx) program aims to equip pharmacists to screen patients for opioid misuse and overdose risk, 
to deliver key opioid-related interventions to patients based on their individual risk for misuse and 
overdose, and ultimately reduce opioid-related harms. It was implemented in 2018 along with a 3-hour 
educational training for pharmacists. From the outset, the researchers identifi ed stigma of pharmacists 
as a potential barrier to implementation and maintenance of the program’s pillars. Thus, components 
within the training to target stigma reduction were developed.
Who is the target audience?
The pharmacy workforce as well as the broader healthcare workforce network are target audiences as 
principles could be applied across disciplines.
Is this based on established work, or does it draw from other existing work?
It is based on established work with the integrative pedagogical perspective, known stigma reduction 
strategies, stigma-free language, and the social distance scale. It draws from other existing work related 
to the (Opioid and Naloxone Education) ONE Rx project. www.onerxproject.org
How does your project or initiative work?
The program works through delivery of stigma-reduction education simultaneously with opioid-related 
education that is directly connected to the work of the healthcare practitioner. Verbal explanation and 
diagram representation of information, application exercises, self- refl ection/examination, drawing 
analogies, role-play, and video demonstration are used in stigma-reduction educational content 
delivery. Procedural information related to educating patients about naloxone, assessing patients 
for opioid-related risks, and other practitioner- specifi c on-the-job tasks is presented in conjunction 
with stigma-reduction content. In this way, refl ections, examples, and analogies allow healthcare 
practitioners to directly apply and integrate stigma-reduction approaches and language into actions 
they perform regularly. Finally, the project involves measurement of attitudes and stigma (via the social 
distance scale) and practice behaviors at baseline, after the education, and 12 months later.
What are the results? If results are not yet available, what results do you hope to achieve?
This program is associated with signifi cant reductions in negative attitudes and stigma among 
pharmacists immediately after the education and 12 months later. It is also associated with signifi cant 
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practice behavior change. Compared with baseline, pharmacists in the program engaged in more 
frequent counseling on opioid misuse and overdose, discussion of medication take back programs, 
and naloxone prescribing 12 months after completion of the training. Thus, a signifi cant reduction in 
negative attitude and stigma from baseline immediately after the training and 12 months later suggests 
a true and sustained adjustment in the pharmacists’ willingness to engage with, form relationships with, 
and care for patients with opioid misuse.
Contact information
Amy Werremeyer, North Dakota State University 
amy.werremeyer@ndsu.edu
Keywords
education, pharmacy, storytelling, training, workforce
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16.  Culture Change in the Emergency Department Saves Lives: Reframing the Role of the 
Hospital in Addiction Treatment
Authors
Arianna Campbell, PA-C
What is your project or initiative?
CA Bridge saves lives by making it possible for people who use drugs to get treatment at any hospital in 
the state, wherever and whenever they need it. CA Bridge was offi  cially launched in 2018 with a grant 
from the California Department of Health Care Services Medications for Addiction Treatment (MAT) 
Expansion Project. We are a program of the Public Health Institute, based in Oakland, California. The CA 
Bridge program’s goal is to create 24/7 access to high-quality substance use treatment in every hospital 
in California by 2025.
Why did you develop this?
Over 21 million people in the United States require substance use disorder (SUD) treatment, however 
less than 4 million people receive treatment. When Arianna Campbell, one of the CA Bridge’s Directors, 
supported her sister through a battle with addiction, she found herself with insider knowledge about 
the stigma held by many medical providers that were creating a barrier to her sister’s treatment. When 
a medical institution gets addiction treatment wrong because of stigma that has permeated its walls, 
the stakes are high. CA Bridge aims to build a system that any patient or family member, like Arianna, 
can access. We know that it comes down to the smallest details, like how the family is greeted by the 
emergency department (ED) nursing staff . CA Bridge has set out to redefi ne 24/7 access to treatment in 
the ED so that patients and families can access high-quality resources whenever they are needed.
Who is the target audience?
This session will be relevant for anyone working to bring patient-centered and respectful treatment to 
people who suff er from addiction. Participants will receive links to our project toolkits so they may take 
action in their own communities.
Is this based on established work, or does it draw from other existing work?
CA Bridge is an ongoing program that is not only funded by the state of California to provide technical 
assistance but is also funded by the FORE Foundation and other sources to provide coaching on a 
national level.
How does your project or initiative work?
Programs in the model of CA Bridge have proved successful in diverse settings, including academic, 
non-academic, urban, and non-urban. Substance Use Navigators (SUN), who have been trained in 
CA Bridge model of care, are proven changemakers in these same hospitals and also serve as part of 
SUD infrastructure in California. These 200+ programs across California include rapid access to MAT 
and linkage support by substance use navigators while promoting a culture of harm reduction in the 
hospital setting.
What are the results? If results are not yet available, what results do you hope to achieve?
To date, hospitals supported by CA Bridge have led to the identifi cation of over 22,000 patients with 
opioid use disorder and the initiation of over 12,000 MAT starts. SUNs have seen over 46,000 unique 
patients (data as of March 31, 2021.) Our initial cohort consisted of 32 sites, rapidly expanded to 52 and 
now stands at 208 acute care hospitals throughout California. Between April 2019 to June 2020, almost 
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12,000 patients were identifi ed at CA Bridge sites, almost 8,000 of those patients accepted treatment 
and referral and almost 5,000 patients completed a follow-up visit. Through this scale and volume, we 
have found that EDs and hospitals serve as an important point for initiating treatment for substance 
use disorders. We have also centered on the importance of equitable access to care. In the recent 
article published in Drug and Alcohol Dependence titled “Voting with their feet: Social factors linked 
with treatment for opioid use disorder using same-day buprenorphine delivered in California hospitals”, 
the ED served as an important access point for those with socio-economic disadvantages.
Contact information
Aria Baylor, CA Bridge
ABaylor@cabridge.org
Keywords
education, emergency medicine, medications for opioid use disorder
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17.  Debunked: A Stigma Reduction Podcast
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What is your project or initiative?
In 2019, the Tribal & Rural Opioid Initiative at Utah State University and Utah Public Radio launched an 
innovative evidence-based podcast. Season One was produced as a 15-episode podcast, “DEBUNKED,” 
which premiered in February 2020. Season One introduced lay audiences to harm reduction and 
substance use disorder (SUD) topics. Currently, Season Two is under production. Each episode 
discredits a myth that perpetuates stigma toward substance use, addiction treatment, and/or harm 
reduction interventions. Episodes feature conversations with harm reduction experts, scientists, 
members of Utah tribes, individuals in recovery, and local public health leaders.
Why did you develop this?
The Tribal and Rural Opioid Initiative (TROI) uses a community-based, participatory-action approach 
to creating local change around opioid use disorder treatment and recovery in rural and tribal 
communities in Utah. The TROI mission is to reduce stigma around harm reduction and SUD, and 
provide holistic wellness programs that promote healthier communities throughout Utah’s rural and 
tribal communities. DEBUNKED is a tool for changing perceptions of harm reduction, which often faces 
public opposition.
Who is the target audience?
We hope to reach a diverse audience of health care professionals, law enforcement, addiction and 
recovery specialists, and the general public through compelling stories of people who have experienced 
SUD and housing insecurity by providing insight into the myriad of stigmas they encountered on their 
journey.
Is this based on established work, or does it draw from other existing work?
Research shows reductions in negative public perceptions of drug treatment after exposure to 
people who were successfully helped by such interventions. Research on other populations, such as 
corrections offi  cers, shows that explaining the science of harm reduction interventions may also lessen 
stigma.
How does your project or initiative work?
Season One was completed in March of 2021. The episodes are housed online at Utah Public Radio 
and YouTube to ensure the content is easily accessible. During Season One, and continuing in Season 
Two, we utilize an active promotion method to publicize and boost the visibility of this important 
work and resource to change the culture of the discussion around myths. Our current DEBUNKED 
season addresses myths related to substance use and homelessness, such as “people just need to pull 
themselves up by their bootstraps.” This season highlights the ways harm reduction principles can be 
mobilized to not only address the complexities of drug use among the ~33% of unhoused people with a 
chronic SUD but also highlight the ways harm reduction principles can be mobilized to assist in housing 
needs. Through a combination of live and produced episodes in Season Two, our target audience is 
exposed to evidence-based and personal experiences to dispel myths.
36
What are the results? If results are not yet available, what results do you hope to achieve?
We hope to build empathy and understanding among the general population towards people who 
use drugs and increase acceptance and knowledge of harm reduction strategies. Through stories 
and evidence, we hope that our audience will understand that the idea of harm reduction is a 
compassionate and eff ective approach to supporting people who use substances and face housing 
insecurity.
Contact information
Katie Zaman, Utah State University, Tribal & Rural Opioid Initiative 
katie.zaman@usu.edu
Keywords
harm reduction, indigenous and tribal communities, lived experience, storytelling
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18.  Decreasing Student Nurses’ Stigma toward People with Substance Use Disorder by 
Strengthening Therapeutic Commitment Skills
Authors
Kimberly Dion, PhD, RN, CNE, CARN; Stephanie Griggs, PhD, RN
What is your project or initiative?
Our initiative was to implement a four-hour training targeted anti-stigma training to fi rst semester 
junior student nurses at a university in Massachusetts.
Why did you develop this?
An estimated 35 million people worldwide had a substance use disorder (SUD) in 2019. Nurses, 
including student nurses, report feeling poorly trained and have the least tolerant attitudes towards 
people with a SUD when compared to other health professions. Student nurses struggle with 
diff erences between their personal beliefs and professional expectations. Nurses have been known to 
stigmatize people with SUD. This is due to a common perception that drug use is under the control of 
the person with a SUD. Stigma has a negative impact on the person with a SUD’s emotional and overall 
well-being.
Who is the target audience?
Student nurses are the target audience for this training but the training is appropriate for any health-
related fi eld.
Is this based on established work, or does it draw from other existing work?
This training is drawn from existing work and the development of an established curriculum for student 
nurses.
How does your project or initiative work?
We used a therapeutic commitment theory to guide our study with the intent of increasing 
practitioners’ feelings of role adequacy, role legitimacy, and role support. We used a quasi-
experimental, repeated measures survey design where all students (n=126) received a four-hour 
anti-stigma intervention that included the physiology of addiction, screening tools for SUD, intranasal 
naloxone training, and presentations by two individuals with a lived experience of SUD. All students 
received the training even if they did not participate in the study. The baseline survey was administered 
prior to the students’ clinical practicum. A certifi ed addiction physician provided the training on the 
physiology of addiction and focused the content on the role of the nurse. One individual with a lived 
experience was a mother who had lost her child to an opioid overdose. The other individual with a lived 
experience was a person in recovery. Both presenters shared their stories and illuminated how stigma 
impacted them and their loved ones. A special emphasis was placed on including their experiences 
with nurses and other health care professionals. Additionally, quotes from the experiences of people 
who inject drugs with nursing care in an acute care hospital were shared with the students. Students 
were instructed in the use of a variety of screening tools, the use of recovery-focused language, trauma-
informed concepts, and were provided with electronic resources to utilize in their clinical setting. 
We used the 20-item Drug and Drug Problems Perception Questionnaire (DDPPQ) ( = 0.79), and the 
8-item Perceived Stigma of Substance Abuse Scale (PSAS) ( = 0.82) at baseline and post-intervention to 
measure stigma and attitudes toward those with a SUD.
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What are the results? If results are not yet available, what results do you hope to achieve?
Following the four-hour educational intervention (n=109), there was a signifi cant improvement in 
overall therapeutic attitudes (M=-14.8, p < 0.001) and perceived stigma (M=-0.87, p=0.014). Paired 
t tests were used to determine the mean diff erences in the total DDPPQ score (overall therapeutic 
attitudes) and in the total PSAS score. This intervention can serve to increase a student’s awareness of 
the physiology of addiction, the impact of stigma and discrimination, and the importance of screening 
tools to identify those at risk for SUD. It is important for educators to develop strategies to increase 
student nurse engagement, motivation, and work satisfaction to improve care for people with SUD. 
Incorporating anti-stigma educational approaches may lead to more nurse involvement, compassionate 
connected care, and help to build therapeutic commitment in student nurses caring for people with 
SUD.
Contact information
Kimberly Dion, UMass Amherst College of Nursing
kadion@nursing.umass.edu
Keywords
education, lived experience, storytelling, training, trauma-informed, workforce
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19.  Decreasing the Stigma of Addiction through the Integration of Medication-Assisted 
Treatment (MAT) Education into a Graduate Nursing Curriculum
Authors
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What is your project or initiative?
This three-year SAMSHA-funded project integrates medication-assisted treatment (MAT) education into 
a Master of Science in Nursing Program so future advanced practice registered nurses (APRNs, also 
known as nurse practitioners) can obtain a DATA waiver to prescribe buprenorphine for the treatment 
of medications for opioid use disorder (MOUD) and provide ongoing recovery support for people living 
with opioid use disorder (OUD).
Why did you develop this?
There is a shortage of MOUD providers available to treat people living with OUD. APRNs, in 
collaboration with MAT prescribing physicians, can increase the number of qualifi ed providers and 
improve access to MAT services for people living with OUD, particularly in rural areas. Providing MOUD 
treatment in a variety of settings, including primary care, will increase access to OUD treatment.
Who is the target audience?
The project involves graduate nursing students at Ursuline College in Cleveland, Ohio, a liberal arts 
college with a well-established and highly ranked graduate nursing department. The goal is to educate 
230 graduate nursing students during the three-year grant period (September 2019 – September 2022).
Is this based on established work, or does it draw from other existing work?
The project draws upon existing education models developed by the Program Evaluation and Research 
Unit (PERU) at the University of Pittsburgh School of Pharmacy. This is the fi rst collaboration between 
PERU and a graduate nursing program. PERU is an established provider of healthcare systems technical 
assistance, evaluation, and research in the areas of substance use disorder (SUD) prevention and 
veteran health. Initiatives include integration of patient SUD screening in multiple public health and 
safety settings and use of the Systems Transformation Framework (STF) to optimize healthcare service 
quality, patient outcomes, and cost savings. The STF utilizes standardized real-time data collection and 
analysis to drive continuous quality improvement. PERU collaborates with academic institutions to 
increase SUD education with a variety of healthcare professionals in the medicine, nursing, pharmacy, 
physical and occupational therapy, clinical rehabilitation and mental health counseling, counseling 
psychology, and social work disciplines.
How does your project or initiative work?
MAT includes more than prescribing and monitoring medications for OUD. A relationship based upon 
therapeutic communication skills and trust is needed between the provider and client. Stigma related 
to people living with OUD is a barrier to establishing this therapeutic relationship. APRNs experiencing 
stigmatizing attitudes towards patients using substances are less likely to obtain a DATA waiver and 
may avoid working with this population. The MAT educational intervention includes 24- hours of online 
MAT education, in-classroom case studies with a faculty champion with expertise in psychiatric/mental 
health nursing and OUD, and clinical observations with addiction medicine physicians in a variety of 
SUD/OUD treatment settings at a major medical center. Educational content focuses on stigma related 
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to people living with OUD and aims to correct common misperceptions and judgmental attitudes. In 
addition to measuring pre- and post- intervention changes in knowledge and perceived competence, 
attitudes and perceptions are measured to ascertain changes related to stigma. Upon completing the 
MAT education, graduates are prepared to apply for a DATA waiver once they are licensed to practice as 
advance practice nurses.
What are the results? If results are not yet available, what results do you hope to achieve?
Results to date are based on analysis of 67 graduate nursing students representing the fi rst fi ve 
cohorts of students in Year 1 of the grant. Signifi cant increases in perceived competence and signifi cant 
increases in improved attitudes/perceptions (decreased stigma-related attitudes and perception) 
toward individuals living with SUD were noted based on the results of paired sample t-test (p<0.05). 
Changes in knowledge were favorable, but not signifi cant. Knowledge questions were examined to 
determine possible content revisions during classroom and clinical observation experiences. The pre- 
and immediate post-test measures provide an opportunity for continuous quality improvement. 
Contact information
Mary Beth Zeni, Ursuline College 
mzeni@ursuline.edu
Keywords
education, medications for opioid use disorder, training, workforce
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20.  DestigmatizER: A Simulation-Based Curriculum Advancing Patient-Centered Care for 
Chronic Pain and Opioid Use in Emergency Medicine
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What is your project or initiative?
The objectives of this project are to:
• identify the evidence-based best practices and communication techniques that most eff ectively 
address issues surrounding chronic pain and opioid use in the emergency department (ED), and to
• create and disseminate an innovative simulation-based educational framework intended to 
develop skills in these practices and techniques among emergency medicine residents.
Why did you develop this?
Despite the prevailing proportion of ED visits by patients with chronic pain and long-term opioid use, 
both patients and clinicians at all levels of training commonly rate these encounters amongst the most 
diffi  cult and dissatisfying. Physicians across specialties, including emergency medicine, overwhelmingly 
report being uncomfortable managing patients with chronic pain and opioid dependence and feel 
that their training in this domain is poor. In addition, the direct and indirect stigmatization of patients 
with opioid use is common, impairing the care of these patients and contributing to several missed 
opportunities for the primary, secondary, and tertiary prevention of opioid-related harm especially 
in the ED. Although we have seen exciting growth, major gaps remain in the education of these 
pathologies as human issues deserving of empathic, stigma-free care, especially in post-graduate 
training. Communication-focused chronic pain management modules are growing in number and 
scope, but are primarily in the form of lengthy online lecture-based video modules. When compared 
to standard didactics, simulation in healthcare education has been shown to be more eff ective in 
teaching empathy skills. However, no simulation-based curriculum targeting the patient-centered care 
of patients with chronic pain and opioid use has been developed for emergency medicine graduate 
and post-graduate training. The resulting training paradigm is expected to become a powerful tool for 
reducing stigma of opioid users and increasing overall competence in their care, thereby leading to 
the elimination of barriers to the eff ective treatment and prevention of opioid misuse, addiction, and 
overdose.
Who is the target audience?
This curriculum will be developed for dissemination to emergency medicine training programs across 
the United States and the world. The intended audience is therefore composed of emergency medicine 
program directors, assistant program directors, directors of simulation, department directors, and 
other agents of change in EDs globally.
Is this based on established work, or does it draw from other existing work?
There is exciting promise of case-based education surrounding opioid-related humanistic issues, 
although none is intended specifi cally for the acute care-minded emergency medicine resident. In that 
vein, we believe the project proposed is innovative because it focuses on the setting-specifi c issues 
in management of chronic pain and opioid-related problems in the ED and simulation-based training 
of specialized skills in eff ective communication, intervention, and harm reduction for new emergency 
physicians.
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How does your project or initiative work?
We plan to develop simulated patient cases and focused debrief frameworks that promote self-
effi  cacy and skills vital to the unbiased patient-centered care of patients with opioid use and chronic 
pain among emergency medicine trainees. This will involve intensive review of available guidelines 
supporting best practices of chronic pain management in the emergency room as well as the literature 
analyzing psychosocial aspects of the pain experience that infl uence the clinician-patient relationship. 
We will conduct further review of the primary literature surrounding principles of simulation in medical 
training, then create and launch the simulation-based curriculum at our institution, incorporating 
feedback prior to reformatting for dissemination.
What are the results? If results are not yet available, what results do you hope to achieve?
Upon achieving the aims of this project, we will have produced an embeddable simulation-based 
curriculum that can be used by any emergency medicine training institution. An instructional module 
will be launched for emergency medicine residents who will complete online surveys prior to 
participation, immediately after completion, and at a delayed point after completion. The surveys will 
examine perceptions including: their performance, the eff ect on topical knowledge, the eff ect on self-
effi  cacy, the likelihood that they will change their future clinical practice, and the barriers to making any 
expected changes. Trainees will also be asked to contribute any suggestions for improvement.
Contact information
Timothy Ibrahim, Loma Linda University Emergency Medicine
tibrahim@llu.edu 
Keywords
chronic pain, education, emergency medicine, simulation, training, workforce
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21.  Destigmatizing Harm Reduction and Medication Treatment Interventions: Curricula 
for Tribal and Non-Tribal Substance Use Treatment Professionals in Rural Utah
Authors
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What is your project or initiative?
Our Utah-based team created novel educational curricula that integrated evidence-based strategies 
for reducing stigma toward medications for opioid use disorder and harm reduction interventions. We 
partnered with a rural community advisory board and members of the Ute tribe to create culturally-
centered curricula tailored to tribal and non-tribal substance use treatment professionals.
Why did you develop this?
A large body of research shows medication treatment for opioid use disorders and harm reduction 
interventions, such as safe consumption facilities, reduce overdose and other health risks. Despite 
this scientifi c support, signifi cant stigma exists toward medication treatment and harm reduction 
interventions among the general public, as well as health professionals, and even addiction 
treatment professionals in the U.S., including in Utah. Such stigma can deter people with opioid and 
other substance use disorders from accessing medication or harm reduction programs, promote 
discrimination by abstinent treatment programs toward patients using medication and harm reduction 
interventions, and limit support for legalizing and funding life-saving harm reduction interventions. 
This stigma is driven in part by inadequate exposure to the evidence base for these interventions and 
limited contact with people who use or provide these services.
Who is the target audience?
Professionals working in Utah’s rural tribal and non-tribal substance use treatment settings, including 
physicians, nurses, therapists, and reception staff .
Is this based on established work, or does it draw from other existing work?
This project was based on a systematic review conducted by the study team of the literature on stigma 
toward harm reduction and treatment interventions, but this systematic review and the resulting 
training were both novel eff orts.
How does your project or initiative work?
The training has been delivered in face-to-face, synchronous online, and asynchronous online formats. 
Each training lasts four hours. All trainings are co-taught by an academic harm reduction researcher 
and a community harm reduction practitioner with lived treatment and recovery experience. Face-to-
face and synchronous trainings include interactive components, including case studies, small group 
discussion, and open large group discussion. The asynchronous format delivers the training via video 
modules. All formats are assessed using pre- and post-training surveys asking about dimensions of 
stigma. These surveys included questions about factual knowledge of intervention effi  cacy, changes in 
attitudes towards interventions, and changes in intended actions, such as intention to refer people to 
syringe services.
What are the results? If results are not yet available, what results do you hope to achieve?
Initial analyses of face-to-face and synchronous online training data from 110 participants who 
completed surveys indicate the training signifi cantly decreased the total stigma score toward 
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medication treatment and harm reduction. At the individual survey item level, 6 of the 22 items showed 
signifi cant change.
Contact information
Erin Fanning Madden, Wayne State University School of Medicine 
efmadden@wayne.edu
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22.  Do Licensure Questions Aff ect Stigma and Help-Seeking Behaviors for Physician 
Assistants?
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What is your project or initiative?
We analyzed initial licensure (n=51) and license renewal (n=47) applications for physician assistants 
(PAs) with regard to questions about physical and mental health. Applications that asked questions 
about current or recent impairment were considered consistent with the Americans with Disabilities 
Act (ADA), while applications that asked about remote history (e.g., “have you ever been diagnosed with 
a mental health condition?”) or were speculative in nature (e.g., “...could possibly cause impairment”) 
were considered not to be consistent with the ADA. We also surveyed practicing PAs to explore the 
relationship between these questions and concern about seeking help for health concerns.
Why did you develop this?
Analysis of the licensure applications for physicians revealed that 2/3 of states had physician licensure 
applications that were NOT consistent with the ADA with regard to mental health. The same study 
found that almost 40% of physicians would be reluctant to seek help for a mental health issue due to 
concerns about licensure repercussions. We sought to explore these questions with practicing PAs.
Who is the target audience?
Practicing clinicians, members of licensing boards, and leaders within the health professions.
Is this based on established work, or does it draw from other existing work?
This is based upon existing work published about physicians.
How does your project or initiative work?
Phase 1 involved the analysis of state licensure applications and renewal applications. Phase 2 involved 
a survey of over 1,500 PAs from nationwide survey administered by the American Academy of PAs.
What are the results? If results are not yet available, what results do you hope to achieve?
Only 18 states were consistent with the ADA for both initial and renewal licensure applications. The 
results of our survey found that 35% of PAs would be reluctant to seek help for a mental health or 
substance use issue due to concerns about licensure (only 12% were reluctant regarding physical 
ailments). PAs in states with licensure language that was inconsistent with the ADA were signifi cantly 
more likely to be reluctant to seek care due to concerns about repercussions on licensure – this was 
true for both physical ailments as well as mental health and/or substance use concerns. Our results 
show considerable stigma with regard to mental health and substance use within our professional lives, 
and state licensure questions seem to adversely infl uence this. We can do better.
Contact information
Chris Roman, Butler University 
croman@butler.edu
Keywords
mental health, policy and guidelines, workforce
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23.  Eff ect of Implementation of a Medication Assisted Treatment and Education 
Program on Perceived Stigma of Healthcare Providers in an Emergency Medicine 
Department 
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What is your project or initiative?
This project is designed to evaluate stigma of healthcare providers towards those with opioid use 
disorder (OUD) and whether or not stigma is aff ected by educating healthcare personnel about OUD 
and stigma. This project also will measure the impact of a Medication Assisted Treatment (MAT) Pilot 
Program on healthcare providers’ perceived stigma towards individuals suff ering from OUD.
Why did you develop this?
Stigma towards various populations has been shown to negatively impact healthcare outcomes. This 
specifi c project has been developed in order to see if stigma can be improved with education and 
understanding of a population (those with OUD) through adopting a new MAT pilot program directly 
addressing the unique medical needs of this population.
Who is the target audience?
The target audience is emergency department (ED) staff : physicians, pharmacists, residents, nurses.
Is this based on established work, or does it draw from other existing work?
This project draws from other existing work.
How does your project or initiative work?
In conjunction with the initiation of our MAT pilot program, there are educational grand rounds, 
discussions at shift change, educational presentations in weekly resident conference, and integrated 
meetings at an administrative level concerning ED protocols.
What are the results? If results are not yet available, what results do you hope to achieve?
Results are not yet available as we are in the data collection phase. We hope to see a progressive 
improvement in scores on the Perceived Stigma of Substance Abuse Scale (PSAS: validated stigma 
questionnaire) with increased amount of stigma education, awareness, and familiarity with MAT 
protocols.
Contact information
Zachary Hollins, University of Tennessee, Nashville Campus at Ascension St. Thomas 
zhollin1@uthsc.edu
Keywords
education, emergency medicine, medications for opioid use disorder, training, workforce
47
24.  Ending Self-Stigma for Justice-Involved Populations Being Treated with Medications 
for Opioid Use Disorder
Authors
Shannon Gwin Mitchell, PhD; Alicia A. Lucksted, PhD
What is your project or initiative?
We plan to modify an existing evidence-based treatment for adults with serious mental illnesses 
(Ending Self Stigma, ESS) so it can be used to reduce internalized stigma (IS) and problematic 
anticipated stigma (PAS) for justice-involved people being treated with or considering the use of 
medications for opioid use disorder (MOUD).
Why did you develop this?
Stigma has been specifi cally identifi ed as a barrier to providing MOUD to justice-involved populations. 
Such people often experience multiple intersecting stigmatized identities, including their justice 
involvement as well as their histories of substance use. Courts/judges, correctional and community 
supervision agents (as well as family, neighbors, peers and others) may hold negative views of MOUD; 
views that the justice-involved populations may seek to avoid and are susceptible to internalizing, 
creating additional barriers to treatment entry and continued engagement. Unfortunately, despite 
these myriad harms to the core goals of addiction treatment, and to MOUD adherence specifi cally, 
there are no evidence-based interventions available to help justice-involved individuals using MOUD 
avoid or resist PAS and IS.
Who is the target audience?
Justice-involved people with OUD who are engaging in recovery treatment either during their 
incarceration or while on probation or parole are the target audience.
Is this based on established work, or does it draw from other existing work?
The proposed project builds on Dr. Lucksted’s existing evidence-based intervention, Ending Self-Stigma 
(ESS). ESS is a 9-session, manualized, group-delivered intervention designed to help adults with serious 
mental illnesses gain tools and strategies to eff ectively cope with societal stigmatization and to reduce 
IS and PAS. To date, it has been tested in two large randomized clinical trials, one in community-based 
psychosocial rehabilitation programs and one in Veterans Administration outpatient mental health 
programs. Additionally, the project builds upon our team’s extensive research with MOUD for justice-
involved people, including studies of interim methadone, methadone, buprenorphine, extended-release 
naltrexone, and extended-release buprenorphine. Successful initiation of MOUD during incarceration 
may still result in rapid treatment drop-out or failure to engage in care upon release. Perceived stigma 
is often noted as a reason for either not initiating MOUD treatment or discontinuing care.
How does your project or initiative work?
This three-phase project will occur over the course of a year and involve the following activities: 
1. Conducting a series of stakeholder focus groups and individual interviews with clients, clinicians, 
and community corrections staff  in order to gather diverse input regarding modifi cations for the 
original ESS to make it better suited to the stigma experienced by justice-involved populations 
receiving MOUD. The fi ndings will be used to generate a fi rst version of the new intervention 
(Ending Self Stigma: Medications for Justice-involved People; ESS-MJP).
2. Refi ning the intervention via serial, iterative pilot administrations of ESS-MJP. This will comprise 
two group treatment cycles of approximately 8 participants each, with participant feedback 
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following each session-by-session to refi ne the intervention and assess feasibility and acceptability 
in the intervention’s content. 
3. Finalizing the ESS-MJP intervention manual and materials based on the pilot testing phase, to be 
tested in a larger trial.
What are the results? If results are not yet available, what results do you hope to achieve?
It is our hope that the project will successfully develop an intervention with the potential to build 
resiliency among justice-involved people who could benefi t from MOUD and enhance their treatment 
outcomes. Modifying ESS for justice-involved populations with OUD has the potential to improve 
outcomes in two important ways: 
1. by increasing receptivity to MOUD for incarcerated populations not currently receiving medication 
(e.g., engaged in drug counseling programs following detox), and 
2. by improving treatment compliance and retention for justice-involved people on MOUD programs 
in the community.
Contact information
Shannon Gwin Mitchell, Friends Research Institute 
smitchell@friendsresearch.org
Keywords
criminal justice, medications for opioid use disorder, mental health, training
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25.  Exploring the Eff ect of Personal Narratives of People Who Use Drugs
Authors
Jessica Holden, DNP, RN-BC; Kimberly Dion, PhD, RN, CNE, CARN; Joan Kuhnly, DNP, NNP-BC, APRN, 
IBCLC, CNE; Amy Davis
What is your project or initiative?
This project intends to expose participants to a documentary produced by Tapestry Health Systems 
that includes personal portrayals of people who use drugs to assess their eff ect on community 
members’ stigma toward people who use drugs. To create this documentary, Tapestry has engaged 
local participants and community members to provide context into the lived experience of people who 
use drugs. Anonymity has been maintained for those who wish without altering the message of the 
insights they have to share. The documentary, which is currently still in production, will be about an 
hour long and is set to be completed by late spring of 2021. The fi lm is a portrayal of the experiences 
of people who use drugs and their experiences of perceived and societal stigma. Exploration of the 
signifi cance of harm reduction is another fi lm component and is presented via the voice of the client, as 
well as harm reduction workers. Stigma is addressed from both personal perspectives, refl ections, and 
observations throughout the documentary. Perceived stigma will be measured pre- and post-survey 
using the Perceived Stigma of Substance Abuse Scale (PSAS) and refl ection will be used with willing view 
participants to assess the eff ect of the documentary on stigmatic tendency. 
There are three specifi c aims for this project, namely:
1. To determine if the participant’s perceived stigma changed over time (pre/post-intervention), 
2. To explore diff erences in perceived stigma by age, race, religion, educational level, experience with 
persons with substance use disorder, and 
3. To explore the impact of this documentary on the participants’ intent to change their attitudes or 
behaviors towards persons who use drugs.
Why did you develop this?
Substance use is identifi ed as a leading health indicator by the US Offi  ce of Disease Prevention and 
Health Promotion. Substance use disorder (SUD) is not only a health-related problem but a fi nancial 
one as well, including lost productivity and crime-related costs estimated to exceed $600 billion 
annually (Healthy People, 2030). The US Offi  ce of Disease Prevention and Health Promotion also details 
how community and legal responses to substance use complicate the public health issue. Evidence 
indicates that current stigmatization of persons who use drugs inhibit the ability to promote health in 
this population. People who use drugs often delay health care, don’t disclose their drug use, and seek 
alternative ways to manage their health care issues than to seek care. Societal stigma exists toward 
people who use drugs. A change of mindset, including embracing concepts such as pragmatism, in that 
none of us have perfect health behaviors, and incremental improvements of decreased stigma can take 
years. Common themes among community members’ perspectives and attitudes toward people who 
use drugs include “being dangerous and self-destructive”, and “the tendency to want to avoid ‘these 
people’”. Evidence to support self-stigma exists, which may explain why persons who use drugs are 
hesitant to seek healthcare for fear of being judged or treated poorly. The use of personal narratives, 
especially those who incorporate barriers to treatment, may be useful in decreasing stigma and 
increasing public support for improving access to services and healthcare for people who use drugs.
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Who is the target audience?
Participants for this initial project will be local community members. However, the documentary may 
also serve to be eff ective for other specifi c groups in the future such as healthcare providers.
Is this based on established work, or does it draw from other existing work?
This project draws from existing work. Evidence exists to support the idea that the use of personal 
narratives has the potential to aff ect mindsets.
How does your project or initiative work?
Participants in the project will be asked to complete the PSAS via an anonymous online survey 
immediately prior to viewing the documentary. Then, immediately following, participants will be 
asked to complete an anonymous survey of open-ended refl ection questions and the PSAS. The open-
ended questions ask about the participant’s intent to change behaviors as a result of viewing the 
documentary. The results of the survey will be analyzed to determine if participants’ perceived stigma 
changed as a result of viewing the documentary.
What are the results? If results are not yet available, what results do you hope to achieve?
Because the project will commence when the documentary is debuted in September 2021, we do not 
have results to share at this time. However, our analysis will include both qualitative and quantitative 
methods and it is our hypothesis that participant’s perceived stigma will decrease following the 
intervention.
Contact information





26.  Exploring the Impact of Intersecting Prescription Opioid and Chronic Pain Stigmas on 
Pain Management in Cancer Survivors
Authors
Hailey Bulls, PhD
What is your project or initiative?
Development of a multi-level intervention to mitigate the negative consequences of intersecting 
stigmas associated with opioids and chronic pain in cancer survivors.
Why did you develop this?
Cancer survivors experience high rates of chronic pain, with up to 40% of cancer survivors reporting 
pain months or years after the completion of their curative treatment. Though a high proportion of 
patients are exposed to opioid pain medications during active treatment, less is known about the 
safety and effi  cacy of opioid pain medications for cancer survivors with chronic pain. Thus, survivors 
and their clinicians are stuck between two worlds – cancer pain, in which opioids are standard of 
care, and chronic pain, in which long-term opioids are known to carry signifi cant risk, including opioid 
misuse, addiction, and death. This challenge is particularly impactful amid the opioid epidemic, in 
which negative attitudes towards opioids and addiction are prevalent. Cancer survivors with chronic 
pain may be at particularly high risk for intersectional stigma arising from addiction stigma (associated 
with prescription opioids) and chronic pain stigma. Unmitigated stigma is associated with worse health 
outcomes and may result in undermanaged pain and worse quality of life in cancer survivors. As the 
population of cancer survivors on long-term opioid therapy continues to increase, understanding and 
mitigating stigmatizing experiences in this group is a time-sensitive, critical need.
Who is the target audience?
Cancer survivors who report chronic pain, their caregivers/family supporters, and clinicians who treat 
cancer survivors as part of their practice (oncologists, primary care physicians, pain management 
specialists, and palliative care physicians, among others.) Each group will be included in the study and 
resulting multi-level intervention to mitigate stigma in cancer survivors.
Is this based on established work, or does it draw from other existing work?
Prescription opioid and chronic pain stigmas are emerging areas of literature and have been described 
in other patient groups. For example, our prior pilot work in patients with active disease indicated 
that a majority of survey respondents reported experiencing at least one aspect of opioid stigma 
(most commonly, fears of addiction and diffi  culty discussing opioid pain management with healthcare 
providers), and over a quarter reported potentially maladaptive behaviors as a result (most commonly, 
taking less medication than needed, resulting in excess medication available in the community). 
However, there is little literature that explores how prescription opioid and chronic pain stigmas 
may intersect to aff ect pain management and quality of life in cancer survivors. Encouragingly, prior 
literature in other medical (e.g., HIV) and mental health populations suggests that stigma can be 
eff ectively addressed and mitigated.
How does your project or initiative work?
This is a qualitative study to understand the experience of co-occurring prescription opioid and 
chronic pain stigmas in cancer survivors. Guided by the Health Stigma and Discrimination Framework, 
we will design and conduct in-depth qualitative interviews exploring prescription opioid and chronic 
pain stigma with 20 cancer survivors with moderate-to-severe pain, 20 caregivers, and 20 clinicians 
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who treat chronic cancer pain in outpatient settings. Recruitment will begin with clinicians, including 
oncologists, primary care physicians, pain management specialists, and palliative care physicians. 
Eligible patients will be cancer survivors who are prescribed opioids for moderate- to-severe cancer 
pain (4+/10 for the past 3 months). Participating patients will be asked to identify a caregiver who meets 
study eligibility criteria. Upon completion of the interviews, we will conduct thematic analysis to identify 
modifi able contributors to stigma in cancer survivors, with an emphasis on potential targets of future 
interventions. We will also explore long-term health outcome that we anticipate will be associated with 
stigma in survivorship.
What are the results? If results are not yet available, what results do you hope to achieve?
The results of this work will provide foundational information for the development of a multi-level 
behavioral intervention to mitigate the impact of stigma and improve pain management in cancer 
survivors with chronic pain.
Contact information
Donna Olejniczak, University of Pittsburgh 
dmo36@pitt.edu
Keywords
chronic pain, lived experience, storytelling
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27.  Healing Stigma through Equity-Informed Hiring, Training and Quality Practices
Authors
Nzinga Harrison, MD; Channah VanRegenmorter, MSSW, PMP; Michael Moeller
What is your project or initiative?
Our overarching project was to create a company culture from scratch that is entirely based on equity 
and empowers all staff  from all areas to create an equitable culture. We sought to build an intentionally 
diverse, stigma-reducing workforce that has skills for increasing equity, reducing disparities, and using 
affi  rmative instead of stigmatizing language.
Why did you develop this?
First, to provide lasting, eff ective care, our team members need to be able to develop deep and 
trusting relationships with our community members. Having staff  skilled in stigma reduction and equity 
conversations are core for achieving these relationships. Second, it’s the right thing to do. Corporations 
have a lot of power to health stigma and ameliorate inequity with intentional policies, procedures, 
and outcomes. Third, it’s pragmatic. To compete in a competitive market, we need to off er people 
something that they believe in and want to be part of. Candidates want places where they feel at home 
and where “there are people who look like me here.” We don’t just have a website with diverse pictures, 
our team has diverse leaders in material roles that are high performing, highly placed role models.
Who is the target audience?
Mental health and addiction boards, executive teams, operational leadership, human resources (HR), 
and quality leaders.
Is this based on established work, or does it draw from other existing work?
The importance of creating healthy, trauma-informed cultures has been proven to help people with 
addiction recover more successfully. We are innovative in seeing racism is a trauma that should be 
explicitly addressed and applied to a people/HR framework. We are also innovative in our investment 
in language, stigma reduction, and equity training. Many companies do not train all team member roles 
in these things, including independent contractors. We are also innovative in our data transparency. 
Achieving racial, ethnic, and LGBTQIA+ equity for our people processes and for our clinical outcomes 
requires transparent measurement and communication.
How does your project or initiative work?
To meet our project goals, we implemented several interventions. The fi rst is equity-informed hiring. 
Our diverse recruiters use data to intentionally recruit from under-represented hiring areas. We screen 
for stigma while screening, asking, “Do you embrace the core principles of whole person care, de-
stigmatization, equity?” Equity-informed team member data tracking. We transparently look at racial 
diversity, LGBTQIA+ diversity, and other factors -- by all team members, by managers, and by directors 
and above. All new team members, whether in information technology or HR, receive equity and 
stigma-informed training and gain skills for practicing affi  rmative language. Our culture is a profound 
conversation about stigma and equity that sets our cultural tone. 
The second is affi  rming corporate language. Reducing stigma is a core value, and our team members 
are trained to treat community members as humans worthy of respect. 
54
The third is team member affi  liation groups. For instance, we have Black Eleanor (an affi  liation group 
specifi c to our organization) and Black Lives Matter employee relation groups. Executive-driven equity 
leadership addresses every signifi cant stigma/racial injustice event through internal communication, 
and, when possible, external communication. We developed reporting that disaggregated our 
outcomes by rate to determine whether we were meeting our equity goals for high quality care for all 
of our community member groups.
What are the results? If results are not yet available, what results do you hope to achieve?
For overall team members, 70% are white, 18% are black and 12% are IPOC/H. For our directors and 
heads of divisions, 71% are white, 10% are Black, and 19% are IPOC/H. For our managers and above, 
63% are white, 20% are Black, and 17% are IPOC/H. For LGBTQIA+ members, 4% are LGBTQIA+ overall, 
10% are Directors or heads of department, and 9% are Managers and above. 
For our mental health improvement outcomes, Black Eleanor members with insurance that covered 
peer support services had a 23% higher depression improvement rate than white members. Black 
Eleanor Members without these services covered by their insurer experienced improvement (70%), but 
it was slightly lower than white members (74%). For our social determinants of health outcomes, 88% 
of our Black Eleanor members and 81% of white Eleanor members receiving Care+ services improved 
at least 5 points on their Recovery Capital Scale. For those whose insurer didn’t cover peer specialist or 
nurse care management services, 57% of Black Eleanor members and 74% of white Eleanor members 
improved without Care+ services.
Contact information
Channah J. VanRegenmorter, Eleanor Health 
channah@eleanorhealth.com
Keywords
person-centered language, training, trauma-informed, workforce
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28.  Hot Button Topic: Combating Opioid Use Disorder Stigma with White Coat Lapel Pins 
at the University of Colorado Anschutz Medical Campus
Authors
D. Tyler Coyle, MD, MS; Sophia Sugar, BA; Arman Saeedi, BA, MPH
What is your project or initiative?
The “X Waiver” authorizes medical providers to prescribe buprenorphine to treat patients with opioid 
use disorder (OUD). Our project is the design, development, and dissemination of white coat lapel pins 
with an “X” design on them – a nod to the X Waiver – to students who complete 8 hours of X Waiver 
training. The pins are supported as part of a SAMHSA-funded initiative to integrate the buprenorphine 
waiver training in the curricula for MD, NP (nurse practitioner), and PA (physician assistant) students 
at the University of Colorado Anschutz Medical Campus. The pin signifi es completion of federally-
approved buprenorphine waiver training and displays the wearer’s interest in talking openly about and 
treating OUD. The “X” pin design is gold and black to refl ect our school colors – Go Buff s! – and could be 
modifi ed to other colors for use at other health professions schools. The pin is intended to be displayed 
to both patients and colleagues alike.
Why did you develop this?
We developed this project to combat OUD stigma among healthcare professionals at the outset of their 
careers. Negative attitudes of health professionals towards patients with substance use disorders are 
common and contribute to suboptimal health care for these patients. Coupling the buprenorphine 
training with a lapel pin provides an opportunity for a conversation about OUD treatment when 
someone asks, “What’s that pin on your coat?” This type of messaging and advocacy can help to engage 
“fence sitters”—people who have some investment in OUD stigma change but limited knowledge about 
how to translate their beliefs into action. 
Who is the target audience?
The target audience is current and future clinical healthcare providers. Our secondary audience is 
patients cared for by pin wearers.
Is this based on established work, or does it draw from other existing work?
Pins and buttons have messaged social change for over a century. In “Button Power: 125 Years of 
Saying It with Buttons,” Christen Carter details the role of buttons in messaging on topics including 
pacifi sm, racism, gentrifi cation, pop culture, and politics. Buttons represent a low-cost, high-visibility 
medium for engaging colleagues and patients about hot button topics. Doctors began wearing white 
coats in the 19th century as a symbol of cleanliness; today, the white canvas of a healthcare provider’s 
coat provides a distinctive backdrop against which to showcase an attractive, understated button about 
an important public health issue.
How does your project or initiative work?
Students in the MD, NP, and PA degree programs at the University of Colorado receive federally-
certifi ed buprenorphine waiver training using the Providers Clinical Support System (PCSS) curriculum 
delivered by addiction experts. Upon completion of the training, learners receive X pins. The X pin 
design is understated; our goal was to create an attractive button that could be a neutral conversation 
starter in a clinical setting. Each ¾” button costs $2.19.
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What are the results? If results are not yet available, what results do you hope to achieve?
The fi rst wave of pins will be distributed to students in Spring 2021. To date, 230 learners have 
completed at least the fi rst 4 hours of the buprenorphine waiver training through this grant eff ort, 
and at least 120 learners have completed 8 hours of the training. The pins have also been distributed 
to approximately 10 attending physicians on the University of Colorado Hospital Addiction Medicine 
Consult Service. The pins are one piece of the SAMHSA grant project’s activities. The grant has also 
supported the creation of the Interprofessional Addiction Medicine Student Interest Group at University 
of Colorado Anschutz Medical Campus, which has held multiple events with overwhelming interest. 
These events have included a virtual Narcan training to over 70 students with in-person distribution 
of Narcan kits, as well as a virtual panel discussion about careers in addiction medicine. Future events 
will include fi eld trips to county drug court and the Harm Reduction Action Center. We hope to spread 
the eff ort to other health professions programs that can use their school colors for the pin. We plan to 
develop and distribute a blueprint to schools to promote interprofessional addiction medicine activities 
for their student bodies.
Contact information
Tyler Coyle, University of Colorado
tyler.coyle@cuanschutz.edu
Keywords
education, medications for opioid use disorder
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29.  “I Do Love My Baby”, Stories of Mothers with Addiction and Recovery
Authors
Mary Ellen Wright, PhD, APRN, CPNP-PC; Heide Temples, PhD, PPCNP-BC, IBCLC
What is your project or initiative?
The project was to give voice to mothers (pregnant or parenting) who have substance use disorder 
(SUD) to share their stories with the world. Stigma for having SUD during pregnancy is often expressed 
by blame and shaming the mother for the misconception that the mother does not care for their infant 
or child. The stories depict the prior trauma experienced by these women and how their child(ren) 
are strong motivators for their recovery. A book titled “I Do Love My Baby”: Stories of Mothers with 
Addiction and Recovery was published on Amazon to share their stories as promised in the qualitative 
research to promote empathy and caring by the public. At the end of each chapter are refl ection 
questions for the reader to consider with the overarching goal to reduce stigma to the marginalized 
population of mothers with SUD. The innovation of this project to address stigma for mothers with 
addiction was multifaceted. University undergraduate research students were included in the data 
collection and had the opportunity to refl ect and contribute each chapter of the book. The students’ 
refl ections of the experience are included in the book and demonstrate increased awareness and 
compassion ignited by the stories of the mothers.
Why did you develop this?
As nurse practitioners, we have heard the language and attitudes expressed to and about women who 
are mothers and have SUD, both in the clinical setting and in public. Mothers with SUD feel reluctant 
to disclose their use and their concerns due to the anticipation of judgment and condemnation. Giving 
voice to the stories of the mothers we hope will bring a new understanding that includes trauma-
informed care and inviting these mothers to engage in healthcare services that are supportive to 
their journey to recovery. We hope the stories inform public policy that addresses SUD to create 
opportunities for recovery instead of punishment.
Who is the target audience?
The target audience of this project is anyone who comes in contact with mothers with SUD, which is 
everyone. The target audience includes anyone who speaks about mothers with addiction and how 
the language they use can infl ict harm on the mother and reduce her likelihood of seeking recovery. 
Included in the audiences are not only healthcare professionals, but families, friends, neighbors, public 
policymakers, members of the press, and the settings of churches, schools, public gathering places and 
social service agencies.
Is this based on established work, or does it draw from other existing work?
The project is a result of an original qualitative research study created by our team. One of the research 
deliverables was the publication of this collection of stories of mothers in book form. The mothers 
were excited at the possibility that their story could be infl uential on the attitudes and beliefs of others 
toward women with substance use disorder. The identifi ers of the stories are removed or changed so 
that the mothers’ stories remain anonymous. In the book are stories of a grandmother, foster mother, 
pregnant woman, and parenting women.
How does your project or initiative work?
The book is available on Amazon. The majority of the proceeds are going to establish a research fund 
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to award to research projects that address pregnant or parenting women with SUD or their infants/
children through the Clemson University Research Foundation. We hope reading the book provides a 
platform for discussion, education and refl ection on how to create a better environment for mothers 
with addiction that removes stigma and condemnation.
What are the results? If results are not yet available, what results do you hope to achieve?
The themes of the qualitative study include:
1. prior trauma for the women in circumstances such as domestic/interpersonal violence, history of 
experiencing maltreatment as a child and loss of loved ones, 
2. multiple prescribed and non-prescribed substances used, 
3. stigma and judgement from healthcare providers during the perinatal period, 
4. positive social support from multiple sources co- occurring with recovery for the mothers, and
5. the children as motivators for recovery. 
The qualitative study is in press in the Journal of Maternal Child Nursing (MCN).
Contact information
Mary Ellen Wright, Clemson University 
Mewrig@clemson.edu
Keywords
lived experience, trauma-informed, women’s health
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30.  Improving Behavioral Health Patient Experiences and Healthcare Worker Wellness 
Through Empathy-Grounded Training in Health Professions
Authors
Melanie Wright, PhD; Elaine Nguyen, PharmD; Mary Nies, RN; Jennifer Adams, PharmD; Krista 
Dominquez-Salazar, PharmD; Tracey Hellem, PhD; Travis Hedwig, PhD; Susan Esp, PhD
What is your project or initiative?
Patients with addiction, mental illness, and developmental disorders (AMD) often feel misunderstood 
by healthcare providers. Stigma and bias toward patients with AMD has been shown to lead to poor 
patient care experiences. Empathy, the process by which a person comes to better understand and 
respond to another person’s needs, reduces stigma and bias. Our project aims to better support 
empathy-grounded care for patients with AMD, identifying, prioritizing, and innovatively addressing 
empathy training needs of future healthcare providers to reduce the eff ects of stereotyping and bias 
negate.
Why did you develop this?
While it is widely accepted that reducing stigma and increasing empathy toward patients with AMD 
is desired, little is known regarding how to develop and sustain the requisite knowledge, skills, 
and attitudes among current and future healthcare workers, so that they are better prepared 
to face challenges encountered in practice. We developed this project because there is a gap in 
interprofessional and innovative approaches to educating frontline healthcare professionals on how to 
provide empathy grounded care to patients with AMD. This project will support identifi cation of gaps 
and approaches to innovate training to address behavioral health knowledge, empathy skills, attitudes, 
and resilience.
Who is the target audience?
We will focus on students enrolled in four health profession programs: nursing (RN), nurse practitioner 
(NP), physician assistant (PA), and pharmacy (PharmD).
Is this based on established work, or does it draw from other existing work?
Our project is based on what is currently known and draws from our previous existing work. Research 
has shown the benefi ts of empathy and related relationship-building activities on health outcomes 
of patients managing chronic illness. Our prior research, a survey of 230 nurses, found that being 
motivated to know what a patient is thinking and feeling is positively linked to nurses’ emotional 
wellness at work. We found that clinicians who were successful at managing agitated or aggressive 
patients described an attitude of empathy as being critical to their approach; however, there is little 
guidance to prioritize training needs of diff erent healthcare providers and even less information on the 
needs of diff erent healthcare students.
How does your project or initiative work?
Enhancing empathy toward patients can improve patient outcomes and healthcare worker emotional 
wellness. There is little guidance in the form of defi ned competencies or recommended approaches to 
educating and training healthcare workers. The proposed project will enhance understanding, prioritize 
training needs and employ innovative approaches to ensure students develop, apply, and sustain 
appropriate empathy skills to support patients with AMD. Applying a consensus building process 
(Delphi process), we will prioritize unmet training needs, gaps, and opportunities for innovation, 
developing an empathy-based training program with directors, faculty, students/alumni, and patients 
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with AMD. We plan to collect preliminary data to assess, tailor, and refi ne the empathy-grounded 
training intervention, addressing profession specifi c, and patient specifi c needs.
What are the results? If results are not yet available, what results do you hope to achieve?
This planned process will generate prioritized lists of research questions, training needs, and innovation 
opportunities for enhancing empathy in the target health professions for patients with AMD. The team 





education, interprofessional, mental health, training
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31.  Innovation and Inclusion: Using Experience Based Co-Design to Improve Care for 
Patients with a Substance Use Disorder
Authors
Tanya Lord, PhD, MPH; Carrie McFadden, MPH
What is your project or initiative?
We used a modifi ed experience based co-design (EBCD) methodology to work in partnership with 
patients who currently use or have a history of using drugs and alcohol to fi rst identify “pain points” and 
then develop solutions to improve healthcare delivery and experience in rural, acute care hospitals.
Why did you develop this?
Programs and initiatives are often created for people with substance use disorder (SUD) but not with 
them. The exclusion of lived experiences is a stigmatizing action and risks creating programs that do 
not address the specifi c needs of those with seeking care whether for their SUD or other medical needs. 
The lack of including the lived experience results in initiatives that are less likely to succeed, resulting 
in patients leaving care against medical orders, facing stigma, and not receiving eff ective care for 
their SUD and other medical conditions. Additionally, staff  and clinicians who do not specialize in SUD 
treatment fi nd that they do not have enough understanding of the disease process and the experience 
of patients to be able to provide care that is truly patient centered.
Who is the target audience?
Inpatient individuals with SUD and the staff  and clinicians who work with them.
Is this based on established work, or does it draw from other existing work?
EBCD was developed in the United Kingdom but was modifi ed to be used with individuals who have 
used drugs or alcohol. Due to COVID-19, we re-designed the process to be used in virtual settings. This 
adaptation provided greater access for patient participants and a layer of security for confi dentiality 
and nervous participants.
How does your project or initiative work?
Our project is using the EBCD model to assess the current landscape and enhance the inpatient 
management of SUD in acute care rural hospitals in New Hampshire.
The EBCD methodology consists of the following steps:
1. Convene focus groups for patients and staff  and clinicians to identify “pain points”. Staff  
representatives come from all areas of the hospital that interact with patients or provide patient 
care, including but certainly not limited to bedside nurses, medical technicians, certifi ed nursing 
assistants, pharmacy, intensive care unit, obstetrics, dietary, and other providers. Patients are 
recruited who have had an inpatient stay in a New Hampshire hospital and have a history or 
currently use drugs or alcohol. Human-centered design strategies are used to encourage creative 
and out of the box thinking for all participants. 
2. Analysis of focus groups. Qualitative analysis of focus group information allows for the 
identifi cation of thematic areas of priority. 
3. The Co-Design meeting will bring together patients, staff  and clinicians to prioritize the items from 
the initial focus groups and generate solutions. Strategies will be identifi ed for implementation 
and evaluation in quality improvement cycles. 
4. The Co-Design workgroup consists of staff , clinicians and patients from the initial focus groups 
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and additional staff  as needed. The work group designs, implements and evaluates the identifi ed 
solution(s).
What are the results? If results are not yet available, what results do you hope to achieve?
Full results from the co-design meetings and workgroup are not yet available. The fi ndings from the 
project so far are the following:
1. Recruitment was most successful when using peer champions, defi ned as individuals with lived 
experience within specifi c communities or populations who can help reach out to individuals who 
tend to distrust healthcare. This method provided opportunities to include individuals who were 
not in recovery or treatment programs. 
2. Themes from the focus groups demonstrated that the primary pain point for patient participants 
was the stigma and inequity of treatment associated with using or having used drugs and alcohol. 
Staff  focused on patient behavior. However, statements such as “Patients lie about substance 
use” were seen as the part of the same problem as “They treat me diff erently when I disclose my 
drug use.” These statements show the urgent need to bring patients and professionals together 
not only to identify problems but to work together towards solutions. Though not yet completed 
this project is providing specifi c insight into how stigma, judgement and lack of understanding of 
addiction as a disease is negatively impacting patients seeking help as well as the professionals 
who want to provide eff ective, compassionate care.
3. This project is being piloted in four rural, acute care hospitals.
When completed each hospital will implement initiatives that have been designed, implemented, and 
evaluated with those with lived experience.
Contact information
Carrie McFadden, Foundation for Healthy Communities/New Hampshire Hospital Association 
cmcfadden@healthynh.org
Keywords
lived experience, training, workforce
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32.  Insights Into Recovery Veteran Video Series: A Veteran-Centered Resource to Support 
a National Quality Improvement Project to Improve Access to Opioid Use Disorder 
Treatment in the Veterans Health Administration
Authors
Mary Ava Nunnery, MPH; Joseph Frank, MD, MPH
What is your project or initiative?
Our project is a series of educational videos that document the real stories of veterans with opioid use 
disorder (OUD) and their experiences seeking treatment. They also highlight a primary care physician’s 
journey in treating this population. The video series will be disseminated as a resource for clinicians and 
staff  in the Veterans Health Administration (VHA) as part of a national quality improvement project, the 
Consortium to Disseminate and Understand Implementation of OUD Treatment (CONDUIT).
Why did you develop this?
We developed this tool to educate clinicians on experiences of stigma in VHA clinics. We hope to change 
some of the culture in the way medications for opioid use disorder treatment are perceived.
Who is the target audience?
The target audience are clinicians and veterans within the VHA.
Is this based on established work, or does it draw from other existing work?
This video series builds on a prior collaboration between an experienced video production team and 
VHA researchers. These videos draw on the expertise and lived experience of members of the VHA’s 
Opioid Addiction & Recovery Veteran Engagement Board. We consulted literature on stigma around 
OUD treatment when creating the interview talking points. We relied on the expertise of the video 
production team in interviewing, recording and editing the materials.
How does your project or initiative work?
In April 2021, the video series was disseminated to implementation teams to support educational 
eff orts and to facilitate practice change among VHA clinicians and staff . We created a Microsoft Stream 
page to house the videos and created a technical guide to support broad dissemination in meetings, 
presentations and email outreach.
What are the results? If results are not yet available, what results do you hope to achieve?
We began dissemination in April 2021 and do not yet have results. We hope our results will improve 
understanding and prompt important conversations about veterans’ lived experience with OUD and its 
evidence-based treatment. Overall, we hope our results will improve access to treatment for OUD and 
thereby save lives.
Contact information
Mary Nunnery, Rocky Mountain Regional VA Medical Center
 Mary.Nunnery@va.gov
Keywords
lived experience, medications for opioid use disorder, story-telling
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33.  Life Unites Us: A Statewide, Evidence-Based Eff ort to Eliminate Opioid Use Disorder 
Stigma
Authors
Övgü Kaynak, PhD; Christopher Whipple, PhD; Erica Saylor, MPH; Jennifer Sittig, MPH; Erika Bonnevie, 
MA; Tim Servinsky, Jr.; Joe Smyser, PhD, MSPH; Weston Kensinger, PhD, CHES; Jennifer Smith
What is your project or initiative?
The Douglas W. Pollock Center for Addiction Outreach and Research at Penn State Harrisburg, The 
Public Good Projects, and Shatterproof partnered with the Pennsylvania Department of Drug and 
Alcohol Programs to implement an interdisciplinary project that uses the collective impact model to 
reduce opioid-related stigma. Life Unites Us (LUU) addresses stigma by pairing a digital media campaign 
with stakeholder involvement, providing resources and assistance to target audiences and community-
based organizations. It further addresses the needs of treatment and recovery providers through 
delivery of a web portal that contains webinar trainings, mapping tools, statewide survey results, and 
stigma-related health indicators.
Why did you develop this?
The opioid epidemic is the deadliest drug crisis in the nation’s history. From 2019-2020, Pennsylvania 
had the third highest number of deaths due to drug overdose in the country. Public awareness of the 
opioid epidemic has increased over time, but stigma surrounding opioid use disorder (OUD) remains a 
signifi cant barrier to treatment and recovery.
Who is the target audience?
Targeting Pennsylvanians with stigma toward OUD, LUU uses statewide contact-based approaches, 
providing the public with educational stigma messaging and personal testimonials of individuals with 
lived experiences.
Is this based on established work, or does it draw from other existing work?
Research has demonstrated that eff ective stigma reduction eff orts normalize substance use disorder 
diagnosis, treatment, and recovery. Successful education and contact-based strategies work to change 
critical infl uencers’ and institutions’ behaviors by educating the public about stigma and showing 
targeted success stories of people who have achieved recovery.
How does your project or initiative work?
Life Unites Us merges evidence-based digital strategies with a collective impact model that relies on 
community networks and individuals as a key component of the program. The campaign utilizes local 
voices to highlight how specifi c groups across Pennsylvania understand OUD and stigma. Importantly, 
this project employs rigorous evaluation methods to determine eff ectiveness. Community-based 
organizations across the state and an advisory board are engaged to support the campaign and 
provide connections to individuals who could provide testimonials; LUU in turn provides content that 
organizations can use to reach their own specifi c audiences. Diverse audiences are reached not only 
through these channels but also through various social media platforms. Social media engagement is 
accomplished through organic reach, paid advertising as well as the use of infl uencers with a personal 
connection to OUD. The campaign represents an updated approach to current strategies to reduce 
OUD stigma and holds promise for scaling and applying to other locations.
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What are the results? If results are not yet available, what results do you hope to achieve?
The baseline and six-month surveys were conducted in June and July of 2020 and February and March 
2021, respectively. Both surveys used a quota-based invitation system to produce a fi nal dataset 
that is representative of Pennsylvania’s population by region, and separately, by age/sex combined 
categories. Overall, the campaign has already produced exceptional results. 26.2% of a representative 
sample of Pennsylvanians (n = 1,034) recalled viewing the campaign over the past six months, equating 
to approximately 2.7 million adult Pennsylvanians over that period; 46.7% of those who viewed the 
campaign (n = 270) feel more prepared to talk with others about stigma against OUD, equating to 
approximately 1.2 million adult Pennsylvanians. Compared to those not exposed to the campaign 
(n=764), we found that more people exposed to the campaign (n=270) strongly agreed that people with 
OUD will, with eff ective treatment, get well and return to productive lives (35.8% vs. 26.7%); agreed 
that buprenorphine is an eff ective treatment for OUD (42.9% vs. 21.2%), and agreed that they would be 
willing to have a person with OUD as a neighbor (52.2% vs. 38.3%).
Contact information
Erica Saylor, Penn State University 
ems6002@psu.edu
Keywords
education, lived experience, policy and guidelines
Disclosure statement
Victoria Bosman from the Department of Drug and Alcohol Programs is on the Stigma of Addiction 
Summit Planning Committee and is involved in the Life Unites Us project and provided edits for the 
abstract. Shatterproof is a partner in the Life Unites Us project and did not have involvement in the 
abstract submission.
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34.  Measuring Arab American Public Stigma towards Substance Use
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What is your project or initiative?
To develop a reliable and valid measure of public stigma to substance use for the Arab American 
community to guide and monitor as an outcome for interventions.
Why did you develop this?
Although substance abuse is a costly public health burden in all racial and ethnic groups, not much 
is known about it among Arab Americans (defi ned as individuals who self-identify as having roots 
in countries of the Middle East and North African where Arabic is spoken). From medical examiner, 
treatment admission, and arrests data, it is clear that substance abuse is present and growing among 
the local Arab American community. An overwhelming barrier to community activities to lower the 
burden of substance abuse among Arab Americans is stigma by the public towards people who use 
and misuse alcohol and drugs. Due to this stigma, people do not want to talk about substance use. 
Reluctance to speak about it by people in the community exists across diff erent cultures but is very 
strong among Arab Americans.
Who is the target audience?
Arab American community.
Is this based on established work, or does it draw from other existing work?
Research has demonstrated that eff ective stigma reduction eff orts normalize substance use disorder 
diagnosis, treatment, and recovery. Successful education and contact-based strategies work to change 
critical infl uencers’ and institutions’ behaviors by educating the public about stigma and showing 
targeted success stories of people who have achieved recovery.
How does your project or initiative work?
To address this barrier, our initial focus is to validate a reliable public stigma measure that can guide 
and monitor the impact of interventions. We are leveraging an ongoing federally-funded Arab American 
Substance Abuse Program Community Coalition by a social service agency and the experience of an 
academic researcher who has published on alcohol and drug use among Arab Americans. To date 
we have identifi ed over 50 possible items for the scale using existing validated scales, had a panel of 
Arab Americans with expertise in behavioral health reduce the number of possible items to 19 based 
upon the utility and acceptance of the wording, and began interviewing people in the community. The 
interviews will address comprehension (do you understand the question) and if so, their response. 
None of the items identify personal or family use. The community group will be recruited to provide 
equal numbers by gender, religion, and nativity (i.e. born in the U.S. or an immigrant). From this we 
intend to develop a scale with high internal consistency across demographic groups. Then we intend to 
replicate the fi ndings in an independent sample along with test-retest reliability. Finally, we intend to 
use the scale with parents at a local school to assess the need to tailor prevention activities.
What are the results? If results are not yet available, what results do you hope to achieve?
We are in the fi eld interviewing community members. We hope to develop a useful scale that is reliable 
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and valid for measuring public stigma for the Arab American community to guide our prevention 
interventions and harm reduction activities.
Contact information





35.  Medication-Assisted Treatment of Substance Use Disorder at Brigham & Women’s 
Primary Care
Authors
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What is your project or initiative?
Providing increased screening for opioid and other substance use disorders (SUD) and medication-
assisted treatment (MAT) in an integrated primary care setting.
Why did you develop this?
The goal is to eliminate the stigma of SUD by treating them like any other chronic condition. Increased 
screening will help identify more patients who are living with SUD and subsequently provide them 
with an opportunity to seek treatment. The trusting relationship patients build with their primary care 
physicians promote their comfort in accepting medical recommendations. Off ering MAT in the primary 
care setting off ers more alternatives for intervention and reduces the stigma associated with having 
to receive treatment from specialized services. Increased screening and reduced stigma will allow for 
more compassionate care as well as decreased mortality and morbidity from SUD.
Who is the target audience?
All primary care patients in the Brigham & Women’s Hospital network. Population statistics would 
suggest that there are many undiagnosed cases of SUD that are not captured by current measures. 
Many patients likely fail to disclose or minimize their use due to the fear and stigma of seeking 
substance use treatment.
Is this based on established work, or does it draw from other existing work?
This program draws on established literature showing the signifi cantly higher success rates of MAT 
over treatment with no medication or with placebos. It also draws on the improved medical outcomes 
shown with integrated primary care approaches in other chronic diseases and integrated behavioral 
health in primary care. Providing MAT at Brigham and Women’s Primary Care is a new initiative, but it 
builds on the extensive SUD experience and programming within the hospital’s network.
How does your project or initiative work?
Beginning with a pilot at four primary care sites connected to the Brigham & Women’s Hospital 
network, the program has begun additional routine screening of patients for alcohol and SUD by 
administering the Audit-C and DAST-1 questionnaires at each annual visit. Patients who display 
increased risk of alcohol or substance use are educated on the options for care that include MAT, 
counseling, partial hospitalization, and treatment referrals, or other resources for intervention. As we 
work to ensure every primary care physician is waivered to administer buprenorphine prescriptions, 
providers are continuing to be educated about language to use to reduce the stigma of substance 
use treatment, the importance of frequent and routine screening, the benefi ts of off ering MAT within 
a primary care setting, the protocols for managing withdrawal, and the processes for in-offi  ce and at 
home induction of MAT. Providers manage patients’ substance use treatment along with social workers 
who provide emotional and behavioral support and nurses who help administer the medication. 
Medical assistants and support personnel are trained to administer initial screenings and fl ag positive 
results for provider follow-up. The entire primary care site is educated about the integrated model 
of substance use treatment and stigma reducing messages including person-fi rst language and 
language that fosters self-effi  cacy and self-worth, the avoidance of jargon to promote clinically accurate 
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terminology in the same way it is used for other medical conditions, and the power of connection, 
community, hope and change.
What are the results? If results are not yet available, what results do you hope to achieve?
The program has started at four pilot sites with a task force of physicians, nurses, pharmacists, support 
staff , and behavioral health experts to develop the appropriate treatment protocols and workfl ows. The 
task force is providing educational workshops for primary care clinics to ensure buy-in for the initiative 
among all staff  at the sites. Since the beginning of the program, additional providers have been 
waivered to administer buprenorphine prescriptions and patients have been successfully screened, 
identifi ed and started on medication-assisted treatment. Ultimately, integrating SUD treatment in 
primary care will reach an additional 150,000 patients with increased screening and identifi cation 
of alcohol, marijuana, tobacco, opioid and other substance use disorders. Along with the increased 
screening will come additional treatment options that will reduce the potential barriers to treatment, 
including allowing patients to detox at home and receive prescriptions at their primary care offi  ce.
Contact information
Brendan McKenna & Janna Levi, Brigham & Women’s Hospital
jlevi@bwh.harvard.edu or blmckenna@bwh.harvard.edu
Keywords
mental health, person-centered language, training, womens health, workforce
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36.  Multiply Stigmatized: The Intersection of Disability, Addiction and Other Identities
Authors
Sharon Reif, PhD; Rachel Sayko Adams, PhD, MPH; Joanne Nicholson, PhD; Monika Mitra, PhD; Emily 
Ledingham Crandall, MPH; Dennis Heaphy, MDiv, MEd, MPH
What is your project or initiative?
INROADS – Intersecting Research on Opioid Addiction and Disability Services – is a NIDILRR-funded 
project that uses mixed methods to examine opioid addiction and treatment among people with 
disabilities, peer support at this intersection, and qualitative work with people with lived experience of 
both disability and opioid use disorders.
Why did you develop this?
People with disabilities are often overlooked when considering other conditions, and evidence about 
substance use disorders (SUD) and treatment in this population is still nascent. Stigma plays a large role 
for both disability and addiction. It further plays a role in many resulting conditions for both disability 
and addiction (e.g., unstable housing, mental disorders, poverty) and with other identities (e.g. race/
ethnicity, LGBT+). These overlapping circles of stigma become additive and can have deep impact on 
the people themselves and on their ability to access services.
Who is the target audience?
Treatment and social service providers and policymakers are the most likely audience, but also peers 
and people with disabilities and/or opioid use disorders.
Is this based on established work, or does it draw from other existing work?
This work stems from our broader project including interviews with people with lived experience, 
and draws upon the extant literature about stigma, critical disability theory, addiction recovery, 
and intersectionality. Critical disability theory is an essential framework to understand the complex 
relationship of disability with other identities. People with both disability and addiction are likely to face 
unique barriers and stigma.
How does your project or initiative work?
The conceptual approach came from literature reviews, research team and advisory board input, and 
feedback as we have presented on this project. We conducted interviews and focus groups with people 
self-identifi ed with a disability and problems stemming from opioid use. We engaged with experts in 
peer supports at the intersection of disability and SUD and with people living with disability who are 
contributing to our knowledge translation eff orts.
What are the results? If results are not yet available, what results do you hope to achieve?
Addiction treatment is often not fully accessible for people with disabilities (PWD) despite the 
Americans with Disabilities Act (ADA). The literature also demonstrates that PWD experience stigma 
and stereotypes that complicate SUD treatment quality and access. Examples of these stigmatizing 
experiences are, “too diffi  cult” to serve, not able to “comply” with treatment or maintain recovery, or 
deserving of pity rather than support. Our qualitative work highlights numerous challenges. Some 
are systemic such as the need for specialized programs for people with multiple and often-complex 
conditions, disability-specifi c accommodations, transportation, and aff ordable quality care. Stigma 
about disability in the context of SUD treatment included concerns about inconveniencing people, 
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being a burden, not wanting to ask for help or bring personal care attendants to sessions, feeling too 
much shame to seek help, or being seen as less of a person. Respondents from other marginalized 
groups expressed further challenges that racism and health inequities bring to treatment and recovery. 
Treatment-specifi c challenges included the need for trauma-informed care since PWD have higher rates 
of trauma, making use of technologies, or considering disability- friendly alternatives when discussing 
relapse prevention strategies. We also heard suggestions for how to reduce this intersectional 
stigma. Sharing stories about recovery is an anti-stigma approach for people with addiction, and can 
be extended to disability populations in recovery. It can reduce shame and increase help-seeking 
among people currently in need and highlights the benefi ts of peer support. Education in the disability 
community about addiction as a chronic disease, support for addiction medications and other SUD 
care, and open discussion of relapse and recovery would also reduce stigma. Eff orts are underway by 
some practitioners and researchers to improve SUD treatment for PWD including mental illness and 
traumatic brain injury. This may include adjustments to traditional modes of treatment, alternative 
treatments, accommodations, and training for clinicians. With this work, we have begun to delve into 
the challenges stemming from stigma and structural barriers to SUD treatment for people with both 
disability and addiction. With the critical disability theory lens, and ongoing eff orts beyond this project 
to reduce stigma around addiction, we are moving forward in the holistic support of people with 
disabilities in their addiction recovery journeys.
Contact information





37.  Online Course “Stigma and Mental Health: Challenges to Building Quality Care,” an 
Innovative Practice from Mexico
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What is your project or initiative?
Implementation of the online course “Stigma and Mental Health. Challenges to building quality care” in 
Mexico.
Why did you develop this?
The stigma and discrimination of people with substance use disorders (SUD) and other mental health 
problems (MHP) produce social inequities that hinder timely care. Research in Mexico shows that 
healthcare personnel are among the leading groups that stigmatize people diagnosed with a severe 
mental disorder or SUD, second to only the family members of aff ected individuals. Previous projects 
focus on the stigma produced by family members; hence there was a need to implement a strategy to 
address the stigma of health professionals towards people with mental health problems and SUD.
Who is the target audience?
The target audience is healthcare professionals who provide clinical and social services to individuals 
aff ected by MHP and SUD.
Is this based on established work, or does it draw from other existing work?
This project stems from the line of research on stigma and mental health, developed by Jazmin Mora-
Rios in Mexico’s National Institute of Psychiatry.
How does your project or initiative work?
Mexico’s National Institute of Psychiatry manages this project through an e-learning platform. The 
online course consists of fi ve modules, built from the research outcome on the experience of people 
with MHP and SUD, family members, healthcare personnel, and the general population. The course 
encourages nationwide healthcare professionals to apply various strategies to foster interpersonal 
contact with people aff ected by mental health problems and SUD.
What are the results? If results are not yet available, what results do you hope to achieve?
Mexico’s National Institute of Psychiatry delivered this free course from July 20 to October 20, 2018. 
A total of 166 healthcare professionals between 21 and 61 years of age participated, the average 
age being 31 years (SD=9.75). Most of the participants (72%) were women from diff erent professions 
(psychology, social work, medicine, and nursing). Four specialized graduate-level tutors supported the 
students’ learning process. Three questionnaires were applied (pre and post-test), including the version 
adapted to Mexico of the Opinion Questionnaire towards Mental Illness (OMI) and qualitative indicators 
to evaluate the course’s eff ect on the participants’ attitudes. The course had an adequate terminal 
effi  ciency (65%) and high acceptance by graduates. Lack of time caused most dropouts. The Cohen’s D 
statistical analysis found signifi cant diff erences in some attitudes measured with the OMI questionnaire 
after taking the course. In another mixed-method assessment that incorporated qualitative indicators, 
the participants mainly reported the following changes after taking the course: 
1. Greater willingness to help, 
2. Acknowledge their stigmatizing attitudes, and
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3. Identify actions to deal with them.
Additionally, participants reinforced positive attitudes. These fi ndings provide preliminary evidence 
of the positive impact of the online course in reducing stigmatizing attitudes of healthcare personnel. 
However, it is necessary to incorporate follow-up studies at three, six, and twelve months, establishing 
control groups to provide evidence on the course’s long-term eff ectiveness.
Contact information
Jazmin Mora-Rios, Mexico’s National Institute of Psychiatry 
morarj@imp.edu.mx
Keywords
education, mental health, training 
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38.  Operation Lighthouse: Bringing the Challenges and Stigma Associated with 
Substance Use Disorder to Light for Startup Companies and Their Employees
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What is your project or initiative?
In collaboration with venture capital fi rm QED Investors and Shatterproof (SP), Operation Lighthouse 
(OL) provided 3 startup companies in QED’s portfolio SP’s “Just Five” program, a series of six brief 
videos about prevention, recognition and management of substance use disorder (SUD) along with 
supplemental content tailored to each lesson to further engage those working in startup companies. 
Access to additional resources on the OL website, including a link to SP’s self-assessment tool and 
information regarding evidence-based treatment was provided.
Why did you develop this?
In 2018 we lost Greg Mazanec after a long battle with SUD. Greg was a son, brother, father, friend, and 
colleague who loved guiding startups through unexpected challenges. OL was created in his memory to 
provide startup leaders and employees with a pathway to personal and corporate health by providing 
SUD education and catalyzing informed discussion to reduce stigma. Entrepreneurs and those who 
work in small startups represent a high risk group for SUD and mental health disorders. SUD are most 
prevalent in people under 30 years of age, matching the demographic of more than 50% of startup 
employees. 15% of persons under 25 have a SUD and another 10% an alcohol use disorder, twice the 
risk of persons over 30. Startup founders are 10 times more likely to have a bipolar disorder. Risk in the 
startup environment is compounded by stressors such as long, irregular work hours. The very success 
of the business may be aff ected if a key employee is struggling with a SUD. Unfortunately, startups 
often lack the resources to assist employees seeking help. Further, stigma remains a signifi cant barrier 
to addressing SUD aff ecting startups.
Who is the target audience?
Entrepreneurs, employees and investors in venture-backed startups.
Is this based on established work, or does it draw from other existing work?
SP developed, in collaboration with experts, educational videos as well as a self-assessment tool 
(Addiction Treatment Needs Assessment ATNA) and guide to treatment (Addiction Treatment Locator 
Assessment and Standards platform ATLAS). These have been adopted by several larger national 
employers. We sought to reach a distinctly diff erent target audience - the smaller startup business.
How does your project or initiative work?
Over the course of three months, OL and QED systematically rolled out educational and informational 
content to the three startups participating in the pilot study and to QED’s own team. The program was 
easily accessible online at no cost to the company. SP’s Just Five videos, which served as the outline 
and anchor of the informational content, were supplemented with links to videos, articles, quizzes, and 
blogs surrounding issues of SUD and other timely topics such as the eff ect of COVID-19 and stress of 
the holidays. The program was self-paced, anonymous, and voluntary. SP tracked participation and 
duration of engagement with the videos and pilot program landing page using anonymous analytics. 
At the conclusion of the program, QED administered SP’s Just Five feedback survey and a supplemental 
impact survey developed by QED and OL. The objective of the pilot was to determine if this educational 
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initiative was accessible, engaging and valuable to the participating startups and to assess the scalability 
to a larger group of QED portfolio companies and other venture capital fi rms.
What are the results? If results are not yet available, what results do you hope to achieve?
35 participants from the four companies responded to the feedback surveys; 18 (51%) viewed 4 or 
more videos. 25 (71%) agreed/strongly agreed the program made discussion of SUD easier. 18 (51%) 
agreed/strongly agreed the company’s culture became more open to mental health discussions. 25 
(71%) were very/extremely likely to recommend the program to a colleague. Anecdotal comments were 
notable for surprise at the extent of the problem and impact of stigma. Respondents felt more likely to 
seek help if needed.
Contact information
Daniel C. Mazanec, The Operation Lighthouse
 danmazanec@gmail.com
Keywords
awareness, education, mental health, person-centered language, workforce
Disclosure statement
Shatterproof is the creator of the Just Five educational module used by the Operation Lighthouse 
project and did not have involvement in the abstract submission or the project itself other than the 
initial technical support provided at launch.
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University Campus Students to Identify and Intervene for an Opioid Overdose
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What is your project or initiative?
A training aimed at the university student to decrease stigma against those with a substance use 
disorder (SUD), incorporation of harm reduction strategies, and to educate about prevention, 
recognition, and treatment for opioid overdose.
Why did you develop this?
Young adults between the ages of 18-25 are at an increased risk for opioid misuse. Stigma and 
misunderstanding campus policies have been shown to be barriers to disclosure of substance use and 
SUD. There have been national media results of students dying as a result of substance use in campus. 
Through formal and informal conversations with students at our university, we found that students had 
many concerns regarding their friends and family member’s drug use. Shared stories included students 
not calling 911 due to fear of repercussions from parents, peers, and the university. Members of our 
inter collaborative team also learned that there was confusion regarding the university campus policies 
for reporting an overdose and the consequences of this action as a result of residential directors and 
assistants interpretation of the campus substance use policy.
Who is the target audience?
Targeted groups included residential assistants, general student body, sorority and fraternity leaders.
Is this based on established work, or does it draw from other existing work?
This project drew from existing work but was a multidisciplinary collaboration between university 
health nurses, state police offi  cers, and community partners.
How does your project or initiative work?
Trainings were held during residential assistant orientation, for fraternities and sororities, and across 
campus for general students. A one-hour training was developed that consisted of the physiology 
of addiction, the impact of stigma, recovery-focused language, how to recognize and intervene for 
an opioid overdose, harm reduction strategies, and campus and community resources. In addition, 
students were educated about fentanyl contamination of commonly used drugs such as counterfeit 
pressed pills, cocaine, MDMA, and ecstasy. Students were provided with intranasal naloxone, resources, 
and refrigerator magnets that outlined how to recognize and intervene for an opioid overdose. 
Incorporation of myth busting by campus police, health care providers, and residential administration 
were incorporated into the training with a focus on putting the safety of their peers fi rst. Resources 
were put together and distributed at the trainings in addition to a number of campus websites.
What are the results? If results are not yet available, what results do you hope to achieve?
Over 400 students have received the training. Students reported an appreciation and need for the 
information but voiced concern regarding a campus medical amnesty policy that appeared to be 
in confl ict with information provided in their orientation and undergraduate handbook. Presenters 
worked with administration to revise the medical amnesty policy to revise language that was being 
misinterpreted by students. Additionally, the campus undergraduate handbook was examined and 
suggested language was provided to administration to align with a harm reduction approach that 
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did not increase perceived stigma. In addition, union policies interfered with residential assistant 
students being able to carry and use intranasal naloxone. Student involvement throughout the training 
encouraged information exchange that led to misperceptions of campus policies that served as barriers 
to students accessing campus resources or emergency services. There was an increase in the number 
of students requesting the presentation for their dormitory fl oor, sorority or fraternity. It was also 
determined that focus groups should be held in advance with key stakeholder students to understand 
barriers and facilitators to implementing the presentation strategies. Acting as a liaison between 
students and residential directors and administration was critical to allow for open communication and 
understanding.
Contact information
Kimberly Dion, UMass Amherst
kadion@nursing.umass.edu
Keywords
awareness, education, harm reduction, young adults
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40.  “Original Body of Pain” Documentary Film of Mothers with Substance Use Disorder
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What is your project or initiative?
The project was the creation of a documentary fi lm that captured a three year ethnography of two 
mothers experiencing substance use disorder (SUD) during pregnancy and parenthood. Original 
Body of Pain captures the intense and often generational nature of adduction through portraits of 
two women in recovery. As their stories unfold the mothers navigate recovery, care for their infant’s 
substance withdrawal, raise their children, redefi ne their goals in life, family relationships, experience 
recurrence of use, and even face incarceration. The fi lm demonstrates the testing of their resolve to 
seek recovery. The fi lm also features a program with a home health nurse visiting mothers and families 
aff ected by SUD and assists in their care of themselves and their infant.
Why did you develop this?
Stigma and judgement surround the social and healthcare environment for women, particularly 
mothers with SUD. The purpose of the documentary was to bring the stories to life of women 
navigating their recovery journey while being mothers of small children. The documentary title came 
from the expression of one of the women of her prior traumas in life that contributed to her use. She 
states you have an original body of pain from which you never recovered. The focus on the multiple 
dimensions of the mother with SUD that includes prior trauma, stigma, and the challenges of recovery 
are depicted as the women share their stories.
Who is the target audience?
Anyone interested in learning more about SUD with a special focus on mothers and developing families 
is the target audience for the documentary fi lm. The creators and associate producer of the fi lm want 
to make the documentary available to healthcare professionals to use as another way to present the 
challenges and successes of mothers with SUD to promote the creation of a more caring environment. 
The fi lm has been shown at national nursing professional organizations, fi lm festivals, and community 
presentations regarding substance exposure and now we would like to share it with this forum to invite 
further sharing of this valuable presentation.
Is this based on established work, or does it draw from other existing work?
The documentary is an original creation, inspired by the associate producer, a nurse practitioner and 
nurse researcher who wanted to have more information go to healthcare providers and the public 
regarding mothers with SUD in an attempt to decrease stigma and poor treatment for these women 
and their families. The fi lmmakers were graduate documentary fi lm students when they started to 
create the fi lm and have gone on in their profession as documentary fi lmmakers. The fi lmmakers spent 
three years fi lming the two women, the healthcare surrounding them the women’s families and their 
recovery to longitudinally show the changes through pregnancy into motherhood.
How does your project or initiative work?
The documentary fi lm is complete and available by request for other healthcare professionals to use 
for education or sharing to make changes in systems to support mothers with addiction. The use of the 
fi lm is free for those purposes with the only stipulation that it cannot be sold by the person showing the 
fi lm or money charged to view the fi lm.
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What are the results? If results are not yet available, what results do you hope to achieve?
In a recent study of over 300 participants viewing the fi lm in a pre- and post-survey design, there 
were signifi cant diff erences (p<0.05) in knowledge, attitudes and beliefs regarding SUD in pregnancy. 
Manuscript preparation is underway for publication in a peer-reviewed journal.
Contact information
Mary Ellen Wright, Clemson University 
Mewrig@clemson.edu
Keywords
awareness, lived experience, womens health
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41.  Overcoming Stigma: Practical Strategies and Approaches to Form Eff ective 
Community Partnerships
Authors
Sy Demsky; Andrew Rosenblum, PhD
What is your project or initiative?
The project utilizes practical strategies and approaches to form eff ective community partnerships. 
Specifi cally, our project is a multilevel continuous community intervention that addresses the deep 
social and structural elements that stigma directs against people with opioid use disorder (OUD), 
especially those who are receiving (or could benefi t from) medications for opioid use disorder (MOUD).
Why did you develop this?
The project was developed to further the mission of Stop Stigma Now (SSN), to change prevailing 
stigmatizing attitudes towards people suff ering from OUD. SSN is a 501(c)(3) founded in 2007 by a 
group of professionals with many years of experience in the fi eld of substance abuse and opioid 
treatment who have been working to end the stigma that has hampered medication-assisted treatment 
(MAT) and MOUD for opioid addiction for much too long. SSN includes a board of directors’ with an 
average of more than 30 years’ experience addressing stigma in communities where they directed 
and worked with opioid treatment programs (OTPs), Despite the escalating opioid addiction crisis 
in the U.S., most persons with OUD are not in treatment and, among those who are, most are not 
exposed to the modality with the strongest evidence-base: MOUD (especially the agonist medications 
buprenorphine and methadone). Stigma against people with OUD imposes a barrier to enrolling in 
and remaining in MOUD. Stigma is a complex social phenomenon based on a relationship between an 
attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that 
attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination 
(National Academies of Sciences, Engineering, and Medicine, 2016). In the case of stigma against MOUD, 
patients (and their providers and families) have to deal with the dual stigmas of a person who uses 
opioids and a person treated with agonist medications.
Who is the target audience?
Counselors, social workers, physicians/nurses, clinicians/pharmacists, treatment program 
administrators, public offi  cials.
Is this based on established work, or does it draw from other existing work?
Our activities are based on consensus practices and original work developed by members of SSN.
How does your project or initiative work?
SSN’s activities include community organizing, transparency practices, education, and sustainable 
and ongoing relationship building to address public, structural, and social stigmas of OUD and the 
use of MOUD and (as needed) other services such as medical care, counseling and other psychosocial 
interventions.
What are the results? If results are not yet available, what results do you hope to achieve?
Over the many years that SSN members have been addressing stigma (both in their professional roles 
and as SSN member) we have conducted eff ective community outreach that involved developing 
relationships with a wide spectrum of stakeholders including business owners, neighborhood advocacy 
groups, schools, law enforcement, real estate, public and private schools, public health and safety 
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agencies and elected offi  cials. Results from this community outreach have included public/private 
partnerships, engagement of key players in host communities, dissemination of education materials, 
which have been used to establish sustainable long-term working relationships with community 
representatives, methods to develop transparency practices that have helped communities understand 
how OTPs function and how MOUD is used to stabilize people with OUD in community settings. Results 
also include a quarterly electronic newsletter that is distributed to more than 3,000 people on our 
mailing list, a radio program (Steppin’ Out Radio), a speakers bureau (where SSN members speak to 
various organizations about how MOUD works and address concerns that participants might have), and 
a research department that has conducted an investigation in how the COVID-19 pandemic spurred 
changes in MOUD distribution and telehealth and how these changes have impacted OTPs and their 
patients (and might inadvertently reduce stigma experienced by MOUD patients).
Contact information
Sy Demsky, Stop Stigma Now 
Sydemsky@gmail.com
Keywords
awareness, medications for opioid use disorder
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42.  Peer Story Telling to Shift Perceptions in Overdose Response Professionals
Authors
Erika Holliday; Bree Sherry; Jennifer Wolfe
What is your project or initiative?
Our initiative creates a lens through the power of storytelling into the world of active addiction. Jennifer 
Wolfe, CPS, is a Peer Support Specialist who struggled with addiction for numerous years. She uses 
her story to increase understanding about the toll of addiction and how it becomes completely life-
changing.
Why did you develop this?
We developed this presentation after having many discussions with local fi rst responders around their 
needs in overdose response. In Kansas City, numerous evidence-based practices are being rolled out 
(take home naloxone, connection to peer support specialists, etc.) but many are not being utilized 
because of the stigma held by the fi rst responder work force. A common piece of feedback we received 
was that it was challenging to continue to have empathy for people who overdose, when there is no 
way to know if they are successfully connected to treatment, especially when they are overdosing again 
and again. This presentation is meant to assist in creating a feedback loop, to show that even from the 
lowest points in addiction, recovery is possible.
Who is the target audience?
This presentation was developed for fi rst responders but has been expanded for any professional who 
works in the addiction workforce.
Is this based on established work, or does it draw from other existing work?
This presentation was created from requests of local fi rst responder stakeholders and drew from the 
work of the DOTS Project out of the Missouri Institute of Mental Health, and the Take ACTION Naloxone 
Training Program from the University of Michigan.
How does your project or initiative work?
By the time of the summit, we will have presented this material to at least one (possibly two) fi rst 
responder agencies, one national webinar, and two medical professional organizations. It is an hour-
long presentation that presents Jennifer’s story of addiction, with pauses throughout to discuss how 
addiction is a chronic relapsing brain disease, stigma in the workforce, and Evidence Based Practices 
(EBPs) in overdose response. The presentation is evaluated by a pre- and post-test.
What are the results? If results are not yet available, what results do you hope to achieve?
The results are not yet available, but our short term goals are to shift initial attitudes towards people 
who use drugs to be less stigmatized, and our long term goals are to see an increase in fi rst responders 
connections to EBPs and an increase in local treatment referrals and intakes.
Contact information
Erika Holliday, Mid America Addiction Technology Transfer Center 
hollidaye@umkc.edu
Keywords
awareness, lived experience, storytelling
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43.  Project Empower: Engaging Medicine Providers on Ways to Enhance Recovery
Authors
Alain Litwin, MD; Mary Ellen Wright, PhD, APRN, CPNP-PC; Lauren Demosthenes, MD; Veronica Parker, 
PhD; Margie Stevens, PhD
What is your project or initiative?
Project EMPOWER (Engaging Medicine Providers on Ways to Enhance Recovery) is a collaborative eff ort 
funded by SAMHSA, including Clemson University School of Nursing, University of South Carolina 
Medical School Greenville, Prisma Health Addiction Research Center and the FAVOR Greenville 
Recovery Center to provide education on opioid use disorder (OUD) for nurse practitioner and medical 
students. The purpose of the project is to educate students about substance use disorders (SUD)/OUD, 
culminating in obtaining the DATA waiver to prescribe medications for opioid use disorder (MOUD) 
upon completion of the program and graduation. A major innovative feature of this educational 
program is the enhanced case discussions that are part of the waiver training. After completing all of 
the PCSS DATA waiver modules, we began case discussions in both a large and small group format. 
Each small group of 10 included both nurse practitioner and medical students, a peer recovery coach 
and a MOUD provider. The peer recovery coaches provided the patient experience and enhanced the 
discussion around the stigma and the barriers they have encountered in the health care system as 
they have sought treatment and recovery. The MOUD provider guided the discussion and brought in a 
variety of perspectives. Discussion points were intermittently brought to the large group.
Why did you develop this?
The American Society of Addiction Medicine (ASAM), the American Association of College of Nursing 
(AACN), and the American Association of Medical Colleges (AAMC) have identifi ed a need for increased 
education on SUD. Adding in the patient experience and working in interprofessional teams were 
components that we believed would enhance the education and help to reduce stigma toward persons 
with OUD.
Who is the target audience?
The target audience is nurse practitioner and medical students participating in our Project EMPOWER 
training.
Is this based on established work, or does it draw from other existing work?
The educational program off ered is through the PCSS MAT national waiver training is supported by 
the SAMHSA training that is used for certifi cation for clinicians to receive a waiver to prescribe MOUD. 
We expanded upon this training by enhancing case discussion by creating groups of 10 students (NP 
and MD students together) with a peer recovery coach and MOUD provider. This allowed for true 
interprofessional conversation. The outcome measure of the Substance Use Disorder Knowledge, 
Attitudes and Beliefs Survey was original to the project and based on modifi cation of prior tools, plus 
original content. The Cronbach alpha of the survey in the study was pre-training coeffi  cients ranged 
from .764 to .974 and post-training coeffi  cients ranged from .843 to .988.
How does your project or initiative work?
Nurse practitioner students and medical students were and are required to participate in the 
educational program as part of their academic programming. The students participated in a pre-
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program and post-program survey and a sample of the participants also participated in focus groups 
regarding the experience of the educational program on SUD/OUD.
What are the results? If results are not yet available, what results do you hope to achieve?
The presented research on the fi rst iteration of the PCSS training demonstrated signifi cant positive 
changes (p<.05) in 33 out of 44 items for the nurse practitioner students and 24 out of 44 items for 
the medical students on the Substance Use Disorder, Knowledge, Attitudes and Beliefs Survey. For 
the new and enhanced experience, preliminary analysis of the qualitative data indicates the peer 
recovery coaches and MOUD providers as an active part of the training provided value to the training. 
One student stated, “Excellent! So important to include their voice. I was very impressed with their 
willingness to speak up and also really appreciated how the providers asked their opinions. A true 
team-based approach.” Further analysis of the outcomes are currently underway. A quote from a 
medical student summarizes the themes of the sentiments expressed in the focus groups “I learned 
that this is why I went into medicine; treating this population is the closest you get to humanity”.
Contact information
Mary Ellen Wright, Clemson University 
Mewrig@clemson.edu
Keywords
education, lived experience, medications for opioid use disorder
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44.  Recovery Ally Training: Building Self-Effi  cacy in Campus Communities to Support 
Students in Recovery and Students with Substance Use Disorder
Authors
Sierra Castedo de Martell, MPH; Ananya Roy, BA, BSA; Tiff any Cunningham, BA; Larkin Cummings, MEd
What is your project or initiative?
The Recovery Ally Training at the University of Texas at Austin’s Center for Students in Recovery.
Why did you develop this?
To lower stigma toward students with substance use disorders (SUD) and to empower allies to support 
and advocate for students with SUD.
Who is the target audience?
Students, staff , and faculty at the University of Texas at Austin.
Is this based on established work, or does it draw from other existing work?
This is not the fi rst Recovery Ally Training created, so it builds off  of existing recovery ally training 
programs at other collegiate recovery programs, as well as building on the work of other types of 
campus ally programs, including the excellent work of LGBTQ+ Ally Programs.
How does your project or initiative work?
Participants attend either a full 2-hour training or a 1-hour in-class training. Full trainings include 
a knowledge component with guided practice and role playing exercises. The in-class trainings are 
primarily knowledge-based. The training targets the common misperceptions about substance use 
disorder that underlie stigma, increase self-effi  cacy to support students with SUD, and raise awareness 
about the underserved population of students in recovery on campus.
What are the results? If results are not yet available, what results do you hope to achieve?
Recovery ally trainings lead to signifi cant increases in perceived self-effi  cacy (0.47, p = 0.000). While 
SUD misperceptions related to stigma did not change, this may be due to selection bias, where trainees 
already low in stigma toward SUD self-select as participants.
Contact information






45.  Reducing Opioid Use Disorder-Related Stigma among Pharmacy Students Using 
Contact-Based Education
Authors
Douglas Thornton, PharmD, PhD, BCPS; Tamara Al Rawwad, PhD, MPH; Christine R. Bakos-Block, PhD, 
LCSW; Christina Nania, MPH; Tiff any Champagne-Langabeer, PhD
What is your project or initiative?
The University of Houston College of Pharmacy (UHCOP), in collaboration with the University of Texas 
Health Science Center at Houston School of Biomedical Informatics will implement a contact-based 
educational intervention addressing stigma against patients with opioid use disorder (OUD). This 
intervention will feature a speaker who is in long term recovery from OUD. The intervention consists 
of a single session, one-hour long interactive lecture that will cover diff erent topics both from lived 
experience with addiction, and from the perspective of a peer recovery support specialist or recovery 
coach. Prospective data collected from students will be used to assess and evaluate the eff ectiveness 
of the intervention in reducing OUD related stigma among pharmacy students. Such data includes: 
demographics including age, race, gender, and pre and post test data from a modifi ed version of Brief 
Opioid Stigma Scale (Yang et al., 2019).
Why did you develop this?
This project was developed to reduce stigma among future pharmacists through contact-based 
education. Pharmacists are in a ubiquitous and unique position to facilitate access to short-term and 
long-term treatment as well as to screen for prescription opioid dependence. While previous studies 
have focused on barriers to access of medical management for OUD among physician and nurse-based 
practices, few interventions have addressed barriers to access in pharmacy settings. Stigma held by 
pharmacists against those on medical management for OUD can limit access to medication assisted 
treatment, such as methadone and buprenorphine-naloxone. Studies have shown that community 
pharmacists do not feel adequately prepared to address issues related to substance misuse due to 
a reported lack of education on this topic during professional training. While previous interventions 
addressing stigma among healthcare students have been studied, there is limited research on contact-
based education using a facilitator who is in long term recovery from OUD.
Who is the target audience?
The target audience for this intervention is third year pharmacy students enrolled in the Psychiatry 
Integrated Course during the Spring semester of 2021 at the University of Houston College of 
Pharmacy. Beyond the direct intervention with pharmacy students, other health system stakeholders 
will benefi t from the data and outcomes.
Is this based on established work, or does it draw from other existing work?
Previous literature has examined the effi  cacy of didactic instruction combined with interactive 
presentations from individuals in recovery from OUD. The results of these studies have shown that 
this combined approach can be eff ective in changing stigmatizing beliefs. However, the outcomes do 
not specifi cally focus on measures of stigma or are not generalizable to a broad range of healthcare 
professionals.
How does your project or initiative work?
Our intervention consists of a single, one-hour long lecture that will cover diff erent topics both from 
lived experience and from the perspective of a recovery coach. The intervention took place in April 2021 
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with 125 students. The recovery coach covered topics relating to how individuals start to use drugs, 
barriers to accessing healthcare, challenges to accessing treatment, facing stigma on a personal basis, 
recovery and success stories, and challenges of long-term recovery. Students completed an anonymous 
online pre-survey and post-survey that included measures of demographic data and a modifi ed version 
of the Brief Opioid Stigma Scale.
What are the results? If results are not yet available, what results do you hope to achieve?
Both quantitative and qualitative results from this intervention are in the process of being analyzed. We 
hope to observe that the intervention succeeds in decreasing opioid use related stigma as measured by 
the Brief Opioid Stigma Scale. Our aim is that this method of delivery of OUD and stigma education by 
an instructor in long-term recovery is an eff ective tool to decrease stigma among pharmacy students. 
We hope that this intervention can be replicated on a larger scale in other pharmacy schools, as well as 
other healthcare education settings.
Contact information
Christina Nania, McGovern Medical School
christina.nania@uth.tmc.edu
Keywords
education, lived experience, pharmacy, storytelling
88
46.  Reducing Stigma of Individuals with Opioid Use Disorders Through Art in Rural 
Appalachia
Authors
Lisham Ashrafi oun, PhD; Kimberly Chiaramonte, MSS; Charmaine Wheatley, BFA; Christine Lasher, BA; 
Michele Lawrence, MBA, MPH; Gloria Baciewicz, MD
What is your project or initiative?
University of Rochester Medicine Recovery Center of Excellence’s (RCOE) stigma campaign applies the 
practices of education and contact through a combination of art and workshops in rural Appalachian 
communities. The art and workshops were developed to provide an innovative way to capture the lived 
experiences of individuals with opioid use disorder (OUD) to inform providers and other community 
members about the impact of stigma and OUD, that recovery is possible and there are eff ective 
treatments available.
Why did you develop this?
Stigma about individuals with OUD is a critical barrier to accessing evidence-based OUD treatments. 
Negative beliefs about individuals with OUD and about the eff ectiveness of treatments often lead to 
suboptimal care. If individuals with OUD are treated poorly because they are stigmatized, it impacts 
how a person with OUD experiences treatment and reduces the likelihood a person will return. Stigma 
is associated with poorer mental and physical health, and increased involvement in risky behaviors. 
People with OUD who are stigmatized will often isolate from others, which also leads to further opioid 
use.
Who is the target audience?
The target audience is for rural community members, and healthcare providers and systems.
Is this based on established work, or does it draw from other existing work?
Education and contact to people with OUD appear to have the strongest evidence of reducing provider 
stigma. This project combines these approaches to reducing stigma and does so through a captivating 
vehicle that has the potential for a longer-term impact. Reducing stigma through art has been utilized 
for other stigmatized populations including those with HIV and those with mental health challenges. We 
are seeking to expand its utility to reduce stigma among individuals in rural communities with OUD.
How does your project or initiative work?
We are developing a training program centered around artwork depicting the lived experience of 
individuals with OUD. The program uses watercolor portraits of the individual with their own words 
on their experiences with stigma and successes during recovery through evidence-based treatments 
for OUD surrounding their image. This artwork will be disseminated throughout areas of communities 
and healthcare systems and will be paired with workshops to elicit discussion of and refl ections on 
the artwork to digest the materials. This approach marries education and contact—evidence-based 
approaches of reducing stigma.
What are the results? If results are not yet available, what results do you hope to achieve?
This project is currently being implemented and results are not yet available. We hope that this 
project raises awareness about stigma, lived experience of people with OUD, that successful recovery 
is possible, particularly through evidence-based approaches for OUD. We hope that this awareness 
changes stigmatizing beliefs, promotes an accepting culture, and improves provider care behaviors that 
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help ensure that individuals with OUD receive compassionate care and have access to evidence-based 
treatments for OUD (e.g., referral to treatment, distribution of naloxone, initiation of evidence-based 
medications for OUD).
Contact information
Lisham Ashrafi oun, University of Rochester
lisham_ashrafi oun@urmc.rochester.edu
Keywords
awareness, lived experience, storytelling
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47.  Reducing the Stigmatizing Beliefs and Behaviors of Inpatient Nurses Towards 
Patients with Substance Use Disorders: The Design of a Blended Learning Program
Authors
Scott LaJoie, PhD, MSPH; Diane M. Zero, MEd
What is your project or initiative?
A blended learning program for inpatient nurses, intended to reduce stigmatizing beliefs and behaviors 
towards patients with substance use disorders (SUD).
Why did you develop this?
At an urban hospital in Kentucky, 22% of patients admitted for conditions related to substance misuse 
had left the hospital against medical advice (AMA). In addition, this population had a high rate of 
dissatisfaction with the care provided by inpatient nursing staff . We identifi ed the need to reduce 
the stigmatizing beliefs and behaviors of inpatient nurses towards their patients with substance use 
disorders. This blended learning program was developed in response.
Who is the target audience?
Inpatient nurses and healthcare administrators are the target audience.
Is this based on established work, or does it draw from other existing work?
It draws from other existing work.
How does your project or initiative work?
The blended learning program consists of a series of vodcasts with supplemental materials and 
knowledge assessments, covering topics such as the principles of harm reduction, understanding 
the harmful eff ects of stigma on patients, safer injection education, behavior change principles, and 
improving communication between the patient and inpatient nurse. In phase two of the study, inpatient 
nurses will take part in a series of lunch and learns led by a harm reduction specialist, providing them 
the opportunity to ask questions about what they learned in the vodcasts and discuss in more detail 
these topics with other nurses. In phase three, we will disseminate a similar blended learning program 
to a wider audience of healthcare providers that is customizable across a variety of settings, such as 
federally qualifi ed health centers and hospital emergency departments
What are the results? If results are not yet available, what results do you hope to achieve?
In the short term, we hope to reduce inpatient nurses’ stigmatizing beliefs and behaviors towards 
their patients with SUD. In the long-term, we hope to increase patients with SUD’s satisfaction with 
healthcare services and reduce the percentage of these patients leaving care AMA.
Contact information





48.  Refi nement of a Provider-level Substance Use Stigma Reduction Intervention
Authors
Abigail W. Batchelder, PhD, MPH; Daniel P. Johnson, PhD
What is your project or initiative?
We have developed and aim to refi ne a provider-level intervention targeting barriers to care for 
individuals with substance use disorders (SUDs), specifi cally provider-level substance use stigma. 
The intervention leverages an innovative combination of carefully selected evidence-based strategies 
including:
1. empirically supported stigma-focused strategies such as didactics and social contact, 
2. evidence- based acceptance and compassion-focused techniques to decrease the impact of 
stigmatizing beliefs and increase compassionate, fl exible behavior in providers (from Acceptance 
and Commitment Therapy, Mindful Self-Compassion, and Dialectical Behavior Therapy), and 
3. recent advances in aff ective science to improve provider awareness of and attunement to patients 
experience of substance use stigma. 
We are planning to refi ne this intervention to be delivered virtually based on stakeholder feedback, 
and then pilot the refi ned virtual version to assess feasibility and acceptability and subsequently 
eff ectiveness.
Why did you develop this?
People with SUD underutilize primary and psychiatric care and are disproportionately high utilizers of 
costly emergent and inpatient hospitalizations. Additionally, substance use stigma, or the negative and 
devaluing beliefs about individuals with SUD, is thought to be ubiquitous in the U.S., including among 
healthcare providers. A systematic review indicates that primary care and psychiatry providers have 
generally negative views about people with SUD and are reluctant to work them, resulting in suboptimal 
healthcare. Consistently, people with SUD report anticipated and enacted substance use stigma from 
providers as reasons for not attending primary care and mental health appointments. Given the high 
prevalence of health and psychiatric comorbidities among people with SUD, substance use stigma is a 
substantial and costly barrier to meeting the needs of people living with SUD. Decreasing substance use 
stigma among primary care and psychiatry providers may ultimately increase utilization of primary care 
and psychiatric services and decrease emergent and inpatient hospitalizations among people with SUD.
Who is the target audience?
Healthcare providers, administrative staff , hospitals and clinics who care for individuals with SUD.
Is this based on established work, or does it draw from other existing work?
Several didactic and contact-based didactic strategies have been documented in the literature, including 
mental illness and HIV stigma reduction provider interventions, resulting in moderate improvements 
on stigma-related knowledge, attitudes, and intended behavior. However, there is limited evidence for 
behavioral changes or lasting impact of these short-term didactic and contact-based interventions. This 
project builds on our previous intervention development work that leverages evidence-based content 
to create a virtual platform to facilitate provider engagement. We hypothesize that refi ning our existing 
intervention for a virtual platform will facilitate providers to not only utilize the intervention but also 
improve their treatment of patients with SUD and improve engagement in medical and psychiatric care 
among people with SUD.
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How does your project or initiative work?
Through interactive didactics, experiential exercises, and skills practice, the refi ned version of our novel 
intervention will infl uence change by:
1. enhancing providers’ empathy and compassion for patients with SUD, 
2. increasing non-stigmatizing provider behaviors (e.g. use of non-stigmatizing language in 
documentation), and 
3. training providers to more compassionately identify and respond to verbal and non- verbal 
communications of perceived stigma and related emotions (e.g., shame and guilt).
What are the results? If results are not yet available, what results do you hope to achieve?
Given the ubiquity of substance use stigma, the prevalence of SUD among patients living with comorbid 
health challenges, and the dearth of evidence-based behaviorally infl uential stigma reduction provider 
level interventions, we foresee wide public health implications for the refi ned virtual version of our 
intervention. In addition to changing providers’ behaviors in caring for individuals with SUD, this 
intervention may lead to reductions in patients’ anticipated substance use stigma, potentially increasing 
engagement in primary and psychiatric care and decreasing costly emergent and inpatient care.
Contact information





49.  REMIND: Recognizing and Engaging Mental Health in Indigent Defense
Authors
Jennay Ghowrwal, MHS; Cassie Wicken, MHS
What is your project or initiative?
REMIND: Recognizing and Engaging Mental Health in Indigent Defense
Why did you develop this?
REMIND seeks to improve the experience and outcomes of indigent persons with substance use and 
mental disorders who are involved with the criminal justice system by training defense attorneys to 
overcome stigma to better communicate with and advocate for them. In the U.S., over 70% of women 
and 55% of men in prisons and jails have at least one mental health or substance use problem. Those 
experiencing substance use and mental health issues face misunderstanding, mistreatment, and worse 
outcomes than their counterparts in the criminal justice system. Prisoners with substance use and 
mental disorders are less likely to receive proper medical treatment, more likely to be victimized while 
incarcerated, and more likely to reoff end. But strong advocacy at every stage of the criminal defense 
process can reduce exposure to these threats, and trusting client-attorney relationships produce the 
highest quality representation. We developed the initiative as a (now-completed, 18-month) 2018 
Open Society Institute-Baltimore Community Fellowship project awarded to Jennay Ghowrwal. REMIND 
developed in close consultation with the Maryland Offi  ce of the Public Defender, with a particular focus 
on attorneys practicing in Baltimore City. However, we have drawn input and direction from a variety 
of resources based throughout the country, and intend to extend REMIND as a resource for indigent 
defense agencies across the U.S. Because of COVID-19, REMIND has not yet fully rolled out in Maryland, 
and we plan to resume its activities by the fall of 2021.
Who is the target audience?
REMIND specifi cally engages public defenders as trainees - to build their capacity as advocates for 
clients facing substance use and mental disorders primarily through the strength of their relationships 
with these clients. In the fi rst week after arrest, a person with mental health or substance use issues is 
likely to encounter about a dozen police offi  cers, corrections offi  cers, and court representatives. None 
of these people are their advocate. Criminal defense attorneys, particularly public defenders and other 
court-appointed counsel, are diff erent. They are the only actor within the system fi ghting for the stated 
interests of a defendant.
Is this based on established work, or does it draw from other existing work?
No such comprehensive, universal program exists to equip attorneys to represent clients experiencing 
substance use and mental disorders. Many indigent defense agencies employ Gideon’s Promise, a 
nationally-renowned training that emphasizes client-centered representation. However, Gideon’s 
Promise does not have a component related to identifying and addressing the role of client mental 
health and substance use issues. REMIND’s philosophy, curriculum, and format draw both from 
extensive consultation with indigent defense experts, including those with lived experience as public 
defender clients, and from academic and policy literature on the intersection of public mental health, 
addiction medicine, and criminal justice.
How does your project or initiative work?
REMIND consists of an interactive, workshop-format curriculum for public defenders. We off er 
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three comprehensive, half-day modules: developing client relationships; doctrine and strategy; and 
advocating for and with ourselves. Broadly speaking, the curriculum and its structure draw heavily from 
critical criminology; harm reduction; social therapy; positive psychology; antiracism organizing; and 
trauma- focused therapeutic analysis.
What are the results? If results are not yet available, what results do you hope to achieve?
REMIND will transform the experience of indigent defendants with mental health and substance use 
concerns by ensuring that their legal advocates are prepared to understand their needs and potential 
outcomes. In discrete terms, the anticipated impact is twofold: improved experience (defi ned generally 
as satisfaction with representation) and better outcomes (in terms of clinical continuity and sentencing 
or diversion) for indigent defendants. Anecdotally, we have already observed these outcomes, along 
with attorney enthusiasm for applying and reproducing the training process.
Contact information
Jennay Ghowrwal, REMIND Project 
jennay@remindproject.org
Keywords
awareness, criminal justice, education, training
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50.  Shared Stories - Vulnerability in Health Care
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What is your project or initiative?
Over the past few years, we have facilitated “shared stories” focus group discussions via Zoom with 
physician assistant (PA) students at various stages of training and across multiple PA programs. These 
have been embedded in diff erent formats and courses, but all stem from the idea that you are not 
alone in whatever you are dealing with. We have those is ‘powerful’ positions such as faculty members, 
clinical PAs, etc., share their vulnerabilities with mental health, including substance use disorders (SUD), 
with students and then lead discussions around vulnerability and stigma in healthcare. We hope to 
continue to grow this experience and training to more programs.
Why did you develop this?
Out of our own experiences with shame and stigma as PAs with lived experiences and as we are PA 
educators, we are seeing this cycle propagate so aim to challenge the infallible role our students are 
cast in.
Who is the target audience?
PA students at any stage of training. We have worked with those in early didactic, late didactic and 
clinical year.
Is this based on established work, or does it draw from other existing work?
This is based on prior work that Stephanie fi rst did with a primarily MD research team with medical 
students from the University of Tel-Aviv. This was adapted to bring to PA students across 3 programs as 
a standalone project. Given the success, it was then built into a 16 week well-being course that is being 
delivered to 4 PA programs (N = 185) concurrently and another 2 programs will take the course starting 
in June.
How does your project or initiative work?
This project has been run a few diff erent ways, but for live sessions, the core framework is to have 1-2 
PAs who are seen as superiors and a group of students. The session begins with each PA telling their 
story in detail to the students (we have done SUD, serious mental illness, anxiety/depression) and then 
opening the fl oor for discussion around mental health, help seeking behaviors, stigma, the hidden 
curriculum in medicine, shame etc. Many students opt to share their own stories as well through this 
discussion. We have also done this with recorded versions of our shared stories and students watch on 
their own then participate in a discussion forum with prompts on vulnerability.
What are the results? If results are not yet available, what results do you hope to achieve?
For the live sessions, we have shown great success with reducing stigma and improving help seeking 
behavior of mental illness as measured by the OMS-HC and the SSOSH surveys. We do not tease out 
by diagnosis so do not have specifi c data on SUD, only SUD as included with other mental illness. For 
the recorded version with discussion forums, this is underway currently and the forum participation 
is incredibly rich but we do not have the supporting pre-post survey data at this time. This will be 
available in late May 2021.
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Stephanie L Neary, Yale University
stephanie.neary@yale.edu
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51.  Stigma Reduction and Prevention in Healthcare: An OPEN Partnership with 
Shatterproof
Authors
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What is your project or initiative?
The Opioid Prescribing Engagement Network (OPEN) has partnered with Shatterproof to raise 
awareness on stigma toward individuals with substance use disorder (SUD) in the healthcare setting. 
Through a summit, online workshops, and self-paced programs, we seek to provide healthcare systems 
with the tools necessary to reduce stigma through evidence-based interventions.
Why did you develop this?
Stigma from providers adversely impacts the care, treatment, and recovery of their patients. When 
subject to stigma, patients are isolated and shamed which creates added barriers to care and impedes 
recovery. Recognition of how stigma manifests in diff erent settings will lead to better development of 
interventions that support the needs of all patients, including those struggling with addiction.
Who is the target audience?
Our initial learning series will focus on the unique needs of obstetrics and gynecology. Our targeted 
audience will encompass a wide range of demographics including healthcare professionals and family 
members of pregnant women with SUD.
Is this based on established work, or does it draw from other existing work?
OPEN has spent the last fi ve years combatting the opioid epidemic in Michigan and beyond, beginning 
fi rst with a preventative approach to the opioid crisis through the introduction of prescribing guidelines 
for postoperative and acute care opioid prescribing. OPEN also provides multitude of educational 
resources for providers, patients, and communities on opioid risk assessment and proper medication 
disposal. Through data driven research, policy suggestions, and community outreach, OPEN is an 
established stakeholder in work done to end the opioid epidemic.
How does your project or initiative work?
OPEN has proven networks of partners that will be leveraged to reach providers spanning a number of 
specialties. Specifi cally, the Blue Cross Blue Shield of Michigan Value Partnerships Program consists of 
over 20 diff erent Collaborative Quality Initiative (CQI) programs that provide a cooperative approach to 
population-based quality improvement, fi nancial support and infrastructure to establish collaborations 
among hospitals and healthcare centers. We will fi rst introduce our Stigma Learning Series to the 
Obstetrics Initiative (OBI) Collaborative to garner interest and participation from providers within 
their 73 maternity hospitals. Providers will learn about initiatives taking place nationally to reduce 
stigma, participate in an OB/GYN focused panel session, and fi nally, they will be off ered an opportunity 
to workshop skills on providing non-stigmatizing within virtual case study session. By sharing lived 
experiences, Shatterproof and OPEN will connect with healthcare professionals and formulate ways to 
reduce stigma and implement interventions in clinical settings. In addition to working with providers, 
families and loved ones of individuals with SUD will have an opportunity to participate in self-paced, 
online programs.
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What are the results? If results are not yet available, what results do you hope to achieve?
Though the project is ongoing, the interventions created by OPEN and Shatterproof are a promising 
step in addressing stigma toward individuals with SUD. By creating spaces for healthcare professionals 
to discuss and be educated on stigma, we hope that providers will be better equipped to support 
patients with SUD, including expectant mothers through our obstetrics initiative.
Contact information
Alexandria Sobczak, Michigan Opioid Prescribing Engagement Network (OPEN) 
sobczaka@med.umich.edu
Keywords
policy and guidelines, womens health
Disclosure statement
Shatterproof is a partner in the Stigma Reduction and Prevention in Healthcare project and did not 
have involvement in the abstract submission.
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52. Stigma Reduction as a Consideration for Choosing Telehealth Care for Substance Use 
Disorders
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What is your project or initiative?
Boulder Care is a mobile application treatment solution off ering long-term support for people 
with substance use disorders (SUD) by delivering access to medical and psychosocial services via 
telehealth. Our interdisciplinary Care Teams (a team clinician, care advocate, and peer coach) provide 
comprehensive, evidence-based, interdisciplinary care for each of our participants.
Why did you develop this?
SUD are a problem of national concern. In the case of opioid use disorder (OUD), medications such 
as buprenorphine reduce opioid use, opioid use associated risks, and death. Despite the evidence 
supporting medications for opioid use disorder (MOUD), more than half of US counties (predominantly 
rural) have no prescribers. Patients travel long distances, join waitlists, or go without treatment. 
Additional barriers to care include lack of transportation, competing demands (e.g., work, childcare) 
and stigma. Combined, this lack of access and additional barriers leave millions without treatment. 
The National Institute of Drug Abuse (NIDA) emphasizes how the complex nature of SUD requires 
long-term care. NIDA supports a multi-faceted approach with adequate treatment time and dynamic, 
individualized treatment based on a person’s unique goals. Given the escalating scale of the epidemic, 
a highly accessible, innovative solution is critical to closing the treatment gap. Telehealth is one such 
solution.
Who is the target audience?
Our target audience consists of people who have one or more SUD, are seeking care, and are amenable 
for care to be provided via telehealth.
Is this based on established work, or does it draw from other existing work?
Our research is based on pioneering interviews -- made possible by a NIDA Small Business Innovation 
Research (SBIR) grant awarded in 2019 -- with people who would be candidates for Boulder Care. These 
interviews sought to understand people’s experiences and thoughts as to why telehealth might be, 
or might not be, a reasonable approach for themselves. The potential for stigma to be in a telehealth 
setting was a signifi cant consideration for a number of study participants. The presented work will 
be an initial qualitative analysis of how past experience with stigma and eff orts to reduce ongoing 
exposure to it may infl uence people’s decisions regarding telehealth-based care.
How does your project or initiative work?
Boulder Care is a mobile application treatment solution off ering long-term support for SUD by 
delivering telehealth access to medical and psychosocial services. Our virtual treatment platform 
ensures the provision of critical components of SUD care with less burden on both the participant 
and caregivers. Care is mediated by a HIPAA-compliant smartphone app which patients download to 
their phones. Eff ective treatment for SUD includes multiple components tailored to meet the needs 
and schedule of an individual. Our solution to reduce the burden of care on prescribing providers 
is to use a care team, combining the skills of care advocates, peer coaches, and team clinicians. The 
focus of the care team is to develop a therapeutic clinical relationship with each patient, led by the 
100
patient’s recovery goals. From the participant’s initial contact with Boulder Care, our comprehensive 
services are provided virtually. In the COVID-19 pandemic, telehealth has become indispensable for 
outpatient health care, including care for SUD. In a recent review of telemedicine interventions for SUD, 
telehealth was eff ective and appreciated; over 75% of patients reported high satisfaction. Provision of 
buprenorphine via telehealth also appears to improve retention at one year compared with in-person 
treatment.
What are the results? If results are not yet available, what results do you hope to achieve?
We are actively analyzing data from our interviews. By the time of the Summit, we will have a refi ned 
understanding of study participants’ consideration of stigma and how it infl uences their preference for 
traditional care or that provided via telehealth.
Contact information
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What is your project or initiative?
Our project is a study to survey police offi  cers to better understand their knowledge, beliefs, and 
attitudes about people who use drugs (PWUD) including stigma held towards them, and responses 
to PWUD including treatment and harm reduction strategies. In addition, it will explore what shapes 
decision making about, and planned behavior towards, PWUD. We will further explore diff erences 
in responses based on offi  cer demographics. The study looks at data from Illinois, Indiana, and 
Massachusetts. There is limited prior research in this area and this study can gain information directly 
from offi  cer’s unique perspectives.
Why did you develop this?
Over 20 million Americans struggle with substance, use and PWUD are highly stigmatized. Stigma 
aff ects PWUD decisions to seek help or share with others and harms their psychological well-being. 
Stigma negatively aff ects police encounters with PWUD, and leads offi  cers to exercise the prerogative to 
arrest when a referral to eff ective treatment would have in fact decreased recidivism and reduced the 
overdose risks a suspect faces as a result of incarceration. As seen in the Derek Chauvin defense’s case 
in the murder of George Floyd, stigma against PWUD, particularly people of color, can be used to justify 
use of force. Ultimately, stigma against PWUD negatively aff ects their overall public health and criminal 
justice outcomes. We need to be able to measure this stigma, systematically understand what shapes 
offi  cer behavior, and develop interventions to constrain and redirect the negative outcome of stigma- 
based decisions by police.
Who is the target audience?
Criminal justice practitioners, public health practitioners, healthcare practitioners, researchers and 
academics.
Is this based on established work, or does it draw from other existing work?
There has been limited prior study of police offi  cer attitudes toward PWUDs. This is original research 
that adds to what is known on this subject.
How does your project or initiative work?
We are distributing an online survey on stigma and the Theory of Planned Behavior using stratifi ed 
random sampling of police departments in Illinois based on characteristics of department jurisdictional 
area type (rural/urban) and department size (number of offi  cers). This strategy is done to ensure 
diverse departments and offi  cers participate in the study and to increase response rates. They are 
accompanied by pre-training surveys that ask an overlapping battery of questions in Indiana and 
Massachusetts. (Present N=approx. 315)
What are the results? If results are not yet available, what results do you hope to achieve?
We have not concluded recruitment for the Illinois arm of the study, but we can share preliminary 
fi ndings if selected. Some of them follow here. To date, we have a sample size of approximately 315 
offi  cers. We will use descriptive statistics and perform statistical tests to explore the strength of the 
associations between offi  cer and department demographics and survey responses. To date, we have 
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found that police perceive they have high levels of control over their decision to arrest a PWUD or not, 
that the attitude of the suspect strongly infl uences their decision (with perceptions informed by stigma), 
that the expectations of their immediate supervisor fi gure prominently in their decisions, and they will 
take eff ective alternatives to arrest into account. Offi  cers also believe people who use drugs will lie 
to them as necessary, and have reduced control over their actions, but recovery is possible, although 
tapering and sobriety should be the ultimate goal. Our research suggests training on the eff ectiveness 
of MOUD and the eff ects of addiction on behavior, and policies that set supervisor expectations 
about defl ection will likely limit and reduce the eff ects of stigma against PWUD in the course of police 
encounters.
Contact information
Brandon del Pozo, The Miriam Hospital / Warren Alpert Medical School of Brown University 
bdelpozo@lifespan.org
Keywords
criminal justice, medications for opioid use disorder
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54.  Strategic Teaching to Transform Language
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What is your project or initiative?
My initiative is to transform the language of addiction to reduce the stigma of substance use disorders 
(SUD). My goal is to strategically teach the next generation of healthcare leaders clinically accurate, 
non-stigmatizing addiction terminology aligned with the Surgeon General’s lexicon for SUD. Learners 
then have curated opportunities over 1-4 weeks to practice using non-stigmatizing language in a clinical 
setting with faculty feedback.
Why did you develop this?
Research shows that stigmatizing and pejorative addiction language negatively impacts patient care and 
adversely aff ects clinician wellness. This is a major driver of stigma that can be remedied if clinicians are 
taught, supervised, and encouraged to use clinically accurate non-stigmatizing terminology.
Who is the target audience?
Those in clinical service and care delivery and in particular, our future generations of healthcare 
leaders: medical and health professions students, resident physicians, fellows, and medical staff  
colleagues and peers.
Is this based on established work, or does it draw from other existing work?
To my knowledge there is no established framework for strategic teaching of non-stigmatizing addiction 
terminology to healthcare learners.
How does your project or initiative work?
This initiative is through the University of Nebraska Medical Center Department of Psychiatry 
Addiction Psychiatry Consultation-Liaison (APCL) Service, an interdisciplinary medical team providing 
consultations to patients with substance use who are medically and surgically admitted to our hospital. 
APCL is a teaching service with learners across the spectrum of medical education. As part of their 
experience on APCL, learners receive a comprehensive orientation including teaching about the stigma 
of addiction language, an overview of the literature surrounding how language impacts patient care, 
and a lexicon of clinically accurate substance use terminology published by the U.S. Surgeon General. 
Special emphasis is placed on the role that healthcare workers have in propagating or reducing stigma. 
Learners are empowered with the knowledge that pejorative language jeopardizes patient care and 
are taught skills needed to reverse this stigma. Throughout their time on APCL, learners practice using 
non-stigmatizing language and begin to incorporate it into their general medical discourse. Learners 
are supervised by expert faculty who provide formative feedback through encouragement and gentle 
correction as well as summative feedback through formal evaluations.
What are the results? If results are not yet available, what results do you hope to achieve?
Anecdotally, nearly all learners report a change in their perception of patients with SUD by the end of 
their APCL rotation. They also report beginning to notice just how many peers and healthcare workers 
use stigmatizing addiction language since it now sounds foreign to them. In trying to quantify these 
fi ndings I plan to administer an anonymous survey at the beginning and end of the APCL rotation to 
assess changes in stigma and attitudes towards patients with SUD.
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What is your project or initiative?
The elimination of stigma surrounding behavioral health conditions has been a public health priority 
internationally since 1996 with the World Psychiatric Association’s Global Program to Fight Stigma 
and Discrimination, “Open the Doors” (Sartorius & Schulze, 2005) and since 1999 in the United States 
(Corrigan & Kosyluk, 2013; Hinshaw & Cicchetti, 2000). Over the past two decades, multiple common 
stigma-reducing approaches have been utilized—protest (e.g. campaigns telling the public not to 
endorse negative stereotypical beliefs about individuals living with behavioral health conditions), 
education (e.g. providing the public with accurate information about behavioral health), contact (e.g. 
personal interaction with individuals living with a behavioral health condition), legislative reform 
(development and enactment of protective legislation), advocacy (use of multiple strategies to increase 
prioritization of behavioral health by decision makers), and stigma self-management (peer and 
recovery-oriented services) (Arboleda-Flórez & Stuart, 2012; Corrigan et al., 2012; Sartorius & Schulze, 
2005)—with research supporting contact-based approaches as superior at changing stigma (Corrigan 
et al., 2012; Sartorius & Schulze, 2005). Common contact-based interactions involve individuals 
sharing their stories of lived experiences with mental illnesses and corresponding symptoms and 
struggles as well as their path to wellness and hope. This Is My Brave (TIMB) is a contact-based stigma 
reduction program where stories are delivered in theaters, live and on-stage (or on virtual stages 
during COVID-19), guided by key ingredients for contact-based stigma change programs put forth 
by Corrigan and Kosyluk (2013). Individuals who participate in a TIMB production (cast members) 
consist of people with lived experience with behavioral health conditions including mental illness and 
substance use disorders. They creatively share not only their lived experiences and struggles but also 
their path to wellness, which conveys messages of recovery and hope. Cast members communicate 
their experiences on-stage through a medium they choose that can include poetry, essay, comedy, 
or original music (https ://thisismybrave.org). Kosyluk et al. (2018, 2020) have completed two studies 
examining the eff ectiveness of TIMB and found the program to be a promising stigma reduction 
program, resulting in audience members experiencing a decrease in public stigma, improvements in 
beliefs about recovery and empowerment, and greater willingness to seek treatment.
Why did you develop this?
Our research team has developed a line of scholarly inquiry using the archival recordings of TIMB 
performances (all performance are recorded and placed online for viewing by an international 
audience). We are qualitatively analyzing these videos to answer a variety of research questions. For 
the purpose of this conference we will report on narratives around substance use and stigma in TIMB 
performances.
Who is the target audience?
The target audience of this presentation ranges from other scholars, behavioral health practitioners, 
people living with behavioral health conditions and their friends and family members.
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Is this based on established work, or does it draw from other existing work?
The research question, “How do TIMB performers communicate about substance use?” is a new 
approach to this data.
How does your project or initiative work?
Our team members will independently code the videos from 14 TIMB performances where substance 
use is discussed and come together to agree on a set of themes.
What are the results? If results are not yet available, what results do you hope to achieve?
Examples of themes we expect will emerge from the data include the language used to describe 
experiences with substance use, coping strategies used to replace substance use behaviors, and 
emotions and thoughts surrounding substance use and recovery.
Contact information
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What is your project or initiative?
The initiative described here is an undergraduate substance use, dependency and addiction course 
which has as one of its learning objectives to describe the social eff ects of substance use, and the 
stigma associated with people who use substances. However, from beginning to end, this course, its 
instructor, teaching methods and assignments recognize and call out stigma.
Why did you develop this?
I inherited this course in 2015, and since then, have made it my own, highlighting what I feel to be 
injustices in the treatment of persons who use substances and who may have substance use disorder. 
Because this is a popular course enrolling 50 to 100 students each semester, it allows dissemination of 
new ideas which change mindsets. In immediate and later feedback (e.g., emails) students share the 
impact. If I remember correctly, it was one my guest speakers who suggested I check out the Narcotica 
Podcast, which lead me to resources such as the Recovery Research Institute, the Truth in Justice Lab 
and Changing the Narrative. Now these resources and more, inform the programming for this course.
Who is the target audience?
A diverse group of undergraduate students (i.e., demographically and by major) at a large NE urban 
university (we are near Kensington in Philadelphia). Course runs twice a year.
Is this based on established work, or does it draw from other existing work?
The course has been revised but builds on my past teaching of the course and new information from 
many of the aforementioned groups.
How does your project or initiative work?
The course is taught in a fl ipped style, such that students read, listen, view content prior to meeting 
live once a week (currently via Zoom). The fi rst two weeks set the stage for the person fi rst lens used 
throughout the semester. For example, students read The AP Learns to Talk about Addiction: Will Others 
Follow? (Szalavitz, 2017); Why I Stopped Calling Myself an Alcoholic (Whitakar, 2019); and review the 
Changing the Narrative website. In class, the students review the Addictionary and note which words 
have stigma alerts, while also considering which ones surprise them and which ones might be missing. 
Students also listen the Narcotica podcast #22 which discusses stigma around substance use and 
also some phrases (epidemic) that do not capture the nature of the overdose crises. Throughout the 
semester we work on using person-fi rst language in our exchanges and pay particular attention to 
stigma and injustice when discussing drug control policy; this year, we were able to explore stigma used 
by the defense team in the Derek Chauvin murder trial. The fi nal project for this class is a PSA or Zine 
that focuses solely on harm reduction (examples available).
What are the results? If results are not yet available, what results do you hope to achieve?
The goal is for graduates of this course to lead by example in their exchanges with others when 
discussing substance use. As I tell them, it takes a long time to change the language we use to talk 
about persons who use substances, but it must start somewhere, and it should start with them. 
Anecdotally, it is working. Students say: “I’ve found myself changing the language that I use and 
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becoming more conscious about how I approach discussions surrounding substances and those who 
use them. I feel like this will defi nitely benefi t me as I continue my education around healthcare.” “It 
has made me aware of harmful language that we use about people with substance use [disorder] on 
the daily. I had to do a trauma population presentation in another class surrounding “drug use in the 
family” and made sure to use no stigmatizing language.”
Contact information
Deirdre A. Dingman Temple University 
tuf86092@temple.edu
Keywords
education, person-centered language, young adults
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What is your project or initiative?
The REACH Project, Inc., a 501(c)3 non-profi t organization, is an independent medical practice. REACH–
an acronym for Respectful, Equitable Access to Compassionate Healthcare–opened in February 2018 
with the goal of building health equity in the Southern Tier region of New York State (NYS) by providing 
access to high quality, evidence-based, stigma-free healthcare to commonly marginalized populations 
through a harm reduction model. REACH off ers low threshold, integrated services including medication 
for opioid use disorder (MOUD) with buprenorphine for opioid use disorder (OUD), comprehensive 
primary care, behavioral health services, and Hepatitis C and HIV testing and treatment. In the Fall 
of 2020, REACH launched outreach-based naloxone training in Ithaca, NY. Naloxone (also known as 
Narcan) is an opioid overdose reversal medication that is available in an easy to use intranasal form, 
commonly distributed to the public. As a mechanism to educate the community on harm reduction 
practices, naloxone training can assist in the reduction of stigma and opioid overdose death. These 
virtual and in-person trainings are delivered by certifi ed REACH staff  with experience in outreach 
service delivery, community health work, and emergency medical response.
Why did you develop this?
In response to the COVID-19 pandemic, REACH implemented outreach services to ensure that people 
experiencing homelessness or housing insecurity in our local community had adequate and safe 
access to healthcare services. In conjunction with facilitated telemedicine, COVID-19 testing, and 
COVID-19 vaccine administration, outreach-based naloxone training off ers an additional level of live-
saving support to vulnerable populations that access outreach services. A reported increase of opioid 
overdoses in Ithaca, particularly within the homeless population REACH serves, led REACH to expand 
naloxone training and distribution through outreach.
Who is the target audience?
The target audience for this project is everyone in REACH’s community. The availability of naloxone 
during an opioid overdose can be life-saving. Through outreach-based trainings, REACH was able to 
specifi cally engage people experiencing homelessness or housing insecurity and those that work closely 
with this population. By promoting and empowering community members, REACH can help to prevent 
overdose deaths and can help people who use drugs feel safe. Furthermore, the expanded availability 
of naloxone promotes reductions in the stigma surrounding substance use.
Is this based on established work, or does it draw from other existing work?
As a designated New York State Opioid Overdose Prevention Program (OOPP) site, REACH provides 
free naloxone to patients and naloxone training participants. To continue providing naloxone trainings 
during the COVID-19 pandemic, REACH has adapted their training to be delivered virtually.
How does your project or initiative work?
As a certifi ed OOPP site, REACH is able to coordinate the distribution of naloxone kits. These kits 
include two doses of intranasal naloxone, a face shield for rescue breathing, and a quick-reference 
opioid overdose identifi cation and naloxone administration sheet. Trainees receive a certifi cation 
of completion card with resources, such as the Offi  ce of Addiction Services and Supports (OASAS) 
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HOPEline. Due to regulatory changes during the pandemic, REACH is able to mail or deliver these kits 
in-person to virtual or in-person training attendees. Finally, REACH developed a voluntary post-training 
survey that is sent via email to all participants for data collection and quality improvement purposes.
What are the results? If results are not yet available, what results do you hope to achieve?
Since the start of the outreach-based training program in October of 2020, REACH has trained 73 
individuals in seven unique trainings on opioid overdose awareness and naloxone administration. 
These individuals include local social service organizations, local businesses, REACH clinical staff  and 
Peer Advisory Board members, and the general community. In the post-training survey, participants 
reported an average confi dence score of 6.6 on a scale from 1-10 (1 being the least confi dent, 10 
being the most confi dent) in their ability to administer naloxone prior to receiving the training. After 
receiving the training, participants reported an average confi dence score of 9.7 in their ability to 
administer naloxone in the event of an overdose. Moving forward, REACH aims to increase the number 
of individuals trained and unique trainings delivered. In order to empower the community and reduce 
stigma, REACH will continue to provide harm reduction services in its low-threshold, integrated setting.
Contact information
Judith Griffi  n, The REACH Project, Inc.
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What is your project or initiative?
The Robert Bree Collaborative (the Collaborative) was established in 2011 to provide a forum in 
which public and private health care stakeholders in Washington State can work together to develop 
evidence-based clinical guidelines in order to improve health care quality, outcomes, aff ordability, 
and equity. The number of people in Washington with substance use disorders and who experience 
variation in whether they are screened, receive any intervention and/or access to treatment, and a 
lack of coordination and communication between primary care, emergency rooms, and treatment 
centers were identifi ed by the Collaborative as a priority area for improvement in 2014 and the 
Collaborative developed clinical, community standards to improve care. Guidelines are based on 
published evidence, stakeholder input and expert opinion, and examine methods of improving the 
ways that those with substance use disorders interact with the health care system. The Guidelines are 
framed around fi ve focus areas and apply to those 13 years of age and older: Reduce Stigma; Increase 
Appropriate Screening; Increase Capacity for Brief Intervention and Treatment; Decrease Barriers for 
Referrals to Treatment Facilities; Address the Opioid Epidemic. Building off  this last focus area and 
recognizing the growing opioid epidemic, the Collaborative developed guidelines in 2017 to address 
lack of access to appropriate, evidence-based opioid use disorder treatment. The goal is a health 
care system that identifi es people with opioid use disorder and facilitates access to comprehensive, 
evidence-based treatment with the patient at the center of care. The workgroup identifi ed the following 
three focus areas to improve outcomes for this population: Access to evidence- based treatment (e.g., 
medication-assisted treatment, reduce stigma); Referral information (e.g., inventory of medication 
treatment prescribers, supportive referrals); Integrated behavioral and physical health to support 
whole-person care (e.g., treatment of comorbid conditions). The Collaborative has since built a 
suite of implementation resources to facilitate broad adoption of these guidelines by delivery sites, 
health plans, and others. Resources include: implementation checklists; core process measures; self-
assessment to measure implementation; topic specifi c webinars related to substance use disorders; 
and an online resource library.
Why did you develop this?
The Collaborative recognizes that full adoption of our guidelines requires a strong foundational system 
that not all delivery sites may have the funding, resources, or staff  to build. These resources are meant 
to be a roadmap toward successful implementation, outlining incremental and actionable steps without 
being overly prescriptive so as to feel overwhelming or impossible to implement.
Who is the target audience?
Our Implementation Checklist and Core Process Measures are meant for outpatient delivery sites. 
Our webinars and online resource library are meant for anyone within our broader community that is 
working to reduce stigma related to addiction and dependence and improve outcomes for people living 
with a substance use disorder.
Is this based on established work, or does it draw from other existing work?
These resources are based on the recommendations written by our workgroup members. A list of 
workgroup members is included in our full reports.
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How does your project or initiative work?
These Implementation resources are open access, available to all within the health care community. 
The initiative is structured to be made of two levels, a more intensive pilot group of out-patient 
primary care delivery sites working toward integrating behavioral health into care and a state-wide 
learning community. This pilot group completed a baseline Bree Collaborative Assessment measuring 
implementation of our Addiction & Dependence Treatment and Opioid Use Disorder Treatment 
guidelines, and a follow-up assessment in January/February 2021. Based on identifi ed gaps within this 
Assessment, each clinical team created an Action Plan of three to four quality improvement items to 
move toward full adoption of recommendations, and ultimately improved care for their substance use 
disorder patients.
What are the results? If results are not yet available, what results do you hope to achieve?
Data refl ecting six clinics showed improvement in the 11 assessment question scores related to our 
Addiction and Dependence and Opioid Use Disorder treatment guidelines, with an overall average 
improvement of 18.4% from 2020 to 2021. The assessment question specifi cally related to training and 
education for staff  on stigmatizing language and perceptions about alcohol and drug misuse showed a 
25.5% increase.
Contact information





59.  Training Child Welfare and Legal Professionals to Eff ectively Address and Support 
Families Impacted by Parental Substance Use
Authors
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What is your project or initiative?
The Philadelphia Coalition on Children and Opioids (“the Coalition”) is a stakeholder group of 
organizations at the intersection of child welfare and substance use treatment in Philadelphia. A 
major initiative of the Coalition is development and implementation of a series of trainings for child 
welfare staff  (case managers, supervisors, and child investigators) and legal professionals (judges, 
attorneys, child advocates, and related staff ) on how to eff ectively address and support families 
aff ected by parental substance use. The trainings include topics ranging from using non-stigmatizing 
approaches, understanding the context in which a parent is using substances, addressing the parent’s 
needs, engaging the parent in treatment and services, and promoting a positive child-parent visitation 
experience.
Why did you develop this?
The Coalition developed these trainings to correct common misperceptions that child welfare-related 
and legal professionals may hold related to parents who use substances. Key informant interviews 
with child welfare case managers in Philadelphia revealed that the current trainings do not equip child 
welfare workers with the knowledge and skills to work eff ectively on opioid-involved cases. They also 
revealed that a case manager’s bias towards substance use can hinder eff ective case management, and 
that a judge’s bias can prevent reunifi cation. In conversations with previously involved parents who 
use substances, parents indicated feeling stigmatized and treated in a punitive approach, especially in 
court, which may hinder their recovery and reunifi cation with their child(ren).
Who is the target audience?
The target audience of the child welfare-related training series include child welfare case managers and 
supervisors, child welfare investigators, and any other staff  who work directly with parents. The target 
audience of the legal professionals training include family court judges, child welfare attorneys, and 
child advocates.
Is this based on established work, or does it draw from other existing work?
While our trainings draw from similar trainings by the National Center on Substance Abuse and Child 
Welfare, our trainings are focused on and tailored to Philadelphia’s child welfare system and culture.
How does your project or initiative work?
The Coalition collaborated with Philadelphia’s Department of Human Services to host mandatory live 
training sessions for child welfare workers in addition to building online training modules that are 
available to all staff . The Coalition is off ering live training sessions for legal professionals in partnership 
with Philadelphia area legal agencies and organizations.
What are the results? If results are not yet available, what results do you hope to achieve?
Pre- and post-training evaluation results for initial training sessions will be available by the Summit. 
We hope that these trainings will: (1) increase the knowledge and skills of those who work with child 
welfare-involved parents who use substances; and (2) allow staff  to recognize how their personal beliefs 
and attitudes may aff ect how they relate to families. Ultimately, we hope that trainings will reduce 
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stigma related to parental substance use and treatment, that families experiencing or impacted by 
substance use will be treated compassionately and supported, and that substance use-related cases 
will be navigated equitably and eff ectively.
Contact information
Kelly Thompson, Public Health Management Corporation
 kthompson@phmc.org
Keywords
awareness, criminal justice, education
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60.  Understanding How Peers Can Shift Stigma to Retain Low-Income, Minority 
Individuals in Opioid Treatment
Authors
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Brown, PhD; Tolu Abidogun, MBBS; Alia Shields; Julia W. Felton, PhD; Jessica F. Magidson, PhD
What is your project or initiative?
Our team is evaluating whether and how a peer recovery specialist (PRS), a person with lived substance 
use experience currently in sustained recovery and trained to support others with substance use 
disorders (SUD) may shift multiple intersecting stigmas, and whether changes in stigma translate 
into improvements in methadone treatment retention. This work is a part of a larger parent award 
evaluating a PRS-delivered behavioral intervention to improve retention in methadone treatment. 
Our stigma initiative employs qualitative and quantitative methods to evaluate how a PRS may shift 
substance use and methadone stigma among individuals with opioid use disorder (OUD). 
We conducted qualitative research with patients, PRSs, staff , and other key stakeholders to understand:
1. how stigma manifests among low- income, minority individuals in methadone treatment, including 
internalized methadone and substance use stigma, and 
2. how a PRS may reduce stigma barriers and improve retention in care, including barriers and 
facilitators to the PRS role in shifting stigma.
Why did you develop this?
Retention in methadone treatment is a persistent challenge, with six-month retention rates below 
50% nationally, and even lower retention rates among low-income, ethnoracial minorities. Stigma is 
a known barrier to methadone retention, particularly within ethnoracial minority communities. The 
PRS workforce has rapidly expanded in the U.S. in order to increase access to treatment for substance 
use, particularly in historically underserved low-income, ethnoracial minority communities. Given 
PRS’ unique shared experience, PRS-led interventions may be well suited to shift stigma and improve 
retention in methadone care. However, this has yet to be empirically tested.
Who is the target audience?
The target audience includes those involved in PRS funding, training and services, as well as methadone 
treatment. We hope this initiative will build empirical support for understanding how PRSs may shift 
stigma, and whether these changes in stigma can improve methadone retention and other treatment 
outcomes.
Is this based on established work, or does it draw from other existing work?
This study is a stigma supplement within a larger parent award funded by the NIH HEAL Initiative, which 
aims to understand the eff ects of a PRS-led behavioral intervention, behavioral activation, on retention 
in methadone care and other treatment outcomes.
How does your project or initiative work?
We have developed a training model to train PRS’s in an evidence-based intervention, behavioral 
activation, which weaves in one’s lived experience. We are conducting qualitative work to inform 
ongoing adaptation of the PRS approach, as well as to understand specifi cally how stigma is a barrier 
to methadone treatment, and how a PRS’s lived experience can be integrated into the behavioral 
activation intervention to further amplify potential eff ects on internalized stigma. Semi-structured 
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qualitative interviews and focus groups were conducted (Phase I) with participants (N=32) including: 
patients currently enrolled in methadone treatment, treatment center staff , and PRSs working in a 
range of substance use treatment settings. Interviews were transcribed, and a codebook was iteratively 
developed to allow for thematic, rapid qualitative analysis. Qualitative results informed a subsequent 
open-label pilot trial (Phase II), in which participants thus far (N = 4) have completed semi-structured 
exit-interviews, which have been transcribed and are being analyzed.
What are the results? If results are not yet available, what results do you hope to achieve?
Several themes emerged from the Phase I interviews and focus groups. Participants described 
internalized as well as enacted methadone and substance use stigma at various levels, such as 
institutional and societal levels, as barriers to reaching successful treatment outcomes, as well as other 
forms of stigma. Participants expressed that a PRS-led intervention may reduce stigma and improve 
retention in care through qualities unique to the PRS role, such as shared experience and being seen 
as a role model, as well as PRS actions/behaviors, such as supporting clients and shifting organizational 
stigma. However, it was noted that the PRS having a diff erent recovery pathway may result in 
stigmatizing the patient, and, thus, may act as a barrier to a PRS-led intervention reducing stigma. Exit 
interviews to date indicate that, as a result of engaging in a PRS intervention, participants felt a shift in 
internalized methadone and substance use stigma.
Contact information
Morgan Anvari, University of Maryland, College Park 
manvari@umd.edu
Keywords
lived experience, medications for opioid use disorder
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61.  Understanding Stigmatizing Healthcare Experiences of Individuals in Recovery from 
Opioid Use Disorder
Authors
Amber Baysinger; Nicholaus Christian; Rebecca Nekolaichuk; Blake Smith; Clarissa Johnston
What is your project or initiative?
Understanding Stigmatizing Healthcare Experiences of Individuals in Recovery from Opioid Use 
Disorder
Why did you develop this?
To understand stigmatizing language and actions that people with lived experience of opioid use 
disorder (OUD) have experienced in diff erent care settings to inform a fl ipped simulated patient 
experience.
Who is the target audience?
Trainees.
Is this based on established work, or does it draw from other existing work?
Based on established work.
How does your project or initiative work?
18 individuals who identifi ed as being in recovery from OUD were recruited via fl yers and word-of-
mouth at a local community recovery organization. Three focus groups were held with six participants 
each. Groups lasted up to 90-minutes and were led by a trained facilitator using a semi-structured 
interview guide that allowed participants to guide the conversation fl ow.
What are the results? If results are not yet available, what results do you hope to achieve?
Preliminary analysis of qualitative interviews using applied thematic analysis elicited the following main 
emergent themes:
1. provider language use and self-identifying language; 
2. provider body language and behavior; 
3. fear and avoidance of the healthcare system; 
4. infrequency of honesty, open communication, and trust between provider and patient; and 
5. inadequate medical care including undertreating pain or overprescribing without inquiring about 
opioid use history. 
Participants noted that characteristics of positive interactions with providers included: 
1. providers educating patients about OUD including harm reduction; 
2. providers explaining to the patient what their care entailed; 
3. collaborative decision-making; and 
4. compassion and empathy. 
These characteristics were viewed as helping to build trust and an open line of communication between 
the provider and the patient.
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Contact information





Richard Bottner, member of the Stigma of Addiction Summit planning committee, is a partner in this 
project and did not have involvement in the abstract submission.
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62.  Underutilization of Buprenorphine and Opioid Use Disorder Stigma in Primary Care: 
A Pilot Intervention for Registered Nurses
Authors
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What is your project or initiative?
This quality improvement (QI) project piloted an evidence-based buprenorphine-specifi c anti-stigma 
intervention that aimed to reduce registered nurses’ (RNs) stigmatizing attitudes towards persons with 
opioid use disorder (OUD) and to increase their participation in providing buprenorphine, a medication 
for OUD, in a primary care community health setting. The organization’s goal was to increase 
buprenorphine prescribing rates and access to care for persons with OUD. The intervention was 
piloted for primary care RNs as non- prescriber members of the primary care team intended to support 
prescribers and patients in buprenorphine management.
Why did you develop this?
Underutilization of buprenorphine in primary care and OUD stigma are two factors that have hindered 
the expansion of access to medications for OUD. Primary care buprenorphine prescribers reported 
lack of clinical support from care team members, specifi cally RNs, and OUD stigma to be common 
barriers. However, recent published buprenorphine education interventions for primary care, designed 
to increase participation in buprenorphine management, did not include anti-stigma curricula and few 
actively included the participation of RNs.
Who is the target audience?
Those in clinical service, including management of direct care delivery, and academia. This feasible low-
cost intervention provides a framework for creating and providing anti-stigma training in the context of 
primary care OUD management and merits further evaluation with larger studies.
Is this based on established work, or does it draw from other existing work?
The buprenorphine-specifi c anti-stigma education intervention combined a validated anti-stigma 
model and evidence-based methods most commonly used for post Drug Enforcement Administration 
X-waiver buprenorphine training in primary care. The anti-stigma model consisted of six elements: the 
signifi cance of recovery, multiple forms of contact, setting the tone, inclusion of personal testimony, 
skill building, and myth busting. The buprenorphine training methods included interactive case studies, 
communication training, and peer mentoring or support.
How does your project or initiative work?
A pre-test and post-test design was used to evaluate changes in stigmatizing attitudes about persons 
with OUD after a two-hour virtual buprenorphine-specifi c anti-stigma education intervention. 
Stigmatizing attitudes were measured with a modifi ed Opening Minds Stigma Scale for Health Care 
providers (OMS-HC). The scale was modifi ed by substituting “opioid use disorder” for the term “mental 
illness”. RNs’ self-reported change in participation with buprenorphine management was evaluated two 
months after the intervention with a novel buprenorphine participation scale created for this project. 
The organization’s rate of unique patients receiving buprenorphine prescriptions was calculated over a 
two-month timeframe before and after the intervention.
What are the results? If results are not yet available, what results do you hope to achieve?
Results from this small (n=12) QI project showed a 4% reduction in stigmatizing attitudes post 
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intervention. A Wilcoxon matched-pairs signed rank test indicated that this decrease was not 
statistically signifi cant (Z = -1.77, p = 0.15). A Cohen’s d eff ect size statistic showed this decrease had 
an intermediate eff ect, d = 0.62. While not statistically signifi cant in this project, the 4% reduction 
magnitude was consistent with the magnitude of change observed in larger studies addressing general 
mental health stigma using a similar design to measure change in OMS-HC after implementing the 
same anti-stigma model. Two months post-intervention, there was no statistically signifi cant change 
in buprenorphine participation (Z= -1.74, p=0.08) or association between the rate of patients receiving 
buprenorphine prescriptions and the intervention (x2 = 2.10, p=0.15), but prescribing rates did increase 
by 36%. Data collection continues to further evaluate the long-term impact of the anti-stigma training. 
Additional data collection is underway to measure the clinical impact from a reduction in healthcare 
team members’ OUD stigma and the project has been expanded by incorporating the anti-stigma 
model in buprenorphine trainings for other primary care team roles (both prescriber and non-
prescriber).
Contact information
Anina Terry, Neighborcare Health
AninaT@neighborcare.org
Keywords
medications for opioid use disorder
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63.  Using Patient Narratives to Reduce Stigma among Primary Care Clinicians towards 
People with Opioid Use Disorder
Authors
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What is your project or initiative?
Our team has created a clinical decision support (CDS) tool in the electronic health record designed to 
help primary care providers identify, screen, diagnose, and treat opioid use disorder (“OUD CDS”). As 
part of this project, we are conducting a clinical trial to examine whether an online training for the OUD 
CDS infused with patient narratives reduces stigma towards people with opioid use disorder among 
primary care clinicians compared to a basic training.
Why did you develop this?
In our preliminary work, we interviewed primary care clinicians about treating patients with opioid 
use disorder, and we heard many common stigmatizing beliefs from those clinicians. In reviewing the 
literature, we learned there is little research on the topic of stigma towards patients with opioid use 
disorder among primary care clinicians. Interventions to address stigma among healthcare providers 
are rare; however, limited research suggests that contact with people who have opioid use disorder is 
one of the best approaches to reduce stigma.
Who is the target audience?
The intervention is targeted towards primary care clinicians.
Is this based on established work, or does it draw from other existing work?
This is a clinical trial of a new intervention founded in previous research.
How does your project or initiative work?
In the intervention group, clinicians complete an online training where they are presented with four 
patient scenarios of when they might use the OUD CDS. In collaboration with a medical historian, we 
wrote patient narratives that tell true stories of patients with OUD (all identifying information was 
changed to protect the patients’ confi dentiality); we hired actors to portray those patients. Clinicians 
watch videos of these patients telling their stories while simultaneously learning how they might 
use the OUD CDS in this scenario. The patient narratives are designed to humanize the patients, 
demonstrate appropriate person-fi rst language, reduce the use of labels (“addict”), and encourage 
clinicians to learn a patient’s story before making assumptions (e.g., that the patient is “drug-seeking”). 
Further, the videos try to dispel stigma of using buprenorphine to treat opioid use disorder by showing 
patients who have successfully been treated using the medication. The attention-control training simply 
walked the clinicians through the same four scenarios on which they might use the OUD CDS; however, 
they did not see the patient videos or hear their stories.
What are the results? If results are not yet available, what results do you hope to achieve?
The intervention is currently in the fi eld and preliminary results are expected in Summer 2021. We hope 
that the intervention, compared to an attention-control training without patient narratives, reduces 
stigma towards people with opioid use disorder among primary care clinicians. Further, we hope that 









64.  Utilizing the Project ECHO Model to Reduce Stigma toward Patients Receiving 
Medication for Opioid Use Disorder (MOUD)
Authors
Adrienne Madhavpeddi, MS; Adrienne Lindsey, MA, DBH; Alison Essary, DHSc, PA-C
What is your project or initiative?
Arizona State University (ASU), in partnership with Blue Cross Blue Shield of Arizona, HonorHealth, and 
Arizona’s Medicaid program developed the Medication-Assisted Treatment (MAT) ECHO program.
Why did you develop this?
Although there have been tremendous eff orts to increase the numbers of buprenorphine-waivered 
providers across Arizona, the shortage of providers integrating MAT practices into their clinic persists. 
The results of provider shortages is catastrophic to population health, as nearly 90,000 overdose 
related deaths occurred in 2020 alone. Common barriers to practice integration include stigma 
associated with both opioid-use disorder (OUD) as well as MAT practices, lack of organizational or 
ongoing support for MAT services, and the inherent complexity of patient cases. Thus, the MAT 
ECHO program addresses these barriers by integrating education around stigma, sharing of best-
practices, normalizing the use of MAT in standard medical practices, and ongoing clinical and technical 
consultation to providers across the state.
Who is the target audience?
The target audience for this program are buprenorphine-waivered medical providers, those who are 
considering becoming waivered, and supportive staff  involved in direct patient care. This includes 
physicians, physician assistants, nurse practitioners, psychiatrists, pharmacists, behavioral health 
providers, social workers, community health workers, peer support, and more.
Is this based on established work, or does it draw from other existing work?
First established in 2003 at the University of New Mexico (UNM), Project ECHO (Extension for 
Community Healthcare Outcomes) is a proven adult learning model for delivering high-quality 
continuing medical education to the current healthcare workforce. To date, there are over 3,400 unique 
ECHO programs operating in 49 countries around the world. These programs have combined to deliver 
2.8 million learning hours to nearly 500,000 unique participants. ASU became an offi  cial replicating 
partner in 2018. To date, ASU has built and is currently operating ten ECHO programs including the 
MAT ECHO, which launched in February 2020. This program meets on a biweekly basis and will operate 
indefi nitely so long as there is a need improve clinical skills in MAT.
How does your project or initiative work?
The primary goal of this project is to establish a state-level collaborative partnership to scale evidence-
based education and practice in the management of patients with OUD. The MAT ECHO program 
is designed to provide the knowledge, support, and resources necessary to increase the capacity 
and confi dence of medical providers to eff ectively provide MAT. By leveraging video-conferencing 
technology, the MAT ECHO program uses a hub-and-spoke model, connecting teams of subject 
matter experts (‘hub’) with medical providers (‘spokes’) through live, virtual, teleECHO clinics. This 
provider network creates a platform for lifelong learning and guided practice for increasing local 
capacity to treat patients and reduce stigma associated with OUD. The MAT program meets virtually, 
via teleconferencing technology, on a biweekly, ongoing basis. Each 60-minute session includes an 
introduction on reducing stigmatizing practices (i.e., ‘word of the day’), a brief didactic presentation, 
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followed by discussion of a patient case (scrubbed of PHI prior to the teleECHO clinic). The curriculum is 
developed annually by the subject matter experts but retains fl exibility to account for the needs of the 
community. Programming is provided free to participants and CME credits are provided at no charge to 
those who qualify.
What are the results? If results are not yet available, what results do you hope to achieve?
Since February 2020, the MAT ECHO program has delivered 28 sessions to 292 unique participants, 
for a total of 8,176 learning hours. A six-month retrospective survey was sent by email to all teleECHO 
participants in November 2020. Across all sessions, 97% of participants report being ‘satisfi ed’ or 
‘extremely satisfi ed’ with program content. When asked about “providing excellent care when working 
with patients that have OUD,” participant confi dence increased from 3.85 at baseline to 4.33 at six 
months and job satisfaction increased from 3.83 to 4.33 among those who regularly attended the MAT 
ECHO program (5 = strongly agree; 4 = agree; 3 = neutral; 2 = disagree; 1 = strongly disagree).
Contact information
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What is your project or initiative?
An immersive virtual simulation about opioid use disorder (OUD) was designed to provide participants 
with the opportunity to experience challenges associated with navigating life as a pregnant mother 
in active addition and to feel the impact of stigma associated with OUD. The Opioid Simulation is an 
experiential learning opportunity to help participants view OUD as a chronic disease for which there is 
treatment and recovery, experience the role of stigma in the disease of addiction, and understand the 
role of resilience in OUD.
Why did you develop this?
OUD is a treatable medical condition with appropriate access to care. Despite advancements in 
treatment and the availability of life-saving medications, provider stigma remains a barrier to reducing 
OUD and decreasing the number of opioid- related deaths. Creating ‘OUD competent’ and sensitive 
healthcare providers will require incorporating OUD education and stigma training into program 
curricula and continuing education. Simulation provides an opportunity for participants to experience 
challenges presented in the virtual realm and promotes introspection in response to these personalized 
experiences.
Who is the target audience?
The simulation is intended for a broad audience of healthcare workers and students in health 
professions programs.
Is this based on established work, or does it draw from other existing work?
First established in 2003 at the University of New Mexico (UNM), Project ECHO (Extension for 
Community Healthcare Outcomes) is a proven adult learning model for delivering high-quality 
continuing medical education to the current healthcare workforce. To date, there are over 3,400 unique 
ECHO programs operating in 49 countries around the world. These programs have combined to deliver 
2.8 million learning hours to nearly 500,000 unique participants. ASU became an offi  cial replicating 
partner in 2018. To date, ASU has built and is currently operating ten ECHO programs including the 
MAT ECHO, which launched in February 2020. This program meets on a biweekly basis and will operate 
indefi nitely so long as there is a need improve clinical skills in MAT.
How does your project or initiative work?
During this simulation, participants play the role of a pregnant mother with an OUD navigating the 
challenges of everyday life such as obtaining healthcare, childcare, and fi nding a job. Participants are 
presented with opportunities to make decisions based on their previous experiences, current resilience, 
and pain levels. All participants progress through active addiction and treatment. After completing 
the simulation, there is a structured virtual debriefi ng during which participants share reactions to 
participating in the simulation and refl ect on their experiences they encountered throughout the 
simulation, including how resilience impacted their decisions, how stigma eff ected them, and how 
participating in the simulation demonstrated that OUD is a chronic, relapsing disorder for which there 
is treatment and recovery.
126
What are the results? If results are not yet available, what results do you hope to achieve?
Results are not yet available. We hope to demonstrate that participation in this virtual simulation 
reduces provider stigma towards pregnant women with OUD. We also hope to expand the simulation 
to provide more education on treatment options for women with OUD and to develop more storylines 
for the virtual simulation, allowing participants to play addition roles in the simulation.
Contact information





66.  Your Rights in Recovery: A Toolkit
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What is your project or initiative?
The “Your Rights in Recovery Toolkit” explains varied treatment options, including clinical interventions, 
peer-based recovery support, and harm reduction for people with opioid use disorder (OUD). It also 
includes facts about an individual’s legal rights, self-advocacy tips and resources on the topics of 
families, housing, education, employment, and the justice system that are important to understand. 
Each chapter addresses a social determinant of health that impacts an individual’s recovery from OUD, 
as well as their overall well-being. For example, the employment chapter explains that most individuals 
have the right to take up to 20 weeks off  work to get treatment for OUD without losing their job. The 
“Your Rights in Recovery Toolkit” was developed through RIZE’s Together in Recovery: Supporting 
Informed Decisions initiative that was launched in April 2019 to foster an accessible, integrated 
treatment and recovery network in Massachusetts that champions evidence-based approaches, 
supports multiple pathways to recovery, and puts people in charge of their treatment choices. The 
Together in Recovery Advisory Committee, comprised of advocates, clinicians, and public offi  cials, 
helped create the “Your Rights in Recovery Toolkit” as a means to improve support for individuals living 
with OUD. The toolkit was launched on April 7, 2021 and in the last two weeks, there were over 500 
unique views and the average time spent on the toolkit is 4 minutes.
Why did you develop this?
The current system of substance use disorder treatment often perpetuates stigma, bias, and a power 
imbalance that keeps vulnerable people stuck in punitive and ineff ective cycles of care. It is affl  icted 
by antiquated policies and procedures, a payment structure that discourages equitable access 
to treatment, and divisive ideological debates that cloud patients’ decisions. In response to these 
challenges, RIZE created and disseminated a toolkit that addresses the rights and protections of people 
with opioid use disorder. Because many people are unaware of the types of treatment available, and 
the rights aff orded to them, only 11% of people who needed substance use treatment received care at 
a specialty facility, according to SAMHSA’s 2018 National Survey on Drug Use and Health.
Who is the target audience?
The audience is people who suff er from OUD and their loved ones; case managers, especially those 
who assist with discharge planning and treatment plans; prescribers of medication for opioid use 
disorder; criminal justice professionals, including probation offi  cers and law professionals; advocates; 
housing specialists; etc.
Is this based on established work, or does it draw from other existing work?
The toolkit pulls information from public sources from the Massachusetts treatment and legal system 
but this is new product developed by RIZE.
How does your project or initiative work?
The “Your Rights in Recovery Toolkit” is designed to empower individuals who may not have access 
to accurate information – often through no fault of their own – to manage their addiction and begin 
to recover safely. It is accessible online at www.rizema.org/yourrights, prints easily, and is available in 
English and Spanish.
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What are the results? If results are not yet available, what results do you hope to achieve?
RIZE is dedicated to highlighting the stigma and inequities in the addiction treatment system and 
making resources accessible to all people and communities to promote equity. We envision a world 
where all people who use drugs and those who have addiction are treated with care, respect, and 
dignity. Stigma associated with drug use or addiction must end. We hope this toolkit provides the 
building blocks needed for this kind of future.
Contact information
Julie Burns, RIZE Massachusetts Foundation 
julie.burns@rizema.org
Keywords
care coordination
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